US20070238746A1 - Thiazolyl-dihydro-chinazoline - Google Patents

Thiazolyl-dihydro-chinazoline Download PDF

Info

Publication number
US20070238746A1
US20070238746A1 US11/690,355 US69035507A US2007238746A1 US 20070238746 A1 US20070238746 A1 US 20070238746A1 US 69035507 A US69035507 A US 69035507A US 2007238746 A1 US2007238746 A1 US 2007238746A1
Authority
US
United States
Prior art keywords
alkyl
cycloalkyl
aryl
optionally
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/690,355
Inventor
Trixi Brandl
Udo Maier
Christoph Hoenke
Anne Joergensen
Alexander Pautsch
Steffen Breitfelder
Matthias Grauert
Matthias Hoffmann
Stefan Scheuerer
Klaus Erb
Michael Pieper
Ingo Pragst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of US20070238746A1 publication Critical patent/US20070238746A1/en
Priority to US12/351,017 priority Critical patent/US8354418B2/en
Assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH reassignment BOEHRINGER INGELHEIM INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOENKE, CHRISTOPH, JOERGENSEN, ANNE T., PAUTSCH, ALEXANDER, BREITFELDER, STEFFEN, GRAUERT, MATTHIAS, HOFFMANN, MATTHIAS, PRAGST, INGO, SCHEUERER, STEFAN, PIEPER, MICHAEL, ERB, KLAUS, MAIER, UDO, BRANDL, TRIXI
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to new thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.
  • general formula (I) wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof
  • Phosphatidylinositol-3-kinases are a subfamily of the lipid kinases which catalyse the transfer of a phosphate group to the 3′-position of the inositol ring of phosphoinositides.
  • PI3-kinases may play a part in numerous tumours, such as e.g. breast cancer, ovarian or pancreatic carcinoma, in tumour types such as carcinomas of the colon, breast or lungs, but particularly in autoimmune diseases such as Crohn's disease or rheumatoid arthritis, for example, or in the cardiovascular system, e.g. in the development of cardiac hypertrophy (Oudit et al., Circulation. 2003 Oct. 28; 108(17):2147-52).
  • PI3-kinase modulators may represent a possible method of anti-inflammatory therapy with comparatively minor side effects (Ward and Finan, Curr Opin Pharmacol. 2003 August; 3(4):426-34).
  • PI3-kinase inhibitors for treating inflammatory diseases are known in the literature.
  • WO 03/072557 discloses 5-phenylthiazole derivatives
  • WO 04/029055 discloses annelated azolpyrimidines
  • WO 04/007491 discloses azolidinone-vinyl linked benzene derivatives.
  • the two specifications WO 04/052373 and WO 04/056820 disclose benzoxazine and benzoxazin-3-one derivatives.
  • the aim of the present invention is to provide new compounds which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used therapeutically for the treatment of inflammatory or allergic diseases.
  • PI3-kinase modulators include inflammatory and allergic respiratory complaints, inflammatory and allergic skin complaints, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic illnesses which involve autoimmune reactions or kidney inflammation.
  • compounds of formula (I) act as inhibitors of PI3-kinase, particularly as inhibitors of PI3-kinase gamma.
  • the compounds according to the invention may be used for example for the treatment of respiratory complaints.
  • the present invention therefore relates to compounds of general formula (I), wherein
  • R a and R 1 to R 16 may have the meaning specified and
  • R 1 to R 16 may have the meaning specified and
  • the invention further relates to compounds of formula (I) for use as pharmaceutical compositions.
  • the invention further relates to the use of the compounds of formula (I) for preparing a pharmaceutical composition for the treatment of diseases in whose pathology an activity of PI3-kinases is implicated, wherein therapeutically effective doses of the compounds of formula (I) may confer a therapeutic benefit.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory and allergic diseases of the airways.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease, which is selected from among chronic bronchitis, bronchitis caused by bacterial or viral infections or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha1-antitrypsin deficiency, coughing, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary oedema, pneumonitis of various causes, such as radiation-induced or caused by aspiration or infection, collagenoses such as lupus erythematodes, systemic sc
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory and allergic diseases of the skin.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among psoriasis, contact dermatitis, atopical dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyoderma, endogenous and exogenous acne, acne rosacea and other inflammatory and allergic or proliferative skin complaints.
  • a disease which is selected from among psoriasis, contact dermatitis, atopical dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpeti
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammation of the eye.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment a disease which is selected from among conjunctivitis of various kinds, such as e.g. caused by fungal or bacterial infections, allergic conjunctivitis, irritable conjunctivitis, conjunctivitis caused by drugs, keratitis and uveitis.
  • a disease which is selected from among conjunctivitis of various kinds, such as e.g. caused by fungal or bacterial infections, allergic conjunctivitis, irritable conjunctivitis, conjunctivitis caused by drugs, keratitis and uveitis.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of diseases of the nasal mucosa.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease, which is selected from among allergic rhinitis, allergic sinusitis and nasal polyps.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory or allergic conditions involving autoimmune reactions.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among Crohn's disease, ulcerative colitis, systemic lupus erythematodes, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatric arthritis, osteoarthritis, rheumatoid spondylitis.
  • a disease which is selected from among Crohn's disease, ulcerative colitis, systemic lupus erythematodes, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatric arthritis, osteoarthritis, rheumatoid spondylitis.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of kidney inflammation.
  • the invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome.
  • Preferred is an inhaled pharmaceutical formulation containing a compound of formula (I).
  • alkyl groups as well as alkyl groups which are part of other groups are meant branched and unbranched alkyl groups with 1 to 10 carbon atoms, preferably 1-6, particularly preferably 1-4 carbon atoms, are meant for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. Unless stated otherwise, the above terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl include all the possible isomeric forms.
  • propyl includes the two isomeric groups n-propyl and iso-propyl
  • butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl
  • pentyl includes isopentyl, neopentyl etc.
  • one or more hydrogen atoms may be replaced by other groups.
  • these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine. The substituents fluorine or chlorine are preferred. It is also possible for all the hydrogen atoms of the alkyl group to be replaced.
  • alkyl bridge is meant, unless stated otherwise, branched and unbranched double-bonded alkyl groups with 4 to 7 carbon atoms, for example, n-butylene, iso-butylene, sec. butylene and tert.-butylene, pentylene, iso-pentylene, neopentylene, etc. bridges. Particularly preferred are n-butylene or n-pentylene bridges. In the above-mentioned alkyl bridges 1 to 2 C atoms may optionally be replaced by one or more heteroatoms selected from among oxygen or sulphur.
  • C 1-6 -alkylene (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 to 6 carbon atoms and by the term “C 1-4 -alkylene” are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms. Preferred are alkylene groups with 1 to 4 carbon atoms. Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene or hexylene.
  • propylene, butylene, pentylene and hexylene include all the possible isomeric forms of the groups in question with the same number of carbons.
  • propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene.
  • alkenyl groups are branched and unbranched alkenyl groups with 2 to 10 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond.
  • alkenyl groups include: ethenyl, propenyl, butenyl, pentenyl etc.
  • propenyl, butenyl etc. include all the possible isomeric forms.
  • butylene includes n-butenyl, 1-methylpropenyl, 2-methylpropenyl, 1,1-dimethylethenyl, 1,2-dimethylethenyl etc.
  • alkenyl groups unless otherwise stated, optionally one or more hydrogen atoms may optionally be replaced by other groups.
  • these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
  • the substituents fluorine and chlorine are preferred. Particularly preferred is the substituent chlorine.
  • all the hydrogen atoms of the alkenyl group may be replaced.
  • C 2-6 -alkenylene (including those which are part of other groups) are meant branched and unbranched alkenylene groups with 2 to 6 carbon atoms and by the term “C 2-4 -alkenylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Alkenylene groups with 2 to 4 carbon atoms are preferred.
  • Examples include: ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene or hexenylene.
  • the definitions propenylene, butenylene, pentenylene and hexenylene include all the possible isomeric forms of the groups in question with the same number of carbons.
  • propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene.
  • alkynyl groups are branched and unbranched alkynyl groups with 2 to 10 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
  • alkynyl groups with 2 to 4 carbon atoms.
  • examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • the definitions propynyl, butynyl, pentynyl and hexynyl include all the possible isomeric forms of the groups in question.
  • propynyl includes 1-propynyl and 2-propynyl
  • butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl etc.
  • one or more hydrogen atoms may optionally be substituted by other groups unless stated otherwise.
  • these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
  • the substituents fluorine and chlorine are preferred.
  • all the hydrogen atoms of the alkynyl group may be replaced.
  • C 2-6 -alkynylene (including those which are part of other groups) are meant branched and unbranched alkynylene groups with 2 to 6 carbon atoms and by the term “C 2-4 -alkynylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Preferred are alkynylene groups with 2 to 4 carbon atoms.
  • Examples include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene or hexynylene.
  • the definitions propynylene, butynylene, pentynylene and hexynylene include all the possible isomeric forms of the groups in question with the same number of carbons.
  • propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene.
  • cycloalkyl groups (including those which are part of other groups) are meant saturated cycloalkyl groups with 3-8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the above-mentioned cycloalkyl groups may optionally carry one or more substituents or be anellated to a benzene ring.
  • the cycloalkyl groups may form, in addition to monocyclic groups, bicyclic, bridged or spirocyclic ring systems.
  • cycloalkenyl (including those which are part of other groups) are meant cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms, which contain one or two double bonds. Examples include: cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl or cyclooctadienyl.
  • the cycloalkenyl groups may form, in addition to monocyclic groups, bicyclic, bridged or spirocyclic ring systems.
  • cycloalkynyl (including those which are part of other groups) are meant cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms, which contain one or two triple bonds. Examples of these include: cyclopentynyl, cyclopentadiynyl, cyclohexynyl, cyclohexadiynyl, cycloheptynyl, cycloheptadiynyl, cyclooctynyl or cyclooctadiynyl.
  • the cycloalkynyl groups may form, in addition to monocyclic ring systems, bicyclic, bridged or spirocyclic ring systems.
  • haloalkyl (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 6 carbon atoms, wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine.
  • C 1-4 -haloalkyl are meant correspondingly branched and unbranched alkyl groups with 1 to 4 carbon atoms, wherein one or more hydrogen atoms are replaced as described above.
  • C 1-4 -haloalkyl is preferred. Examples of these include: CH 2 F, CHF 2 , CF 3 .
  • aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, for example phenyl or naphthyl, preferably phenyl, which, unless otherwise described, may have one or more substituents, for example.
  • each of the above-mentioned aryl systems may optionally be anellated to a heterocycloalkyl group or a cycloalkyl group. Examples include: 2,3-dihydro-benzo[1,4]dioxine, benzo[1,3]dioxole, 1,2,3,4-tetrahydro-naphthalene and 3,4-dihydro-1H-quinolin-2-one.
  • heterocycloalkyl groups are meant, unless otherwise described in the definitions, 5-, 6- or 7-membered, saturated or unsaturated, bridged, mono- or bicyclic heterocycles wherein up to four C atoms may be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur, for example tetrahydrofuran, tetrahydrofuranone, ⁇ -butyrolactone, ⁇ -pyran, ⁇ -pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan,
  • a heterocyclic ring may be provided with a keto group. Examples of these include.
  • Examples of 5-10-membered bicyclic heterorings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine,
  • heteroaryl examples include 5-10-membered mono- or bicyclic heteroaryl rings in which up to three C atoms may be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur, while these may contain so many conjugated double bonds that an aromatic system is formed.
  • Each of the above-mentioned heterocycles may optionally also be anellated to a benzene ring.
  • Preferred examples of anellated heteraryl groups are: benzimidazole, indole and pyrimidopyrimidine.
  • each of the above-mentioned heterocycles may optionally be anellated to a heterocycloalkyl group or a cycloalkyl group.
  • heteroaryl rings may, for example, unless otherwise described, carry one or more substituents, preferably halogen or methyl.
  • the ring may be linked to the molecule through a carbon atom or if present through a nitrogen atom.
  • Examples of 5-10-membered bicyclic heteroaryl rings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine.
  • heterocyclic spiro rings 5-10 membered, spirocyclic rings which may optionally contain one, two or three heteroatoms, selected from among oxygen, sulphur and nitrogen, while the ring may be connected to the molecule via a carbon atom or, if present, via a nitrogen atom.
  • a spirocyclic ring may be provided with a keto group. Examples include:
  • lower-molecular groups regarded as chemically meaningful are groups consisting of 1-200 atoms. Preferably such groups have no negative effect on the pharmacological efficacy of the compounds.
  • the groups may comprise:
  • ⁇ O denotes an oxygen atom linked by a double bond.
  • halogen generally denotes fluorine, chlorine, bromine or iodine.
  • the compounds according to the invention may occur in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • pharmacologically acceptable acids such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • the substituent R a may be hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl and C 3 -
  • R a may preferably be substituted by one or more, preferably one or two, groups selected from among C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, C 1 -C 4 -alkoxy, CN, NO 2 , NR 10 R 11 , OR 10 , COR 10 , COOR 10 , CONR 10 R 11 , NR 10 COR 11 , NR 10 (CO)NR 11 R 12 , O(CO)NR 10 R 11 , NR 10 (CO)OR 11 , SO 2 R 10 , SOR 10 , SO 2 NR 10 R 11 , NR 10 SO 2 NR 11 R 12 and NR 10 SO 2 R 11 , preferably C 1 -C 6 -haloalkyl, halogen and CONR 10 R 11 , particularly
  • R a denotes phenyl, substituted by one or more of the groups selected from among CF 3 , F, Cl, Br and CONHCH 3 . Also particularly preferably R a denotes butyl.
  • the substituents R 10 , R 11 , R 12 which may be identical or different, may denote hydrogen or a group selected from among
  • R 10 , R 11 , R 12 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen.
  • the substituent R b may represent hydrogen, OH or NH 2
  • C 1 -C 8 -alkyl C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl, CONH 2 , C 6 -C 14 -aryl, C 6 -C 14 -
  • C 1 -C 6 -alkyl C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, OMe, CN, NH 2 , NHMe and NMe 2 .
  • R b denotes hydrogen OH or NH 2 , or a group selected from among C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkyl, C 6 -C 14 -aryl, haloalkyl, C 5 -C 10 -heteroaryl and C 6 -C 14 -aryl-NH, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, OMe, CN, NH 2 , NHMe, NMe 2 .
  • R b denotes hydrogen
  • the substituent R 1 may represent hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl and C 6 -C 14 -aryl-C 1 -C 5 -alkyl.
  • R 1 denotes hydrogen, C 1 -C 5 -alkyl or C 3 -C 8 -cycloalkyl.
  • the substituent R 1 denotes hydrogen or a group selected from among methyl, ethyl, propyl, cyclopropyl, cyclobutyl and piperidine; particularly preferably R 1 denotes hydrogen or methyl.
  • the substituent R 1 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, COOH, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)alkyl and —(CO)O—C 1 -C 4 -alkyl.
  • the substituent R 2 may represent hydrogen or an optionally substituted group selected from among C 1 -C 8 alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 6 -alkyl, C 9 -C 13 -spiro, C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloal
  • R 2 denotes hydrogen or a group selected from among C 1 -C 5 -alkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 6 -alkyl- and C 5 -C 10 -heteroaryl-C 1 -C 6 -alkyl-.
  • R 2 denotes hydrogen or a group selected from among methyl, ethyl, propyl, butyl, pentyl, C 3 -C 6 -cycloalkyl and phenyl, particularly preferably hydrogen or methyl.
  • the substituent R 2 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among ⁇ O halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)alkyl and —(CO)O—C 1 -C 4 -alkyl.
  • the substituents R 1 and R 2 may together form an optionally substituted, five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen, preferably nitrogen.
  • the group NR 1 R 2 denotes an optionally substituted pyrrolidinyl or morpholine group.
  • the ring formed from the substituents R 1 and R 2 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among heterocycloalkyl, halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)alkyl and —(CO)O—C 1 -C 4 -alkyl.
  • the substituents R 1 and R 2 may together form an optionally substituted nine- to thirteen-membered spirocyclic ring, preferably which is preferably substituted by a group selected from among methyl, ethyl, OH, ⁇ O and phenyl.
  • the substituent R 2 may furthermore denote a group selected from among general formulae (A1) to (A18) preferably (A1), (A2), (A3), (A6), (A8), (A10), (A11), (A17) and (A18).
  • X and Y may be linked to the same or different atoms of G.
  • X may denote a bond or an optionally substituted group selected from among C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, preferably a bond, methylene and ethylene.
  • X may form together with R 1 , R 3 or R 4 a C 1 -C 7 -alkylene bridge, preferably may form a 5- or 6-membered heterocyclic group with R 1 , R 3 or R 4 , particularly preferably may form a piperidinone or pyrrolidinone ring with R 3 or R 4 , which may optionally be substituted.
  • the substituent R1 and X together preferably form a pyrrolidine or piperidine group.
  • Y may represent a bond or optionally substituted C 1 -C 4 -alkylene, preferably a bond, methylene or ethylene.
  • Q may denote an optionally substituted group selected from among C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene; preferably optionally substituted C 1 -C 3 -alkylene, particularly preferably ethyl and propyl.
  • R 1 , R 3 or R 4 may form a C 1 -C 7 -alkylene bridge.
  • R1 and Q preferably form a pyrrolidins or piperidine group.
  • R 3 , R 4 , R 5 which may be identical or different, may denote hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, NR 7 R 8 , NR 7 R 8 —C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 6 -C 14 -aryl and C 5 -C 10 -heteroaryl; preferably hydrogen, or an optionally substituted group selected from among C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy and C 3
  • Two of the substituents R 3 , R 4 , R 5 may together form an optionally substituted five-, six- or seven-membered ring, preferably a 5- or 6-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; preferably from oxygen or nitrogen.
  • the group NR 3 R 4 denotes pyrrolidine, piperidine or morpholine.
  • the substituents R 3 , R 4 , R 5 or the ring formed from them may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, NR 9 R 10 , —NH(CO)—C 1 -C 4 -alkyl and MeO.
  • A may represent N or CH, preferably N.
  • G may represent a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 4 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur.
  • G may represent a saturated, partially saturated or unsaturated ring system consisting of 3-8 C atoms, particularly preferably 5-6 C atoms, wherein optionally up to 6 C atoms, particularly preferably up to 4 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur.
  • G denotes a ring system consisting of one or two 5-6-membered rings, particularly preferably selected from among furan, cyclohexyl, cyclopropyl, phenyl, pyrrolidine, piperidine, tetrahydroquinoline, tetrahydroisoquinoline, indole, dihydroisoindole, piperazine, pyrrole, pyrazole, pyridine, imidazolidine, imidazole, thiophene, thiazole, triazole, oxazole, oxadiazole, tetrazole, morpholine, benzimidazole, benzopyrrole, benzodioxole, and dihydro-benzo[1,4]dioxine, particularly preferably furan, cyclohexyl, cyclopropyl, phenyl, pyrrolidine, piperidine, tetrahydroquinoline, tetra
  • the substituent R 6 may denote hydrogen or an optionally substituted group, selected from among C 1 -C 8 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 5 -C 10 -heteroaryl, C 3 -C 8 -heterocycloalkyl, preferably hydrogen or an optionally substituted group selected from among C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 6 -C 14 -aryl, C 5 -C 6 -heterocycloalkyl, and C 5 -C 6 -heteroaryl, particularly preferably hydrogen or an optionally substituted group selected from among C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 5 -C 6 -heteroaryl, particularly preferably
  • NR 7 R 8 preferably it denotes a group selected from among ⁇ O, NR 7 R 8 , OR 7 , —CO—C 1 -C 3 -alkyl-NR 7 R 8 , CONR 7 R 7 R 8 , NR 7 (CO)OR 8 , NR 7 COR 8 , —CO—C 1 -C 3 -alkyl-NR 7 (CO)OR 8 , NR 7 (CO)NR 8 R 9 , NR 7 (CO)OR 8 , (CO)OR 7 , COR 7 , (SO 2 )R 7 und CN, particularly preferably ⁇ O, OMe, —N Me-CO—NH—C 1 -C 3 -alkyl, —NH—CO—C 1 -C 4 -alkyl, —NH—COO—C 1 -C 4 -alkyl, —COO—C 1 -C 4 -alkyl and C 1 -C 4 -alkyl.
  • the substituent R 6 may denote hydrogen or a group selected from among ⁇ O, OH, CN, CF 3 , NH 2 , OCF 3 , NHCOMe, NHCO-butyl, NHCO-cyclopentyl, NHCOcyclopropyl, NHCO-morpholine, NHCO—NHMe, NHCO—NHpropyl, NHCO-NMeMe, NHCO-NMepropyl, NHCOpropyl, NHCO-pyrrolidine, NHSO 2 -Me, CONH 2 CONH, COOH, CONHMe, CONHpropyl, CONMe 2 , CONMe-butyl, CONMe, CONH-cyclohexyl, CONH-cyclopropyl, COO-butyl, SO 2 Me, NHSO 2 —NMeMe, NMe 2 , NMeCOMe, NMeCOObutyl, NMeMe, phenyl, methyl
  • the substituent R 6 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among ⁇ O, NH 2 , NHMe, NMe 2 , OH, OMe, CN, —C 1 -C 3 -alkyl-C 6 -C 14 -aryl, —NH—CO—NH—C 1 -C 3 -alkyl and —(CO)O—C 1 -C 4 -alkyl.
  • n denotes 1, 2 or 3, preferably 1 or 2, particularly preferably 1.
  • R 7 , R 8 , R 9 which may be identical or different, may denote hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 3 -alkyl, C 6 -C 14 -aryl, C 1 -C 4 -alkyl-C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 4 -alkyl, C 3 -C 8 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -
  • R 7 , R 8 , R 9 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; preferably an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen; particularly preferably nitrogen,
  • the substituents R 7 , R 8 , R 9 or the ring system formed therefrom may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, OMe, NHMe, NMe 2 , C 1 -C 6 -alkyl and (CO)OC 1 -C 6 -alkyl.
  • a suitable base e.g. selected from, but not restricted to, the group comprising sodium methoxide, sodium ethoxide, lithium hexamethylsilazide, sodium hydride
  • a suitable acylating reagent (V) into the intermediate compound (VI).
  • R b has the meaning given hereinbefore.
  • Rz is a suitable leaving group e.g.
  • reaction to obtain the ureas of general formula (I) or (Ia) is then carried out using one of the following methods: Direct reaction with a suitable isocyanate (XIII) leads directly to compounds of formula (Ia).
  • Reaction with a suitable reagent (XIV) leads to compounds of formula (I), wherein Rx denotes a suitable leaving group selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-attracting groups (e.g. nitro).
  • Another possibility is to react the aminothiazole (IX) with a reagent of general formula (X) to obtain an activated intermediate compound (XI).
  • Rx and Ry are identical or suitable leaving groups selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl, O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by ist suitable electron-attracting groups (e.g. nitro).
  • the intermediate compound (XI) is optionally in equilibrium with the isocyanate (XII), which may be formed by elimination of the leaving group Ry from (XI).
  • the further reaction of the intermediate compound (XI), (XII) or a mixture of the two with suitable amines of general formula (XV) leads to the desired compounds of general formula (I).
  • R 1 and R 2 have the meanings given hereinbefore. Diagram 2:
  • the intermediate compound (XVII) is obtained.
  • PG1 is a suitable nitrogen-protective group selected from, for example, but not restricted to the group comprising alkylcarbonyl-(carbamate), phthalimides, benzyl (optionally substituted e.g. p-methoxybenzyl).
  • the reagent (XVI) may be used as of one of the two possible enantiomers or as a racemate. After the protective group PG1 has been cleaved the intermediate compound (XVIII) is obtained.
  • Rx and Rv are suitable leaving groups selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-attracting groups (e.g. nitro).
  • the compounds of general formula (Ig) may also be obtained, analogously to the method described in Diagram 1, by reacting the intermediate compound (XVIII) with the reagent of formula (X) described previously and subsequently reacting the intermediate compound (XXV) obtained with suitable amines of formula (XXV).
  • R 3 and R 4 here also have the meanings described hereinbefore.
  • PG1 is a suitable nitrogen protecting group selected from, for example, but not restricted to the group comprising alkylcarbonyl-(carbamates), phthalimides, benzyl (optionally substituted e.g. p-methoxybenzyl).
  • PG1 is a suitable nitrogen protecting group selected from, for example, but not restricted to the group comprising alkylcarbonyl-(carbamates), phthalimides, benzyl (optionally substituted e.g. p-methoxybenzyl).
  • the intermediate compound (XXX) may be obtained.
  • Compounds of general formula (Ii) and (Ij) may be obtained by reacting this intermediate compound (XXX) with the reagents of formula (XXIII) or (XXIV) described hereinbefore.
  • the compounds of general formula (Ij) may also be obtained, analogously to the method described in Diagram 1, by reacting the intermediate compound (XXX) with the reagent of formula (X) described hereinbefore and subsequently reacting the intermediate compound (XXXI) obtained with suitable amines of formula (XXV).
  • R 3 and R 4 here also have the meanings described hereinbefore.
  • R 5 and R 6 have the meanings described hereinbefore.
  • the new compounds of general formula (I) may be prepared analogously to the following Examples.
  • the Examples described below are intended as an illustration of invention without restricting it.
  • LiHMDS lithium hexamethyl disilazide
  • the suspension is stirred for 1 hour at ⁇ 50° C., then within 16 hours allowed to come up to ambient temperature.
  • the reaction mixture is diluted with dichloromethane and extracted with 1 molar hydrochloric acid, 1 molar sodium carbonate solution and water.
  • the organic phase is dried and evaporated to dryness.
  • reaction mixture is stirred for 1.5 hours at ⁇ 70° C., then slowly allowed to come up to ambient temperature. It is diluted with dichloromethane and washed with 1 molar hydrochloric acid, saturated sodium carbonate solution, water and saturated sodium chloride solution. The organic phase is dried and evaporated to dryness.
  • N-hydroxy-propionamidine 2.00 g (22.70 mmol) N-hydroxy-propionamidine are placed in 10 ml dimethylformamide and molecular sieve. 0.999 g (24.97 mmol) sodium hydride
  • the intermediates (VIII.2) to (VIII.6) may also be obtained analogously by reacting the intermediate (VI.1) with the appropriate amidines (VII.2-VII.6). Synthesis of Intermediate Compound (IX.1)
  • the intermediates (IX.2) to (IX.6) may also be prepared analogously by saponification of the intermediates (VIII.2) to (VIII.6). Synthesis of Intermediate Compound (XI.1)
  • the intermediates (XI.2) to (XI.6) may also be prepared analogously by reacting the intermediates (IX.2) to (IX.6) with ethylchlorothiolformate (X.1). Synthesis of Intermediate Compound (XVII.1)
  • the intermediate compound (XVII.2) may also be obtained analogously. Synthesis of Intermediate Compound (XVIII.1)
  • the intermediate compound may also be obtained analogously (XVIII.2). Synthesis of Intermediate Compound (XXVII.1)
  • Method A column XTerra®, MS C 18 2.5 ⁇ m, 4.6 mm ⁇ 30 mm.
  • method B column Merck ChromolithTM SpeedROD RP-18e, 4.6 mm ⁇ 50 mm.
  • Method B 2.00 mL/min time (min) % L1 % L2 0.0 95 5 0.1 95 5 3.1 2 98 4.5 2 98 5.0 95 5
  • Methods C and D Waters ZMD, Alliance 2790/2795 HPLC, Waters 2700 Autosampler, Waters 996/2996 Diode array detector (wavelength range 210-500 nm).
  • Stationary phase (column temperature: constant at 40° C.): column X-Terra MS C18 4.6 ⁇ 50 mm, 3.5 ⁇ m.
  • Examples 1, 6-16, 18-153 and 264 may also be obtained analogously by reacting the appropriate intermediate products (XI.1)-(XI.6) in each case with the appropriate amines (either known from the literature or described under “Synthesis of the reagents”).
  • Examples 155-223 may also be obtained analogously by reacting the appropriate intermediate products (XI.1)-(XI.6) with the appropriate amines (either known from the literature or described under “Synthesis of the reagents”).
  • Examples 224 and 226-237 may also be obtained analogously by reacting the intermediate products (XVIII.1) with the respective appropriate carboxylic acid chlorides, sulphonic acid chlorides, carbamoyl chlorides, sulphamoyl chlorides or chloroformates.
  • Examples 279 and 280 may be prepared analogously starting from intermediate compound (XXX.1).
  • Example 239 may also be prepared analogously by reacting the intermediate products (XVIII.1) with the appropriate carboxylic acid.
  • Examples 240 and 242-249 may also be obtained analogously by reacting the intermediate compound (XVIII.2) with the respective appropriate carboxylic acid chlorides, sulphonic acid chlorides, carbamoyl chlorides, sulphamoyl chlorides or chloroformates.
  • Example 251 may also be prepared analogously by reacting the intermediate compound (XVIII.2) with the appropriate carboxylic acid.
  • Examples 253-259 may also be obtained analogously by reacting the intermediate compound (XXVII.1) with the appropriate amines.
  • Examples 261-263 and 265 may also be obtained analogously by reacting the intermediate compound (XXV.1) with the appropriate amines.
  • Examples 267-273 may also be obtained analogously by reacting the intermediate products of the intermediate compound (XVIII.1) with the respective appropriate carboxylic acids.
  • Examples 275-278 may also be obtained analogously by reacting the intermediate compound (XXX.1) with the respective appropriate carboxylic acids.
  • Examples 282-293 may also be obtained analogously by reacting the intermediate compound (XXXIII.1) with the appropriate amines.
  • Examples 295-299 may also be obtained analogously by reacting the intermediate compound (XXXI.1) with the appropriate amines.
  • Example compound 133 20 mg (0.032 mmol) of the Example compound 133 are stirred in 20 ml ethereal hydrochloric acid for 16 hours at ambient temperature. Then the precipitate is suction filtered and dried.
  • Examples 2 and 4 may be obtained from the Example compounds 132 and 135, respectively.
  • the compounds of formula (I) mentioned by way of example are characterised by an affinity for PI3-kinase, i.e. in the test by an IC50 value of below 800 nmol/litre.
  • lipid vesicles PIP 2 (0.7 ⁇ g/well), phosphatidylethanolamine (7.5 ⁇ g/well), phosphatidylserine (7.5 ⁇ g/well), sphingomyelin (0.7 ⁇ g/well) and phosphatidylcholine (3.2 ⁇ g/well)
  • PIP 2 lipid vesicles
  • phosphatidylethanolamine 7.5 ⁇ g/well
  • phosphatidylserine 7.5 ⁇ g/well
  • sphingomyelin 0.7 ⁇ g/well
  • phosphatidylcholine 3.2 ⁇ g/well
  • reaction was started by the addition of 10 ⁇ l reaction buffer (40 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM EGTA, 1 mM ⁇ -glycerophosphate, 1 mM DTT, 7 mM MgCl 2 and 0.1% BSA; 1 ⁇ M ATP and 0.2 ⁇ Ci [ ⁇ - 33 P]-ATP) and incubated for 120 min at ambient temperature.
  • the reaction solution was sucked through the filters by the application of a vacuum and washed with 200 ⁇ l PBS. After the plates had been dried at 50° C. the radioactivity remaining in the plates was determined after the addition of 50 ⁇ l scintillation liquid using a Top-Count measuring device.
  • the compounds of formula (I) are characterised by a variety of possible applications in the therapeutic field. Particular mention should be made of those applications for which the compounds of formula (I) according to the invention are preferably used by virtue of their pharmaceutical activity as PI3-kinase modulators.
  • inflammatory and allergic respiratory complaints inflammatory diseases of the gastrointestinal tract, inflammatory diseases of the motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic ailments which involve autoimmune reactions or inflammation of the kidneys.
  • the treatment may be symptomatic, adaptive, curative or preventative.
  • the compounds of formula I according to the invention may, by virtue of their pharmacological properties, bring about a reduction in
  • the compounds according to the invention are particularly preferred for preparing a medicament for the treatment of chronic bronchitis, acute bronchitis, bronchitis caused by bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive pulmonary disease (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases such as e.g.
  • pulmonary fibrosis pulmonary fibrosis, asbestosis and silicosis and alveolitis
  • hyperreactive airways nasal polyps, pulmonary oedema such as e.g. toxic pulmonary oedema and ARDS/IRDS, pneumonitis of different origins, e.g. radiation-induced or caused by aspiration or infectious pneumonitis, collagenoses such as lupus erythematodes, systemic sclerodermy, sarcoidosis or Boeck's disease.
  • the compounds of formula (I) are also suitable for the treatment of diseases of the skin, such as e.g. psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyodermy, endogenous and exogenous acne, acne rosacea and other inflammatory or allergic or proliferative skin diseases.
  • diseases of the skin such as e.g. psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, scleroder
  • the compounds of formula (I) are suitable for therapeutic use in cases of inflammatory or allergic complaints which involve autoimmune reactions, such as e.g. inflammatory bowel diseases, e.g. Crohn's disease or ulcerative colitis; diseases of the arthritis type, such as e.g. rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis.
  • autoimmune reactions such as e.g. inflammatory bowel diseases, e.g. Crohn's disease or ulcerative colitis
  • diseases of the arthritis type such as e.g. rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis.
  • Other diseases which may be treated with a drug containing compounds of formula (I) on the basis of their pharmacological activity include toxic or septic shock syndrome, atherosclerosis, middle ear infections (otitis media), hypertrophy of the heart, cardiac insufficiency, stroke, ischaemic reperfusion injury or neurodegenerative diseases such as Parkinson's disease or Alzheimer's.
  • the compounds of formula (I) may be used on their own or in combination with other active substances of formula (I). If desired the compounds of formula (I) may also be used in combination with W, where W denotes a pharmacologically active substance and (for example) is selected from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors, preferably PI3- ⁇ tilde over ( ⁇ ) ⁇ Kinase inhibitors.
  • W denotes a pharmacologically active substance and (for example) is selected from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI
  • the compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active constituents.
  • the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions.
  • the chlorides, bromides, iodides and methanesulphonates are particularly preferred.
  • corticosteroids it is preferable to use compounds selected from among prednisolone, prednisone, butixocort propionate, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, betamethasone, deflazacort, RPR-106541, NS-126, ST-26 and
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325.366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, CI-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • the dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • the PAF-antagonists used are preferably compounds selected from among
  • the PI3-kinase- ⁇ -inhibitors used are preferably compounds selected from among: IC87114, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one; 2-(6-aminopurin-o-ylmethyl)-6-bromo-3-(2-chlorophenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-o-ylmethyl)-3-(2-chlorophenyl)-7-fluoro-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-6-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one; 2-(6-a
  • the compounds according to the invention may be administered by oral, transdermal, inhalative, parenteral or sublingual route.
  • the compounds according to the invention are present as active ingredients in conventional preparations, for example in compositions consisting essentially of an inert pharmaceutical carrier and an effective dose of the active substance, such as for example tablets, coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc.
  • An effective dose of the compounds according to the invention is between 0.1 and 5000, preferably between 1 and 500, more preferably between 5-300 mg/dose for oral administration, and between 0.001 and 50, preferably between 0.1 and 10 mg/dose for intravenous. subcutaneous or intramuscular administration.
  • inhalable formulations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions.
  • propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions.
  • powders ethanolic or aqueous solutions.
  • solutions containing 0.01 to 1.0, preferably 0.1 to 0.5% active substance are suitable. It is also possible to use the compounds according to the invention as a solution for infusion, preferably in a physiological saline or nutrient saline solution.
  • the compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
  • Suitable formulations include, for example, tablets, capsules, suppositories, solutions, syrups, emulsions or dispersible powders.
  • Corresponding tablets may be obtained for example by mixing the active substance(s) with known excipients, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core may also consist of a number of layers.
  • the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • a sweetener such as saccharine, cyclamate, glycerol or sugar
  • a flavour enhancer e.g. a flavouring such as vanillin or orange extract.
  • suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • Solutions for injection are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
  • preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid
  • Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • the inhalable powders which may be used according to the invention may contain the active substance according to the invention either on its own or in admixture with suitable physiologically acceptable excipients.
  • physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, saccharose, maltose
  • oligo- and polysaccharides e.g. dextrans
  • polyalcohols e.g. sorbitol, mannitol, xylitol
  • salts e.g. sodium chloride, calcium carbonate
  • lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
  • the excipients have a maximum average particle size of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, most preferably between 15 and 80 ⁇ m. In some cases it may seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 ⁇ m to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore.
  • micronised active substances according to the invention preferably with an average particle size of 0.5 to 10 ⁇ m, more preferably from 1 to 5 ⁇ m, are added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and finally mixing the ingredients together are known from the prior art.
  • the inhalable powders according to the invention may be administered using inhalers known from the prior art.
  • Inhalation aerosols containing propellant gas according to the invention may contain active substances according to the invention dissolved in the propellant gas or in dispersed form.
  • the propellant gases which may be used to prepare the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the above-mentioned propellant gases may be used on their own or in admixture. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
  • the propellant-driven inhalation aerosols may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
  • the active substances according to the invention may be administered in the form of propellant-free inhalable solutions and suspensions.
  • the solvent used may be an aqueous or alcoholic, preferably an ethanolic solution.
  • the solvent may be water on its own or a mixture of water and ethanol.
  • the relative proportion of ethanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of water.
  • the solutions or suspensions containing the active substance according to the invention are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids.
  • the pH may be adjusted using acids selected from inorganic or organic acids.
  • Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
  • Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc.
  • Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred.
  • mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example.
  • editic acid or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent may optionally be omitted in these formulations.
  • Other embodiments may contain this compound or these compounds.
  • the content based on sodium edetate is less than 100 mg/100 ml, preferably less than 50 mg/100 ml, more preferably less than 20 mg/100 ml.
  • inhalable solutions in which the content of sodium edetate is from 0 to 10 mg/100 ml are preferred.
  • Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols—particularly isopropyl alcohol, glycols—particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation.
  • these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect.
  • the excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
  • the additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
  • the preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
  • Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • the preservatives mentioned above are preferably present in concentrations of up to 50 mg/100 ml, more preferably between 5 and 20 mg/100 ml.
  • Preferred formulations contain, in addition to the solvent water and the active substance according to the invention, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is present.
  • a therapeutically effective daily dose is between 1 and 2000 mg, preferably 10-500 mg per adult.
  • the active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water.
  • the moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen.
  • convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine.
  • the tablet cores thus produced are coated in a known manner with a covering consisting essentially of sugar and talc.
  • the finished coated tablets are polished with wax D)
  • the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
  • the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
  • the ampoules contain 5 mg, 25 mg and 50 mg of active substance.
  • Distilled water is heated to 70° C. Hydroxyethyl-cellulose is dissolved therein with stirring. After the addition of sorbitol solution and glycerol the mixture is cooled to ambient temperature. At ambient temperature, sorbic acid, flavouring and substance are added. To eliminate air from the suspension it is evacuated with stirring.
  • the suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 ⁇ l of suspension are delivered per spray.
  • the active substance may also be metered in higher doses if desired.
  • Metered-dose aerosol (solution) active substance 0.3 wt. %. % abs. ethanol 20 wt. % aqueous HCl 0.01 mol/l 2.0 wt. % HFA134A 77.7 wt. %
  • the powder for inhalation is produced in the usual way by mixing the individual ingredients together.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are compounds of general formula (I),
Figure US20070238746A1-20071011-C00001
wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Description

  • This application claims priority benefit to EP 06112296, filed Apr. 6, 2006, the entirety of which is incorporated herein.
  • The present invention relates to new thiazolyl-dihydro-quinazolines of general formula (I)
    Figure US20070238746A1-20071011-C00002
    wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.
    • BACKGROUND TO THE INVENTION
  • Phosphatidylinositol-3-kinases (PI3-kinases) are a subfamily of the lipid kinases which catalyse the transfer of a phosphate group to the 3′-position of the inositol ring of phosphoinositides.
  • They have a role in numerous cell processes such as e.g. cell growth and differentiation processes, the control of cytoskeletal changes and the regulation of intracellular transport processes (Vanhaesebroeck et al., Annu Rev Biochem. 2001; 70:535-602).
  • PI3-kinases may play a part in numerous tumours, such as e.g. breast cancer, ovarian or pancreatic carcinoma, in tumour types such as carcinomas of the colon, breast or lungs, but particularly in autoimmune diseases such as Crohn's disease or rheumatoid arthritis, for example, or in the cardiovascular system, e.g. in the development of cardiac hypertrophy (Oudit et al., Circulation. 2003 Oct. 28; 108(17):2147-52). PI3-kinase modulators may represent a possible method of anti-inflammatory therapy with comparatively minor side effects (Ward and Finan, Curr Opin Pharmacol. 2003 August; 3(4):426-34).
  • PI3-kinase inhibitors for treating inflammatory diseases are known in the literature. Thus, WO 03/072557 discloses 5-phenylthiazole derivatives, WO 04/029055 discloses annelated azolpyrimidines and WO 04/007491 discloses azolidinone-vinyl linked benzene derivatives. Moreover, the two specifications WO 04/052373 and WO 04/056820 disclose benzoxazine and benzoxazin-3-one derivatives.
  • The aim of the present invention is to provide new compounds which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used therapeutically for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory and allergic skin complaints, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic illnesses which involve autoimmune reactions or kidney inflammation.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Surprisingly it has been found that the above problem is solved by means of compounds of formula (I), wherein A and the groups R1, R2, Ra and Rb have the meanings given hereinafter.
  • It has been found, in particular, that compounds of formula (I) act as inhibitors of PI3-kinase, particularly as inhibitors of PI3-kinase gamma. Thus the compounds according to the invention may be used for example for the treatment of respiratory complaints.
  • The present invention therefore relates to compounds of general formula (I),
    Figure US20070238746A1-20071011-C00003
    wherein
    • A denotes N or CH;
    • Ra denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl and C3-C8-heterocycloalkyl-C1-C4-alkyl,
    • Rb denotes hydrogen, OH or NH2
      • or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl, CONH2, C6-C14-aryl-NH, C3-C8-heterocycloalkyl-NH— and O—C1-C3-alkyl,
    • R1 denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl and C6-C14-aryl-C1-C5-alkyl-;
      • or
    • R2 denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C6-alkyl, C9-C13-spiro, C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C6-C14-aryl-C1-C6-alkyl-;
      • or
    • R1 and R2 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen.
      • or
    • R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
      • or
    • R2 denotes a group selected from among general formulae (A1) to (A18)
      Figure US20070238746A1-20071011-C00004
      Figure US20070238746A1-20071011-C00005
      wherein
    • X and Y may be linked to the same or different atoms of G, and
    • X denotes a bond or an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene,
      • or
    • X together with R1, R3 or R4 may form a C1-C7-alkylene bridge;
    • Y denotes a bond or optionally substituted C1-C4-alkylene;
    • Q denotes an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene, or
    • Q together with R1, R3 or R4 may form a C1-C7-alkylene bridge;
    • R3, R4, R5 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, NR7R8, NR7R8—C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, C6-C14-aryl and C5-C10-heteroaryl;
      • or in each case two of the substituents
    • R3, R4, R5 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
    • G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;
    • R6 which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C1-C8-alkyl, C2-C6-alkenyl C3-C8-cycloalkyl, C2-C6-haloalkyl, C6-C14-aryl, C5-C10-heteroaryl and C3-C8-heterocycloalkyl,
      • or
      • a group selected from among NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8—O—C1-C3-alkyl-NR7R8, CONR7R8, NR7COR8, —CO—C1-C3-alkyl-NR7(CO)OR8, —O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, —O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl and halogen;
    • n denotes 1, 2 or 3
    • R7, R8, R9 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, C6-C14-aryl, C1-C4-alkyl-C6-C14-aryl, C6-C14-aryl-C1-C4-alkyl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C4-alkyl, C1-C4-alkyl (CO)— and C1-C4-alkyl-O(CO)—;
      • or in each case two of the substituents
    • R7, R8, R9 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
      • optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, as well as optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof,
      • with the proviso that the following compounds are excluded:
    • a) 8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • b) 1-methyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • c) 1,1-dimethyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • d) 1-(2-dimethylamino-ethyl)-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • e) 4-methyl-piperazine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
    • f) piperidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
    • g) pyrrolidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
    • h) 1-methyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • i) (8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
    • j) 1,1-dimethyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea and
    • k) [8-(2-methoxy-phenyl)-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl]-urea and
    • l) morpholine-4-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide.
  • Preferred are compounds of formula (I), wherein
    • X, Y, Q and G may have the meaning specified and
    • A denotes N,
    • Ra denotes hydrogen or a group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl and C3-C8-heterocycloalkyl-C1-C4-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among
      • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C2-C6-alkynyl-NR5R6, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, C1-C4-alkoxy, CN, NO2, NR10R11, OR10, COR10, COOR10, CONR10R11, NR10COR11, NR10(CO)NR11R12, O(CO)NR10R11, NR10(CO)OR11, SO2R10, SOR10, SO2NR10R11, NR10SO2NR11R12 and NR10SO2R11;
      • or Ra is optionally substituted by a group of general formula (B)
        Figure US20070238746A1-20071011-C00006
      • wherein,
      • R13 to R16 which may be identical or different, represent hydrogen or C1-C6-alkyl,
      • or two of the substituents
      • R13 to R16 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
    • R10, R11, R12 which may be identical or different, denote hydrogen or a group selected from among
      • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl and C1-C6 haloalkyl;
      • or
      • in each case two of the groups
    • R10, R11, R12 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
    • Rb denotes hydrogen, OH or NH2
      • or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl, CONH2, C6-C14-aryl-NH, C3-C8-heterocycloalkyl-NH— and O—C1-C3-alkyl,
      • which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among
      • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, OMe, CN, NH2, NHMe and NMe2;
    • R1 denotes hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl and C6-C14-aryl-C1-C5-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, COOH, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)-alkyl and —(CO)O-alkyl,
    • R2 denotes hydrogen or a group selected from among C1-C8 alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C6-alkyl, C9-C13-spiro, C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C6-C14-aryl-C1-C6-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)-alkyl, ═O, COOH and —(CO)O-alkyl.
      • or
    • R1 and R2 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)—C1-C4-alkyl, and —(CO)O—C1-C4-alkyl.
      • or
    • R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
      • or
    • R2 denotes a group selected from among general formulae (A1) to (A18)
      Figure US20070238746A1-20071011-C00007
      Figure US20070238746A1-20071011-C00008
      wherein
    • R3, R4, R5 which may be identical or different, denote hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, NR7R8, NR7R8—C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, C6-C14-aryl and C5-C10-heteroaryl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, NR9R10, —NH(CO)—C1-C4-alkyl and MeO,
      • or in each case two of the substituents
    • R3, R4, R5 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, NR9R10, —NH(CO)—C1-C4-alkyl and MeO,
    • R6 which may be identical or different, denote hydrogen or a group, selected from among C1-C8-alkyl, C2-C6-alkenyl C3-C8-cycloalkyl, C2-C6-haloalkyl, C6-C1-4-aryl, C5-C10-heteroaryl and C3-C8-heterocycloalkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among NH2, NHMe, NMe2, OH, OMe, CN, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl, C1-C6-alkyl and —(CO)O—C1-C6-alkyl
      • or
      • a group selected from among ═O, NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8—O—C1-C3-alkyl-NR7R8, CONR7R8, NR7COR8, —CO—C1-C3-alkyl-NR7(CO)OR8, —O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, —O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN and halogen;
    • n denotes 1, 2 or 3
    • R7, R8, R9 which may be identical or different, denote hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, C6-C14-aryl, C1-C4-alkyl-C6-C14-aryl, C6-C14-aryl-C1-C4-alkyl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C4-alkyl, C1-C4-alkyl(CO)— and C1-C4-alkyl-O(CO), which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, OMe, NHMe, NMe2, C1-C6-alkyl and (CO)O C1-C6-alkyl,
      • or in each case two of the substituents
    • R7, R8, R9 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, OMe, NH Me, NMe2, C1-C6-alkyl and (CO)OC1-C6-alkyl.
  • Also preferred are compounds of formula (I), wherein
  • A, Ra and R1 to R16 may have the meaning specified and
    • Rb denotes hydrogen.
  • Also preferred are compounds of formula (I), wherein
  • R1 to R16 may have the meaning specified and
    • Ra denotes C6-C14-aryl or C1-C6-alkyl
      • wherein Ra may optionally be substituted by one or more of the groups, which may be identical or different, selected from among
      • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, C1-C4-alkoxy, CN, NO2, NR10R11, OR10, COR10, COOR10, CONR10R11, NR10COR11, NR10(CO)NR11R12, O(CO)NR10R11, NR10(CO)OR11, SO2R10, SOR10, SO2NR10R11, NR10SO2NR11R12 and NR10SO2R11;
      • and
    • Rb denotes hydrogen.
  • Also preferred are compounds of formula (I), wherein
    • A, Ra and Rb may have the meaning specified and
    • R1 denotes hydrogen, C1-C5-alkyl or C3-C8-cycloalkyl,
    • R2 denotes hydrogen, C1-C5-alkyl or C3-C8-cycloalkyl, phenyl
      • or
    • R1 and R2 together form an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1 to 2 nitrogen atoms,
      • or
    • R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
      • or
    • R1, R2 which may be identical or different, denote a group selected from among general formulae (A1)-A(17),
      • wherein
    • X denotes a bond or an optionally substituted C1-C3-alkylene,
      • or
    • X together with R1, R3 or R4 may form a C1-7 alkylene bridge;
    • Q denotes an optionally substituted C1-C3-alkylene,
    • Q together with R1, R3 or R4 may form a C1-C7— alkylene bridge;
    • R3, R4, R5 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C4-alkyl, C1-C4-alkoxy, C3-C6-cycloalkyl, C3-C8-heterocycloalkyl, —C1-C3-alkyl-C3-C6-cycloalkyl, phenyl and C5-C10-heteroaryl
      • or in each case two of the substituents
    • R3, R4, R5 together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.
  • Particularly preferred are compounds of formula (I), wherein
    • A, Ra and Rb may have the meaning specified and
    • R1 denotes H, Me
    • R2 denotes hydrogen or a group of general formulae (A18),
      • wherein
    • X denotes a bond or an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene,
      • or
    • X together with R1 may form a C1-7-alkylene bridge;
    • Y denotes a bond or methylene, ethylene;
    • X and Y may be linked to the same or different atoms of G, and
    • G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;
    • R6 which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C1-C4-alkyl, C2-C6-alkenyl, C3-C6-cycloalkyl, C6-C14-aryl, C5-C6-heterocycloalkyl, and C5-C6-heteroaryl
      • or
      • a group selected from among NR7R8, OR7, —O—C1-C3-alkyl-NR7R8, CONR7R8, CO—C1-C3-alkyl-NR7R8NR7COR8, NR7(CO)OR8, —CO—C1-C3-alkyl-NR7(CO)OR8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, COR7, (SO2)R7, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl and CN,
    • n denotes 1 or 2
    • R7, R8, R9 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C5-alkyl, C1-C4-alkyl-C6-C14-aryl, C3-C6-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl and C3-C6-cycloalkyl,
      • or in each case two of the substituents
    • R7, R8, R9 together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.
  • The invention further relates to compounds of formula (I) for use as pharmaceutical compositions.
  • The invention further relates to the use of the compounds of formula (I) for preparing a pharmaceutical composition for the treatment of diseases in whose pathology an activity of PI3-kinases is implicated, wherein therapeutically effective doses of the compounds of formula (I) may confer a therapeutic benefit.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory and allergic diseases of the airways.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease, which is selected from among chronic bronchitis, bronchitis caused by bacterial or viral infections or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha1-antitrypsin deficiency, coughing, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary oedema, pneumonitis of various causes, such as radiation-induced or caused by aspiration or infection, collagenoses such as lupus erythematodes, systemic scleroderma, sarcoidosis and Boeck's disease.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory and allergic diseases of the skin.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among psoriasis, contact dermatitis, atopical dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyoderma, endogenous and exogenous acne, acne rosacea and other inflammatory and allergic or proliferative skin complaints.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammation of the eye.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment a disease which is selected from among conjunctivitis of various kinds, such as e.g. caused by fungal or bacterial infections, allergic conjunctivitis, irritable conjunctivitis, conjunctivitis caused by drugs, keratitis and uveitis.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of diseases of the nasal mucosa.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease, which is selected from among allergic rhinitis, allergic sinusitis and nasal polyps.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of inflammatory or allergic conditions involving autoimmune reactions.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among Crohn's disease, ulcerative colitis, systemic lupus erythematodes, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatric arthritis, osteoarthritis, rheumatoid spondylitis.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of kidney inflammation.
  • The invention further relates to the use of the compounds of formula (I), for preparing a pharmaceutical composition for the treatment of a disease which is selected from among glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome.
  • Of particular importance according to the invention is a pharmaceutical formulation containing a compound of formula (I).
  • Preferred is an inhaled pharmaceutical formulation containing a compound of formula (I).
  • Also preferred is an orally administered pharmaceutical formulation containing a compound of formula (I).
  • Terms and Definitions Used
  • By alkyl groups as well as alkyl groups which are part of other groups are meant branched and unbranched alkyl groups with 1 to 10 carbon atoms, preferably 1-6, particularly preferably 1-4 carbon atoms, are meant for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. Unless stated otherwise, the above terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl include all the possible isomeric forms. For example the term propyl includes the two isomeric groups n-propyl and iso-propyl, the term butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl, the term pentyl includes isopentyl, neopentyl etc. In the above-mentioned alkyl groups, unless otherwise specified, one or more hydrogen atoms may be replaced by other groups. For example these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine. The substituents fluorine or chlorine are preferred. It is also possible for all the hydrogen atoms of the alkyl group to be replaced.
  • By alkyl bridge is meant, unless stated otherwise, branched and unbranched double-bonded alkyl groups with 4 to 7 carbon atoms, for example, n-butylene, iso-butylene, sec. butylene and tert.-butylene, pentylene, iso-pentylene, neopentylene, etc. bridges. Particularly preferred are n-butylene or n-pentylene bridges. In the above-mentioned alkyl bridges 1 to 2 C atoms may optionally be replaced by one or more heteroatoms selected from among oxygen or sulphur.
  • By the term “C1-6-alkylene” (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 to 6 carbon atoms and by the term “C1-4-alkylene” are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms. Preferred are alkylene groups with 1 to 4 carbon atoms. Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene or hexylene. Unless stated otherwise, the definitions propylene, butylene, pentylene and hexylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example, propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene.
  • Examples of alkenyl groups (including those which are part of other groups) are branched and unbranched alkenyl groups with 2 to 10 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond. Examples include: ethenyl, propenyl, butenyl, pentenyl etc. Unless stated otherwise, the above-mentioned terms propenyl, butenyl etc. include all the possible isomeric forms. For example the term butylene includes n-butenyl, 1-methylpropenyl, 2-methylpropenyl, 1,1-dimethylethenyl, 1,2-dimethylethenyl etc.
  • In the above-mentioned alkenyl groups, unless otherwise stated, optionally one or more hydrogen atoms may optionally be replaced by other groups. For example these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine. The substituents fluorine and chlorine are preferred. Particularly preferred is the substituent chlorine. Optionally all the hydrogen atoms of the alkenyl group may be replaced.
  • By the term “C2-6-alkenylene” (including those which are part of other groups) are meant branched and unbranched alkenylene groups with 2 to 6 carbon atoms and by the term “C2-4-alkenylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Alkenylene groups with 2 to 4 carbon atoms are preferred. Examples include: ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene or hexenylene. Unless stated otherwise, the definitions propenylene, butenylene, pentenylene and hexenylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example, propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene.
  • Examples of alkynyl groups (including those which are part of other groups) are branched and unbranched alkynyl groups with 2 to 10 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
  • Preferred are alkynyl groups with 2 to 4 carbon atoms. Examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl. Unless stated otherwise, the definitions propynyl, butynyl, pentynyl and hexynyl include all the possible isomeric forms of the groups in question. Thus, for example propynyl includes 1-propynyl and 2-propynyl, butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl etc.
  • In the above-mentioned alkynyl groups one or more hydrogen atoms may optionally be substituted by other groups unless stated otherwise. For example these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine. The substituents fluorine and chlorine are preferred. Optionally all the hydrogen atoms of the alkynyl group may be replaced.
  • By the term “C2-6-alkynylene” (including those which are part of other groups) are meant branched and unbranched alkynylene groups with 2 to 6 carbon atoms and by the term “C2-4-alkynylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Preferred are alkynylene groups with 2 to 4 carbon atoms. Examples include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene or hexynylene. Unless stated otherwise, the definitions propynylene, butynylene, pentynylene and hexynylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene.
  • By cycloalkyl groups (including those which are part of other groups) are meant saturated cycloalkyl groups with 3-8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the above-mentioned cycloalkyl groups may optionally carry one or more substituents or be anellated to a benzene ring. Moreover the cycloalkyl groups may form, in addition to monocyclic groups, bicyclic, bridged or spirocyclic ring systems.
  • By cycloalkenyl (including those which are part of other groups) are meant cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms, which contain one or two double bonds. Examples include: cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl or cyclooctadienyl. Moreover the cycloalkenyl groups may form, in addition to monocyclic groups, bicyclic, bridged or spirocyclic ring systems.
  • By cycloalkynyl (including those which are part of other groups) are meant cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms, which contain one or two triple bonds. Examples of these include: cyclopentynyl, cyclopentadiynyl, cyclohexynyl, cyclohexadiynyl, cycloheptynyl, cycloheptadiynyl, cyclooctynyl or cyclooctadiynyl. Moreover the cycloalkynyl groups may form, in addition to monocyclic ring systems, bicyclic, bridged or spirocyclic ring systems.
  • By haloalkyl (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 6 carbon atoms, wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine. By the term “C1-4-haloalkyl” are meant correspondingly branched and unbranched alkyl groups with 1 to 4 carbon atoms, wherein one or more hydrogen atoms are replaced as described above. C1-4-haloalkyl is preferred. Examples of these include: CH2F, CHF2, CF3.
  • The term aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, for example phenyl or naphthyl, preferably phenyl, which, unless otherwise described, may have one or more substituents, for example. Moreover each of the above-mentioned aryl systems may optionally be anellated to a heterocycloalkyl group or a cycloalkyl group. Examples include: 2,3-dihydro-benzo[1,4]dioxine, benzo[1,3]dioxole, 1,2,3,4-tetrahydro-naphthalene and 3,4-dihydro-1H-quinolin-2-one.
  • By heterocycloalkyl groups are meant, unless otherwise described in the definitions, 5-, 6- or 7-membered, saturated or unsaturated, bridged, mono- or bicyclic heterocycles wherein up to four C atoms may be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur, for example tetrahydrofuran, tetrahydrofuranone, γ-butyrolactone, α-pyran, γ-pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazine, tetrahydro-oxazinyl, isothiazole, pyrazolidine, preferably pyrazolyl, pyrrolidinyl, piperidinyl, piperazinyl or tetrahydro-oxazinyl, while the heterocycle may optionally be substituted, preferably by fluorine or methyl. The ring may be linked to the molecule through a carbon atom or if available through a nitrogen atom.
  • Unless otherwise mentioned, a heterocyclic ring may be provided with a keto group. Examples of these include.
    Figure US20070238746A1-20071011-C00009
  • Examples of 5-10-membered bicyclic heterorings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine,
    Figure US20070238746A1-20071011-C00010
  • Examples of heteroaryl include 5-10-membered mono- or bicyclic heteroaryl rings in which up to three C atoms may be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur, while these may contain so many conjugated double bonds that an aromatic system is formed. Each of the above-mentioned heterocycles may optionally also be anellated to a benzene ring. Preferred examples of anellated heteraryl groups are: benzimidazole, indole and pyrimidopyrimidine. Moreover each of the above-mentioned heterocycles may optionally be anellated to a heterocycloalkyl group or a cycloalkyl group.
  • The heteroaryl rings may, for example, unless otherwise described, carry one or more substituents, preferably halogen or methyl.
  • The ring may be linked to the molecule through a carbon atom or if present through a nitrogen atom. The following are examples of five- or six-membered heterocyclic aromatic groups:
    Figure US20070238746A1-20071011-C00011
  • Examples of 5-10-membered bicyclic heteroaryl rings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine.
  • By the term heterocyclic spiro rings (“spiro”) are meant 5-10 membered, spirocyclic rings which may optionally contain one, two or three heteroatoms, selected from among oxygen, sulphur and nitrogen, while the ring may be connected to the molecule via a carbon atom or, if present, via a nitrogen atom. Unless otherwise stated, a spirocyclic ring may be provided with a keto group. Examples include:
    Figure US20070238746A1-20071011-C00012
  • By the term “optionally substituted” is meant, unless stated otherwise, within the scope of the invention the above-mentioned group, optionally substituted by a lower-molecular group. Examples of lower-molecular groups regarded as chemically meaningful are groups consisting of 1-200 atoms. Preferably such groups have no negative effect on the pharmacological efficacy of the compounds. For example the groups may comprise:
      • Straight-chain or branched carbon chains, optionally interrupted by heteroatoms, optionally substituted by rings, heteroatoms or other common functional groups.
      • Aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms, which may in turn be substituted by functional groups.
      • A number of aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms which may be linked by one or more carbon chains, optionally interrupted by heteroatoms, optionally substituted by heteroatoms or other common functional groups.
  • “═O” denotes an oxygen atom linked by a double bond.
  • The term halogen generally denotes fluorine, chlorine, bromine or iodine.
  • The compounds according to the invention may occur in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • Where a hyphen open on one side “-” is used in the structural formula of a substituent, this hyphen is to be understood as the linkage point to the remainder of the molecule. The substituent replaces the corresponding groups R2, R6, etc. If no hyphen open on one side is used in the structural formula of a substituent, the linkage point to the remainder of the molecule is clear from the structural formula itself.
  • The substituent Ra may be hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl and C3-C8-heterocycloalkyl-C1-C4-alkyl, preferably phenyl,
  • wherein Ra may preferably be substituted by one or more, preferably one or two, groups selected from among C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, C1-C4-alkoxy, CN, NO2, NR10R11, OR10, COR10, COOR10, CONR10R11, NR10COR11, NR10(CO)NR11R12, O(CO)NR10R11, NR10(CO)OR11, SO2R10, SOR10, SO2NR10R11, NR10SO2NR11R12 and NR10SO2R11, preferably C1-C6-haloalkyl, halogen and CONR10R11, particularly preferably CF3, F, Cl, Br and CONHCH3.
  • Particularly preferably Ra denotes phenyl, substituted by one or more of the groups selected from among CF3, F, Cl, Br and CONHCH3. Also particularly preferably Ra denotes butyl.
  • The substituents R10, R11, R12, which may be identical or different, may denote hydrogen or a group selected from among
  • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl and C1-C6 haloalkyl; or
  • in each case two of the groups
  • R10, R11, R12 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen.
  • The substituent Rb may represent hydrogen, OH or NH2
  • or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl, CONH2, C6-C14-aryl-NH, C3-C8-heterocycloalkyl-NH— and O—C1-C3-alkyl, which is preferably unsubstituted or substituted by one or more of the groups, which may be identical or different, selected from among
  • C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, OMe, CN, NH2, NHMe and NMe2.
  • Preferably Rb denotes hydrogen OH or NH2, or a group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C6-C14-aryl, haloalkyl, C5-C10-heteroaryl and C6-C14-aryl-NH, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, OMe, CN, NH2, NHMe, NMe2.
  • Particularly preferably Rb denotes hydrogen.
  • The substituent R1 may represent hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl and C6-C14-aryl-C1-C5-alkyl. Preferably R1 denotes hydrogen, C1-C5-alkyl or C3-C8-cycloalkyl. Particularly preferably the substituent R1 denotes hydrogen or a group selected from among methyl, ethyl, propyl, cyclopropyl, cyclobutyl and piperidine; particularly preferably R1 denotes hydrogen or methyl.
  • The substituent R1 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, COOH, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)alkyl and —(CO)O—C1-C4-alkyl.
  • The substituent R2 may represent hydrogen or an optionally substituted group selected from among C1-C8 alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C6-alkyl, C9-C13-spiro, C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C6-C14-aryl-C1-C6-alkyl-. Preferably R2 denotes hydrogen or a group selected from among C1-C5-alkyl, C3-C8-cycloalkyl-C1-C4-alkyl, C6-C14-aryl-C1-C5-alkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C5-C10-heteroaryl-C1-C6-alkyl-. Particularly preferably R2 denotes hydrogen or a group selected from among methyl, ethyl, propyl, butyl, pentyl, C3-C6-cycloalkyl and phenyl, particularly preferably hydrogen or methyl.
  • The substituent R2 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among ═O halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)alkyl and —(CO)O—C1-C4-alkyl.
  • The substituents R1 and R2 may together form an optionally substituted, five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen, preferably nitrogen. Particularly preferably the group NR1R2 denotes an optionally substituted pyrrolidinyl or morpholine group.
  • The ring formed from the substituents R1 and R2 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among heterocycloalkyl, halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)alkyl and —(CO)O—C1-C4-alkyl.
  • The substituents R1 and R2 may together form an optionally substituted nine- to thirteen-membered spirocyclic ring, preferably
    Figure US20070238746A1-20071011-C00013
    which is preferably substituted by a group selected from among methyl, ethyl, OH, ═O and phenyl.
  • The substituent R2 may furthermore denote a group selected from among general formulae (A1) to (A18)
    Figure US20070238746A1-20071011-C00014
    Figure US20070238746A1-20071011-C00015
    preferably (A1), (A2), (A3), (A6), (A8), (A10), (A11), (A17) and (A18).
  • X and Y may be linked to the same or different atoms of G.
  • X may denote a bond or an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene, preferably a bond, methylene and ethylene.
  • X may form together with R1, R3 or R4 a C1-C7-alkylene bridge, preferably may form a 5- or 6-membered heterocyclic group with R1, R3 or R4, particularly preferably may form a piperidinone or pyrrolidinone ring with R3 or R4, which may optionally be substituted. The substituent R1 and X together preferably form a pyrrolidine or piperidine group.
  • Y may represent a bond or optionally substituted C1-C4-alkylene, preferably a bond, methylene or ethylene.
  • Q may denote an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene; preferably optionally substituted C1-C3-alkylene, particularly preferably ethyl and propyl.
  • Q together with R1, R3 or R4 may form a C1-C7-alkylene bridge. R1 and Q preferably form a pyrrolidins or piperidine group.
  • The substituents R3, R4, R5 which may be identical or different, may denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, NR7R8, NR7R8—C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, C6-C14-aryl and C5-C10-heteroaryl; preferably hydrogen, or an optionally substituted group selected from among C1-C4-alkyl, C1-C4-alkoxy and C3-C6-cycloalkyl, particularly preferably hydrogen, methyl, methoxy, ethoxy, propyloxy, butyloxy, cyclopropyl and cyclopentyl.
  • Two of the substituents R3, R4, R5 may together form an optionally substituted five-, six- or seven-membered ring, preferably a 5- or 6-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; preferably from oxygen or nitrogen. Preferably the group NR3R4 denotes pyrrolidine, piperidine or morpholine.
  • The substituents R3, R4, R5 or the ring formed from them may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, NR9R10, —NH(CO)—C1-C4-alkyl and MeO.
  • A may represent N or CH, preferably N.
  • G may represent a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 4 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur. Preferably G may represent a saturated, partially saturated or unsaturated ring system consisting of 3-8 C atoms, particularly preferably 5-6 C atoms, wherein optionally up to 6 C atoms, particularly preferably up to 4 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur. Preferably G denotes a ring system consisting of one or two 5-6-membered rings, particularly preferably selected from among furan, cyclohexyl, cyclopropyl, phenyl, pyrrolidine, piperidine, tetrahydroquinoline, tetrahydroisoquinoline, indole, dihydroisoindole, piperazine, pyrrole, pyrazole, pyridine, imidazolidine, imidazole, thiophene, thiazole, triazole, oxazole, oxadiazole, tetrazole, morpholine, benzimidazole, benzopyrrole, benzodioxole, and dihydro-benzo[1,4]dioxine, particularly preferably furan, cyclohexyl, cyclopropyl, phenyl, pyrrolidine, piperidine, tetrahydroquinoline, tetrahydroisoquinoline, dihydroisoindole, pyrrole, pyrazole, pyridine, imidazolidine, imidazole, thiophene, thiazole, oxazole, oxadiazole, tetrazole, morpholine, benzimidazole, benzodioxole and dihydro-benzo[1,4]dioxine.
  • The substituent R6, which may be identical or different, may denote hydrogen or an optionally substituted group, selected from among C1-C8-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C6-C14-aryl, C5-C10-heteroaryl, C3-C8-heterocycloalkyl, preferably hydrogen or an optionally substituted group selected from among C1-C4-alkyl, C3-C6-cycloalkyl, C6-C14-aryl, C5-C6-heterocycloalkyl, and C5-C6-heteroaryl, particularly preferably hydrogen or an optionally substituted group selected from among C1-C4-alkyl, C3-C6-cycloalkyl, C5-C6-heterocycloalkyl, C5-C6-heteroaryl and phenyl, or
  • denotes a group selected from among ═O, NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8, —O—C1-C3-alkyl-NR7R8, CONR7R7R8, NR7COR8, NR7(CO)OR8, —CO—C1-C3-alkyl-NR7(CO)OR8, —O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, —O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN and halogen;
  • preferably it denotes a group selected from among ═O, NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8, CONR7R7R8, NR7(CO)OR8, NR7COR8, —CO—C1-C3-alkyl-NR7(CO)OR8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, COR7, (SO2)R7und CN, particularly preferably ═O, OMe, —N Me-CO—NH—C1-C3-alkyl, —NH—CO—C1-C4-alkyl, —NH—COO—C1-C4-alkyl, —COO—C1-C4-alkyl and C1-C4-alkyl.
  • Particularly preferably the substituent R6 may denote hydrogen or a group selected from among ═O, OH, CN, CF3, NH2, OCF3, NHCOMe, NHCO-butyl, NHCO-cyclopentyl, NHCOcyclopropyl, NHCO-morpholine, NHCO—NHMe, NHCO—NHpropyl, NHCO-NMeMe, NHCO-NMepropyl, NHCOpropyl, NHCO-pyrrolidine, NHSO2-Me, CONH2 CONH, COOH, CONHMe, CONHpropyl, CONMe2, CONMe-butyl, CONMe, CONH-cyclohexyl, CONH-cyclopropyl, COO-butyl, SO2Me, NHSO2—NMeMe, NMe2, NMeCOMe, NMeCOObutyl, NMeMe, phenyl, methyl, ethyl, propyl, butyl, methoxy, phenyl, oxazolidine, morpholine, imidazole, imidazolidine, pyrazole, piperazine, piperidine, pyrimidine, pyrrolidine, pyrrolidine-CO, cyclopropyl, cyclopentyl and cyclohexyl.
  • The substituent R6 may preferably be substituted by one or more of the groups, which may be identical or different, selected from among ═O, NH2, NHMe, NMe2, OH, OMe, CN, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl and —(CO)O—C1-C4-alkyl.
  • n denotes 1, 2 or 3, preferably 1 or 2, particularly preferably 1.
  • The substituents R7, R8, R9 which may be identical or different, may denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, C6-C14-aryl, C1-C4-alkyl-C6-C14-aryl, C6-C14-aryl-C1-C4-alkyl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C4-alkyl, C1-C4-alkyl(CO)— and C1-C4-alkyl-O(CO)—; preferably C1-C4-alkyl, C1-C2-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, phenyl, C1-C4-alkyl-C6-C14-aryl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C1-C4-alkyl(CO)— and C1-C4-alkyl-O(CO), particularly preferably C1-C5-alkyl, C1-C4-alkyl-C6-C14-aryl, C3-C6-heterocycloalkyl and C1-C5-alkyl-C3-C8-heterocycloalkyl,
  • or in each case two of the substituents R7, R8, R9 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; preferably an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen; particularly preferably nitrogen,
  • The substituents R7, R8, R9 or the ring system formed therefrom may preferably be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, OMe, NHMe, NMe2, C1-C6-alkyl and (CO)OC1-C6-alkyl.
  • Preparation Processes
  • The compounds of general formula (I) may be prepared according to the following synthesis schemes (Diagrams 1-5), wherein the substituents of general formula (I) have the above-mentioned meanings. These processes are intended as an illustration of the invention without restricting it to their content.
    Diagram 1:
    Figure US20070238746A1-20071011-C00016
  • By deprotonation of the intermediate compound (IV) with a suitable base e.g. selected from, but not restricted to, the group comprising sodium methoxide, sodium ethoxide, lithium hexamethylsilazide, sodium hydride, it is converted with a suitable acylating reagent (V) into the intermediate compound (VI). Rb has the meaning given hereinbefore. Rz is a suitable leaving group e.g. selected from, but not restricted to, the group comprising halogen, S-alkyl, S-aryl, O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-attracting groups (e.g. nitro). By reacting with a suitable amidine (VII) or one of the salts thereof the intermediate compound (VIII) is obtained. Ra has the meanings given hereinbefore. The compound thus obtained is then converted into the free aminothiazole (IX) by cleaving the acetyl group (e.g. by acidic or basic saponification or reaction with hydrazine hydrate). The reaction to obtain the ureas of general formula (I) or (Ia) is then carried out using one of the following methods: Direct reaction with a suitable isocyanate (XIII) leads directly to compounds of formula (Ia). Reaction with a suitable reagent (XIV) leads to compounds of formula (I), wherein Rx denotes a suitable leaving group selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-attracting groups (e.g. nitro). Another possibility is to react the aminothiazole (IX) with a reagent of general formula (X) to obtain an activated intermediate compound (XI). Rx and Ry are identical or suitable leaving groups selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl, O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by durch suitable electron-attracting groups (e.g. nitro). Depending on the nature of the leaving group and the temperature, the intermediate compound (XI) is optionally in equilibrium with the isocyanate (XII), which may be formed by elimination of the leaving group Ry from (XI). The further reaction of the intermediate compound (XI), (XII) or a mixture of the two with suitable amines of general formula (XV) leads to the desired compounds of general formula (I). R1 and R2 have the meanings given hereinbefore.
    Diagram 2:
    Figure US20070238746A1-20071011-C00017
    Figure US20070238746A1-20071011-C00018
  • By reacting the intermediate compound (XI) with a reagent of general formula (XVI), the intermediate compound (XVII) is obtained. PG1 is a suitable nitrogen-protective group selected from, for example, but not restricted to the group comprising alkylcarbonyl-(carbamate), phthalimides, benzyl (optionally substituted e.g. p-methoxybenzyl). The reagent (XVI) may be used as of one of the two possible enantiomers or as a racemate. After the protective group PG1 has been cleaved the intermediate compound (XVIII) is obtained. Reacting this intermediate compound with reagents of the type (XIX), (XX), (XXI), (XXII), (XXIII) or (XXIV) leads to the compounds (Ib), (Ic), (Id), (Ie), (If) or (Ig). R5 and R6 have the meanings described hereinbefore. Rx and Rv are suitable leaving groups selected from, for example, but not restricted to the group comprising halogen, S-alkyl, S-aryl O-alkylsulphonyl, O-arylsulphonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-attracting groups (e.g. nitro). Alternatively the compounds of general formula (Ig) may also be obtained, analogously to the method described in Diagram 1, by reacting the intermediate compound (XVIII) with the reagent of formula (X) described previously and subsequently reacting the intermediate compound (XXV) obtained with suitable amines of formula (XXV). R3 and R4 here also have the meanings described hereinbefore.
    Diagram 3:
    Figure US20070238746A1-20071011-C00019
  • By reacting the intermediate compound (XI) with the amino acid (XXVI) the carboxylic acid (XXVII) can be obtained, which after suitable activation by methods known from the literature can be reacted with amines of formula (XXV) described hereinbefore. Compounds of general formula (Ih) are obtained. R3 and R4 have the meanings described hereinbefore.
    Diagram 4:
    Figure US20070238746A1-20071011-C00020
  • By reacting the intermediate compound (XI) with a reagent of formula (XXVIII) compounds of general formula (XXIX) are obtained. PG1 is a suitable nitrogen protecting group selected from, for example, but not restricted to the group comprising alkylcarbonyl-(carbamates), phthalimides, benzyl (optionally substituted e.g. p-methoxybenzyl). After the protective group PG1 has been cleaved the intermediate compound (XXX) may be obtained. Compounds of general formula (Ii) and (Ij) may be obtained by reacting this intermediate compound (XXX) with the reagents of formula (XXIII) or (XXIV) described hereinbefore. Alternatively the compounds of general formula (Ij) may also be obtained, analogously to the method described in Diagram 1, by reacting the intermediate compound (XXX) with the reagent of formula (X) described hereinbefore and subsequently reacting the intermediate compound (XXXI) obtained with suitable amines of formula (XXV). R3 and R4 here also have the meanings described hereinbefore. R5 and R6 have the meanings described hereinbefore.
    Diagram 5:
    Figure US20070238746A1-20071011-C00021
  • By reacting the intermediate compound (XI) with the amino acid (XXXII) the carboxylic acid (XXXIII) can be obtained, which after suitable activation can be reacted by methods known from the literature with amines of formula (XXV) described above. Compounds of general formula (Ik) are obtained as well as byproducts of general formula (XXXIV). The latter can be separated from the desired products by chromatographic methods. R3 and R4 have the meanings described hereinbefore.
  • The new compounds of general formula (I) may be prepared analogously to the following Examples. The Examples described below are intended as an illustration of invention without restricting it.
  • Synthesis of the Reagents:
    • 2-chloro-3-fluoro-benzamidine (VII.1)
  • Figure US20070238746A1-20071011-C00022
  • 320 ml (0.32 mmol) of a 1 molar solution of lithium hexamethyl disilazide (LiHMDS) in hexane are placed in 800 ml diethyl ether and combined at ambient temperature with 25.0 g (0.161) 2-chloro-3-fluoro-benzonitrile. The mixture is stirred for 2 h at ambient temperature and after cooling to 0° C. it is combined with 280 ml 3 normal hydrochloric acid. The precipitate formed is suction filtered, washed with water and dried.
  • Yield: 16.5 g (49% of theory).
    • 3-isopropyl-benzylamine hydrochloride (XV.1)
  • Figure US20070238746A1-20071011-C00023
    • 3-isopropyl-benzonitrile
  • Figure US20070238746A1-20071011-C00024
  • 5.15 g (25.87 mmol) m-bromo-isopropyl-benzene and 2.69 g (30.04 mmol) copper cyamide are stirred in 2.50 ml of pyridine for 24 hours at 180° C. Then 15 ml of water, 15 ml of toluene and 15 ml conc. ammonia solution are added, then the mixture is extracted. The organic phase is dried and evaporated to dryness. Yield: 5.00 g (100% of theoretical)
    • 3-isopropyl-benzylamine hydrochloride (XV.1)
  • 5.00 g (34.43 mmol) 3-isopropyl-benzonitrile and 5.00 g Raney nickel are hydrogenated in 500 ml methanolic ammonia solution for 8 hours at ambient temperature under a pressure of 50 psi. After the catalyst has been filtered off the mixture is evaporated down and the residue is precipitated as the hydrochloride. Yield: 2.90 g (45% of theoretical)
    Synthesis of the Reagent (XV.2)
    Figure US20070238746A1-20071011-C00025
    • 1-(2-chloro-ethyl)-3-(3-cyano-phenyl)-urea
  • Figure US20070238746A1-20071011-C00026
  • 65.00 g (550 mmol) 3-amino-benzonitrile are dissolved in 450 ml dioxane, 56 ml (660 mmol) 1-chloro-2-isocyanato-ethane dissolved in 60 ml dioxane are added dropwise. The reaction mixture is stirred for 3 hours at 60° C. and for 16 hours at ambient temperature. Then the precipitate is suction filtered, washed with diethyl ether and dried.
  • Yield: 110.00 g (90% of theoretical)
  • mp: 138°-139° C.
    • 3-(2-oxo-imidazolidin-1-yl)-benzonitrile
  • Figure US20070238746A1-20071011-C00027
  • 110.00 g (490 mmol) 1-(2-chloro-ethyl)-3-(3-cyano-phenyl)-urea are dissolved in 2000 ml of ethanol at 50° C. and a solution of 42.00 g (640 mmol) potassium hydroxide in 390 ml of ethanol is added within 1.5 hours. The reaction mixture is stirred for 16 hours at ambient temperature, then the precipitate formed is suction filtered, washed with water and dried.
  • Yield: 68.00 g (75% of theoretical)
  • mp: 149°-150° C.
    • 1-(3-aminomethyl-phenyl)-imidazolidin-2-one hydrochloride (XV.2)
  • 40.00 g (210 mmol) 3-(2-oxo-imidazolidin-1-yl)-benzonitrile are suspended in 1500 ml of methanol, 53 ml 37% hydrochloric acid are added. The mixture is hydrogenated for 20 hours at ambient temperature under a pressure of 7 bar with 4.00 g palladium/charcoal. The catalyst is filtered off, the filtrate is concentrated and the precipitate formed is suction filtered, washed with acetone and dried. Yield: 42.00 g (88% of theoretical)
  • mp: 238°-239° C.
    Synthesis of the Reagent (XV.3)
    Figure US20070238746A1-20071011-C00028
    • tert-butyl (3-amino-benzyl)-carbamate
  • Figure US20070238746A1-20071011-C00029
  • 9.35 g (76.49 mmol) 3-aminomethyl-phenylamine are dissolved in 200 ml dichloromethane and 100 ml of tetrahydrofuran, a solution of 17.03 g (78.02 mmol) Boc-anhydride in 200 ml dichloromethane is added dropwise. The mixture is stirred for 2.5 hours at ambient temperature, then evaporated down. The residue is precipitated as the hydrochloride.
  • Yield: 17.48 g (88% of theoretical)
    • tert-butyl 3-(4-chloro-butyrylamino)-benzyl]-carbamate
  • Figure US20070238746A1-20071011-C00030
  • 1.00 g (4.46 mmol) tert-butyl (3-amino-benzyl)-carbamate are liberated as the base, then placed in 40 ml chloroform, 1.20 ml (8.66 mmol) triethylamine and 0.50 ml (4.46 mmol) 4-chlorobutyryl chloride are added. The reaction mixture is stirred for 16 hours at ambient temperature, then extracted with chloroform and water and sodium carbonate solution. The organic phase is dried and evaporated to dryness.
  • Yield: 1.20 g (95% of theoretical)
    • tert-butyl[3-(2-oxo-pyrrolidin-1-yl)-benzyl]-carbamate
  • Figure US20070238746A1-20071011-C00031
  • 1.20 g (3.67 mmol) tert-butyl 3-(4-chloro-butyrylamino)-benzyl]-carbamate and 0.950 g (8.47 mmol) potassium tert.butoxide are placed in 40 ml of tetrahydrofuran at 0° C. and stirred for 3 hours at ambient temperature. Then the reaction mixture is added to water and extracted with dichloromethane. The organic phase is dried and evaporated to dryness. The residue is purified by chromatography.
  • Yield: 0.500 g (47% of theoretical)
    • 1-(3-aminomethyl-phenyl)-pyrrolidin-2-one hydrochloride (XV.3)
  • 500 mg (1.72 mmol) tert-butyl[3-(2-oxo-pyrrolidin-1-yl)-benzyl]-carbamate are placed in 2 ml dichloromethane, 4.00 ml (8 mmol) 2 molar ethereal hydrochloric acid are added. The mixture is stirred for 16 hours at ambient temperature, then evaporated down. The residue is crystallised with acetone/ethanol and diethyl ether.
  • Yield: 220 mg (56% d. Th)
    Synthesis of the Reagent (XV.4)
    Figure US20070238746A1-20071011-C00032
    • 2-chloro-ethyl[3-(tert-butoxycarbonylamino-methyl)-phenyl]-carbamate
  • Figure US20070238746A1-20071011-C00033
  • 900 mg g (3.48 mmol) tert-butyl 3-amino-benzyl)-carbamate are liberated as the base, then placed in 40 ml of tetrahydrofuran, and 1.11 ml (8 mmol) triethylamine and 0.75 ml (6.82 mmol) 2-chloroethylchloroformate are added. The reaction mixture is stirred for 16 hours at ambient temperature, then extracted with dichloromethane and water. The organic phase is separated off using a phase separation cartridge and evaporated to dryness.
  • Yield: 1.20 g (100% of theoretical)
    • tert-butyl[3-(2-oxo-oxazolidin-3-yl)-benzyl]-carbamate
  • Figure US20070238746A1-20071011-C00034
  • 1.20 g (3.65 mmol) 2-chloro-ethyl[3-(tert-butoxycarbonylamino-methyl)-phenyl]-carbamate and 0.850 g (7.58 mmol) potassium tert.butoxide are placed at 0° C. in 30 ml of tetrahydrofuran and the mixture is stirred for 3 hours at ambient temperature. Then the reaction mixture is added to water and extracted with dichloromethane. The organic phase is dried and evaporated to dryness. The residue is purified by chromatography.
  • Yield: 0.250 g (23% of theoretical)
    • 3-(3-aminomethyl-phenyl)-oxazolidin-2-one hydrochloride (XV.4)
  • 380 mg (1.30 mmol) tert-butyl[3-(2-oxo-oxazolidin-3-yl)-benzyl]-carbamate are placed in 2 ml dichloromethane, 4.00 ml (8 mmol) 2 molar ethereal hydrochloric acid are added. The mixture is stirred for 16 hours at ambient temperature, then evaporated down. The residue is lyophilised.
  • Yield: 300 mg (100% of theoretical)
    Synthesis of the Reagent (XV.5)
    Figure US20070238746A1-20071011-C00035
    • 3-dimethylaminomethyl-benzonitrile
  • Figure US20070238746A1-20071011-C00036
  • 5.00 g (37.37 mmol) 3-cyanobenzaldehyde and 20.00 ml (40 mmol) dimethylamine (2 molar solution in tetrahydrofuran) are placed in 150 ml of tetrahydrofuran and cooled to 0° C. 12.40 g (81.73 mmol) sodium triacetoxyborohydride are added, then the mixture is stirred for 2 hours at 0° C. and 2 hours at ambient temperature. The reaction mixture is combined with 25 ml of 15% potassium carbonate solution and stirred for 0.5 hours. After the addition of ethyl acetate the mixture is extracted. The organic phase is washed with potassium carbonate solution, dried and evaporated to dryness.
  • Yield: 7.00 g (94% of theoretical)
    • 3-dimethylaminomethyl-benzylamine (XV.5)
  • 7.00 g (34.95 mmol) 3-dimethylaminomethyl-benzonitrile are placed in 100 ml of methanolic ammonia solution and hydrogenated with 1.40 g Raney nickel at ambient temperature under a pressure of 3 bar. The catalyst is suction filtered, the filtrate is evaporated down. The residue is purified by chromatography. Yield: 2.40 g (42% of theoretical)
    Synthesis of the Reagent (XV.6)
    Figure US20070238746A1-20071011-C00037
    • 7,8-dihydro-6H-imidazo[1,5-c]pyrimidin-5-one
  • Figure US20070238746A1-20071011-C00038
  • 50.00 g (450 mmol) histamine are dissolved in 1500 ml dimethylformamide, 73.87 g (450 mmol) carbonyldiimidazole are added. The reaction mixture is stirred for 5 hours at 70° C. and for 16 hours at ambient temperature. Then it is evaporated down, and the residue is extracted hot from acetonitrile.
  • Yield: 53.73 g (87% of theoretical)
    • 2-ethyl-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium; bromide
  • Figure US20070238746A1-20071011-C00039
  • 1.00 g (7 mmol) 7,8-dihydro-6H-imidazo[1,5-c]pyrimidin-5-one and 1.57 ml (21 mmol) ethylbromide are stirred in 12 ml acetonitrile for 16 hours at 80° C. After cooling the suspension is suction filtered, washed and dried.
  • Yield: 1.40 g (78% of theoretical)
    • 2-(1-ethyl-1H-imidazol-4-yl)-ethylamine oxalate (XV.6)
  • 1.16 g (5 mmol) 2-ethyl-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium; bromide are refluxed in 7 ml (14 mmol) 2 molar hydrochloric acid for 16 hours with stirring. Then the mixture is evaporated down, the residue is recrystallised from acetonitrile/ethanol. The very hygroscopic crystals obtained are made neutral and evaporated down. The residue is precipitated as the oxalate and recrystallised from ethanol.
  • Yield: 1.00 g (93% of theoretical)
    Synthesis of the Reagent (XV.7)
    Figure US20070238746A1-20071011-C00040
    • 5-oxo-2-propyl-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium; bromide
  • Figure US20070238746A1-20071011-C00041
  • 2.00 g (15 mmol) 7,8-dihydro-6H-imidazo[1,5-c]pyrimidin-5-one and 6.83 mmol) (75 mmol) propylbromide are stirred in 20 ml acetonitrile for 72 hours at 85° C. After cooling the suspension is suction filtered, washed and dried.
  • Yield: 3.48 g
    • 2-(1-propyl-1H-imidazol-4-yl)-ethylamine (XV.7)
  • 100 mg (0.384 mmol) 5-oxo-2-propyl-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium; bromide are refluxed in 192 μl (1.15 mmol) 6 molar hydrochloric acid for 16 hours with stirring. Then the solution is lyophilised.
  • Yield: 81.30 mg (64% of theoretical)
    Synthesis of the Reagent (XV.8)
    Figure US20070238746A1-20071011-C00042
  • 2-(4-ethyl-thiazol-2-yl)-ethylamine hydrobromide (XV.8):
  • 2.00 g (9.50 mmol) tert.butyl N(3-amino-3-thioxopropyl)carbamate and 1.58 g (10.45 mmol) 1-bromo-2-butanone are refluxed in 40 ml of ethanol for 16 hours with stirring. The reaction mixture is evaporated down, the residue is purified by chromatography.
  • Yield: 2.00 g (89% of theoretical)
    Synthesis of the Reagent (XV.9)
    Figure US20070238746A1-20071011-C00043
    • benzyl[2-(2-hydroxy-butylcarbamoyl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00044
  • 23.20 g (103.93 mmol) 3-benzyloxycarbonylamino-propionic acid, 14.10 g (104.35 mmol) 1-hydroxybenzotriazole, 18.80 ml (135.07 mmol) triethylamine and 21.00 g
  • (135.27 mmol) (ethyl-3-(3-dimethylamino)-propylcarbondiimide hydrochloride
  • (EDAC) are placed in 150 ml dichloromethane, cooled to 0° C. and stirred for 0.75 hours at this temperature. Then 10.50 g (114.26 mmol) 1-amino-2-butanol are added, the mixture is stirred for 2.5 hours at 0°-5° C. The reaction mixture is extracted with water and 1 molar sodium carbonate solution, the organic phase is dried and evaporated to dryness. The residue is extracted again with dichloromethane and sodium carbonate solution.
  • Yield: 12.30 g (40% of theoretical) benzyl[2-(2-oxo-butylcarbamoyl)-ethyl]-carbamate:
    Figure US20070238746A1-20071011-C00045
  • 2.20 ml (26.05 mmol) oxalyl chloride are placed in 10 ml dichloromethane, the solution is cooled to −53° C. 2.45 ml (34.49 mmol) dimethylsulphoxide in 5 ml dichloromethane are slowly added dropwise, the mixture is stirred for 0.25 hours, then a solution of 6.30 g (21.40 mmol) benzyl[2-(2-hydroxy-butylcarbamoyl)-ethyl]-carbamate in 30 ml dichloromethane is added. The mixture is stirred for 1.5 hours at −60° C., then 12.60 ml triethylamine are added dropwise. The suspension is stirred for 1 hour at −50° C., then within 16 hours allowed to come up to ambient temperature. The reaction mixture is diluted with dichloromethane and extracted with 1 molar hydrochloric acid, 1 molar sodium carbonate solution and water. The organic phase is dried and evaporated to dryness.
  • Yield: 5.82 g (93% of theoretical)
    • benzyl[2-(5-ethyl-oxazol-2-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00046
  • 23.07 g (49.60 mmol) PS-triphenylphosphine are suspended in 200 ml dichloromethane, 12.65 g (49.82 mmol) iodine are added. The mixture is stirred for 0.1 hours at ambient temperature, then 13.80 ml (99.28 mmol) triethylamine are added dropwise. 5.80 g (19.84 mmol) benzyl[2-(2-oxo-butylcarbamoyl)-ethyl]-carbamate dissolved in 150 ml dichloromethane are added. The reaction mixture is stirred for 72 hours at ambient temperature, then the precipitate is filtered off. The filtrate is extracted with water, the organic phase is dried and evaporated to dryness.
  • Yield: 3.35 g (31% of theoretical)
    • 2-(5-ethyl-oxazol-2-yl)-ethylamine (XV.9)
  • 2.86 g (10.43 mmol) benzyl[2-(5-ethyl-oxazol-2-yl)-ethyl]-carbamate are placed in 130 ml of methanol, 0.910 mg palladium/charcoal 10% are added, then the mixture is hydrogenated for 5 hours at ambient temperature under a pressure of 14 psi. Then the catalyst is suction filtered and the solution is evaporated down. Yield: 1.45 g (99% of theoretical)
    Synthesis of the Reagent (XV.10)
    Figure US20070238746A1-20071011-C00047
    • tert-butyl[3-oxo-3-(N′-propionyl-hydrazino)-propyl]-carbamate
  • Figure US20070238746A1-20071011-C00048
  • 25.00 g (132 mmol) 3-tert-butoxycarbonylamino-propionic acid, 11.45 g (130 mmol) ethanoic acid hydrazide, 50.91 g (159 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 50 ml diisopropylethylamine are stirred in 500 ml of tetrahydrofuran/dichloromethane for 24 hours at ambient temperature. Then the mixture is evaporated down, the residue is extracted with ethyl acetate and 10% potassium hydrogen carbonate solution. The organic phase is dried and evaporated to dryness. The residue is crystallised from isopropylether.
  • Yield: 3.20 g (9% of theoretical)
    • tert-butyl[2-(5-ethyl-[1,3,4]oxadiazol-2-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00049
  • 11.49 g (24.70 mmol) PS-triphenylphosphine are placed in 240 ml dichloromethane, 6.27 g (24.70 mmol) iodine are added. The mixture is stirred for 0.1 hours at ambient temperature, then 7.00 ml (50.50 mmol) triethylamine are added dropwise. 3.20 g (12.34 mmol) tert-butyl[3-oxo-3-(N′-propionyl-hydrazino)-propyl]-carbamate dissolved in 150 ml dichloromethane are added. The reaction mixture is stirred for 24 hours at ambient temperature, then the precipitate is filtered off. The filtrate is evaporated down and purified by chromatography.
  • Yield: 2.95 g (99% of theoretical)
    • 2-(5-ethyl-[1,3,4]oxadiazol-2-yl)-ethylamine (XV.10)
  • 2.95 g (12.23 mmol) tert-butyl[2-(5-ethyl-[1,3,4]oxadiazol-2-yl)-ethyl]-carbamate and 10 ml trifluoroacetic acid are stirred in 100 ml dichloromethane for 24 hours at ambient temperature. Then the mixture is evaporated down, the residue is made basic and extracted with ethyl acetate. The organic phase is dried and evaporated to dryness.
  • Yield: 0.410 g (24% of theoretical)
    Synthesis of the Reagent (XV.11)
    Figure US20070238746A1-20071011-C00050
    • benzyl[2-(2-hydroxy-3-methyl-butylcarbamoyl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00051
  • 46.00 g (206.07 mmol) 3-benzyloxycarbonylamino-propionic acid, 51.37 g (267.95 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 27.85 g (206.07 mmol) hydroxybenzotriazole (HOBT) and 37.14 ml (267.95 mmol) triethylamine are placed in 700 ml dichloromethane, the mixture is stirred for 0.5 hours at 0°, then 23.70 g (229.73 mmol) 1-amino-3-methyl-butan-2-ol are added. The reaction mixture is stirred for 16 hours at ambient temperature. Then it is extracted with potassium carbonate solution and dichloromethane. The organic phase is washed with 1 molar sodium hydroxide solution, dried and evaporated to dryness. The residue is extracted with diethyl ether, then recrystallised with acetonitrile.
  • Yield: 32.40 g (51% of theoretical)
    • benzyl[2-(3-methyl-2-oxo-butylcarbamoyl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00052
  • 10.81 ml (126.08 mmol) oxalyl chloride are placed in 300 ml dichloromethane and cooled to −70° C. 11.94 ml (168.11 mmol) dimethylsulphoxide are slowly added dropwise. The mixture is stirred for 0.1 hours, then 32.40 g (105.07 mmol) benzyl [2-(2-hydroxy-3-methyl-butylcarbamoyl)-ethyl]-carbamate in 70 ml dichloromethane are added. The mixture is stirred for 1 hour, then 62.48 ml (450.72 mmol) triethylamine are added dropwise. The reaction mixture is stirred for 1.5 hours at −70° C., then slowly allowed to come up to ambient temperature. It is diluted with dichloromethane and washed with 1 molar hydrochloric acid, saturated sodium carbonate solution, water and saturated sodium chloride solution. The organic phase is dried and evaporated to dryness.
  • Yield: 30.80 g (96% of theoretical)
    • benzyl[2-(5-isopropyl-oxazol-2-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00053
  • 100.00 g (215 mmol) PS-triphenylphosphine are suspended in 1000 ml dichloromethane, 59.92 g (236.06 mmol) iodine are added. The mixture is stirred for 0.1 hours at ambient temperature, then 65.32 ml (470.24 mmol) triethylamine are added dropwise. 28.80 g (94.91 mmol) benzyl[2-(3-methyl-2-oxo-butylcarbamoyl)-ethyl]-carbamate dissolved in 200 ml dichloromethane are added. The reaction mixture is stirred for 16 hours at ambient temperature. If the reaction is incomplete, a further 0.1 eq triphenylphosphine and 0.1 eq iodine are added. The mixture is stirred for 16 hours at ambient temperature, then the precipitate is filtered off. The filtrate is evaporated down, the residue is extracted with water and chloroform, the organic phase is dried and evaporated to dryness. The residue is purified by chromatography.
  • Yield: 12.50 g (46% of theoretical)
    • 2-(5-isopropyl-oxazol-2-yl)-ethylamine (XV.11)
  • 6.50 g (22.54 mmol) benzyl[2-(5-isopropyl-oxazol-2-yl)-ethyl]-carbamate are placed in 130 ml of methanol, 3.50 g of 10% palladium/charcoal are added, then the mixture is hydrogenated for 5 hours at ambient temperature under a pressure of 14 psi. Then the catalyst is removed by suction filtering and the solution is evaporated down. The residue is extracted with dichloromethane and potassium carbonate solution, the organic phase is dried and evaporated to dryness. Yield: 3.20 g (92% of theoretical)
    Synthesis of the Reagent (XV.12)
    Figure US20070238746A1-20071011-C00054
    • tert-butyl[3-(N′-isobutyryl-hydrazino)-3-oxo-propyl]-carbamate
  • Figure US20070238746A1-20071011-C00055
  • 25.00 g (132 mmol) 3-tert-butoxycarbonylamino-propionic acid, 13.50 g (132 mmol) isobutyric acid hydrazide, 50.91 g (159 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 50 ml diisopropylethylamine are stirred in 500 ml of tetrahydrofuran/dichloromethane for 24 hours at ambient temperature. Then the mixture is evaporated down, the residue is extracted with ethyl acetate and 10% potassium hydrogen carbonate solution. The organic phase is dried and evaporated to dryness. The residue is crystallised from toluene/isopropylether.
  • Yield: 16.55 g (46% of theoretical)
    • tert-butyl[2-(5-isopropyl-[1,3,4]oxadiazol-2-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00056
  • 20.00 g (43.00 mmol) PS-triphenylphosphine are placed in 240 ml dichloromethane, 10.88 g (42.87 mmol) iodine are added. The mixture is stirred for 0.1 hours at ambient temperature, then 12.10 ml (87.29 mmol) triethylamine are added dropwise. 5.83 g (21.33 mmol) tert-butyl[3-(N′-isobutyryl-hydrazino)-3-oxo-propyl]-carbamate dissolved in 150 ml dichloromethane are added. The reaction mixture is stirred for 24 hours at ambient temperature, then the precipitate is filtered off. The filtrate is evaporated down and purified by chromatography. Yield: 5.40 g (99% of theoretical)
    • 2-(5-isopropyl-[1,3,4]oxadiazol-2-yl)-ethylamine (XV.12)
  • 4.00 g (15.67 mmol) tert-butyl[2-(5-isopropyl-[1,3,4]oxadiazol-2-yl)-ethyl]-carbamate and 20 ml trifluoroacetic acid are stirred in 200 ml dichloromethane for 24 hours at ambient temperature. Then the mixture is evaporated down, the residue is made basic and extracted with ethyl acetate. The organic phase is dried and evaporated to dryness.
  • Yield: 1.440 g (59% of theoretical)
    Synthesis of the Reagent (XV.13)
    Figure US20070238746A1-20071011-C00057
    • methyl 3-tert-butoxycarbonylamino-propionate
  • Figure US20070238746A1-20071011-C00058
  • 9.90 g (70.93 mmol) β-alaninemethylester hydrochloride are placed in 200 ml acetonitrile, 10 ml (72.14 mmol) triethylamine are added. The mixture is stirred for 0.3 hours at ambient temperature, and first 15.48 g (70.93 mmol) Boc-anhydride, then 1.65 g (7.09 mmol) Zirkon(IV) chloride are added. The reaction mixture is stirred for 2 hours at ambient temperature, then evaporated down. The residue is extracted with ethyl acetate and water. The organic phase is dried and evaporated to dryness.
  • Yield: 12.50 g (87% of theoretical)
  • N-hydroxy-propionamidine:
    Figure US20070238746A1-20071011-C00059
  • 8.00 g (57.88 mmol) potassium carbonate are dissolved in 25 ml of water, 80 ml of ethanol, 4.00 g (57.56 mmol) hydroxylamine and 4.11 ml (57.56 mmol) propionitrile are added. The reaction mixture is stirred for 18 hours at ambient temperature, then evaporated down, and re-evaporated with toluene. The residue is combined with ethanol, suction filtered and the filtrate is evaporated to dryness. Yield: 3.70 g (73% of theoretical)
    • tert-butyl[2-(3-ethyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00060
  • 2.00 g (22.70 mmol) N-hydroxy-propionamidine are placed in 10 ml dimethylformamide and molecular sieve. 0.999 g (24.97 mmol) sodium hydride
  • (60% in mineral oil) are added. The mixture is stirred for 0.1 hours at 50° C., then 5.00 g (24.60 mmol) methyl3-tert-butoxycarbonylamino-propionate in 20 ml dimethylformamide are added. The reaction mixture is stirred for 3 hours at 50° C. After cooling 15 ml of water are added, and the mixture is suction filtered through Celite. The 2 phases of the filtrate are separated and the organic phase is evaporated down. The residue is purified by chromatography.
  • Yield: 2.05 g (37% of theoretical)
    • 2-(3-ethyl-[1,2,4]oxadiazol-5-yl)-ethylamine hydrochloride (XV.13)
  • 2.05 g (8.50 mmol) tert-butyl[2-(3-ethyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate are placed in 20 ml dichloromethane and 40 ml of 1 molar ethereal hydrochloric acid are added. The reaction mixture is stirred for 16 hours at ambient temperature and 4 hours at 40° C. After the addition of a further 10 ml ethereal hydrochloric acid stirring is continued for 72 hours at ambient temperature. The suspension is evaporated down.
  • Yield: 1.50 g (99% of theoretical)
    Synthesis of the Reagent (XV.14)
    Figure US20070238746A1-20071011-C00061
    • N-hydroxy-isobutyramidine
  • Figure US20070238746A1-20071011-C00062
  • 6.00 g (43.41 mmol) potassium carbonate are dissolved in 19 ml of water, 60 ml of ethanol, 3.00 g (43.17 mmol) hydroxylamine and 3.95 ml (43.44 mmol) isobutyronitrile are added. The reaction mixture is stirred for 18 hours at ambient temperature, then evaporated down, and re-evaporated with toluene. The residue is mixed with ethanol, suction filtered and the filtrate is evaporated to dryness. Yield: 3.70 g (84% of theoretical)
    • tert-butyl[2-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00063
  • 2.20 g (21.54 mmol) N-hydroxy-isobutyramidine are placed in 10 ml dimethylformamide and molecular sieve. 0.948 g (23.69 mmol) sodium hydride (60% in mineral oil) are added. The mixture is stirred for 0.1 hours at 50° C., then 6.20 g (30.51 mmol) methyl 3-tert-butoxycarbonylamino-propionate in 20 ml dimethylformamide are added. The reaction mixture is stirred for 3 hours at 50° C. After cooling 15 ml of water are added and the mixture is suction filtered through Celite. The 2 phases of the filtrate are separated, the aqueous phase is extracted with ethyl acetate, the combined organic phases are evaporated down. The residue is purified by chromatography.
  • Yield: 0.900 g (16% of theoretical)
    • 2-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-ethylamine hydrochloride (XV.14)
  • 900 mg (3.53 mmol) tert-butyl[2-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate are placed in 10 ml dichloromethane, 20 ml 1 molar ethereal hydrochloric acid are added. The reaction mixture is stirred for 16 hours at ambient temperature. After the further addition of 10 ml ethereal hydrochloric acid the mixture is stirred for another 72 hours at ambient temperature and 4 hours at 40° C. The suspension is evaporated down. The residue is dissolved in acetone, mixed with diethyl ether and suction filtered.
  • Yield: 530 mg (78% of theoretical)
    Synthesis of the Reagent (XV.15)
    Figure US20070238746A1-20071011-C00064
    • ethyl 3-tert-butoxycarbonylamino-propionate
  • Figure US20070238746A1-20071011-C00065
  • 5.00 g (32.55 mmol) β-alanine ethyl ester hydrochloride are placed in 100 ml acetonitrile, 4.75 ml (34.27 mmol) triethylamine are added. The mixture is stirred for 0.3 hours at ambient temperature, and first 7.30 g (33.45 mmol) Boc-anhydride, then 0.759 g (3.26 mmol) zirconium(IV) chloride are added. The reaction mixture is stirred for 2 hours at ambient temperature, then evaporated down. The residue is extracted with ethyl acetate and water. The organic phase is dried and evaporated to dryness.
  • Yield: 7.50 g (100% of theoretical)
    • N-hydroxy-cyclopropanecarboxamidine
  • Figure US20070238746A1-20071011-C00066
  • 6.00 g (43.41 mmol) potassium carbonate are dissolved in 19 ml of water, 60 ml of ethanol, 3.00 g (43.17 mmol) hydroxylamine and 3.25 ml (43.25 mmol) cyclopropylcyamide are added. The reaction mixture is stirred for 18 hours at ambient temperature, then evaporated down and re-evaporated with toluene. The residue is mixed with ethanol, suction filtered and the filtrate is evaporated to dryness.
  • Yield: 3.47 g (80% of theoretical)
    • tert-butyl[2-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate
  • Figure US20070238746A1-20071011-C00067
  • 3.10 g (30.96 mmol) N-hydroxy-cyclopropanecarboxamidine are placed in 10 ml dimethylformamide and molecular sieve. 1.32 g (34.06 mmol) sodium hydride (60% in mineral oil) are added. The mixture is stirred for 0.1 hours at 50° C., then 7.40 g (34.06 mmol) ethyl 3-tert-butoxycarbonylamino-propionate in 20 ml dimethylformamide are added. The reaction mixture is stirred for 3 hours at 50° C. After cooling 15 ml of water are added, the mixture is suction filtered through Celite. The 2 phases of the filtrate are separated, the aqueous phase is extracted with ethyl acetate, the combined organic phase is evaporated down. The residue is purified by chromatography.
  • Yield: 4.00 g (51% of theoretical)
    • 2-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-ethylamine hydrochloride (XV.15)
  • 4.00 g (15.79 mmol) tert-butyl[2-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-ethyl]-carbamate are placed in 40 ml dichloromethane, 80 ml 1 molar ethereal hydrochloric acid are added. The reaction mixture is stirred for 3 hours at reflux temperature and for 72 hours at ambient temperature, then evaporated down. The residue is dissolved in acetone, mixed with diethyl ether and suction filtered. Yield: 1.30 g (43% of theoretical)
  • Synthesis of the Intermediate Compounds
  • Synthesis of Intermediate Compound (IV)
    Figure US20070238746A1-20071011-C00068
  • 112 g (1.0 mol) 1,3-cyclohexanedione are suspended in 700 mL ice water and 51.6 mL (1.0 mol) bromine are added dropwise at 0° C. within 45 minutes. The suspension is stirred for 3.5 hours at max. 10° C. Then it is suction filtered and the solid is stirred in 800 mL water, suction filtered, washed with 3 L water and dried. The solid obtained is recrystallised from ethanol. Yield: 37 g (m.p.: 159-160° C.)
  • 15.5 g (0.2 mol) thiourea are placed in 200 mL ethanol at ambient temperature. To this suspension are added batchwise 37.1 g (0.2 mol) of the intermediate described above, then the mixture is rinsed with 60 mL ethanol. The solution that gradually forms is refluxed for 2 hours with stirring and then evaporated down. The residue is extracted with water and diethyl ether, the aqueous phase is made basic with sodium carbonate solution. The resulting solid is suction filtered, washed with water, then stirred with methanol and evaporated to dryness.
  • Yield: 22 g (m.p.: 265-268° C.)
  • 230 mL (2.4 mol) acetic anhydride are placed at ambient temperature, 22 g (0.13 mol) of the intermediate described above are added and the mixture is refluxed for 3 hours with stirring. The suspension goes partly into solution. After cooling with ice/common salt bath the solid is solid suction filtered, decocted 2× in 150 mL acetone, suction filtered and dried.
  • Yield: 25 g (m.p.: 268-272° C.) of the intermediate compound (IV)
    Synthesis of Intermediate Compound (VI.1)
    Figure US20070238746A1-20071011-C00069
  • 20 g (0.37 mol) sodium methoxide are suspended in 50 mL dimethylformamide, a suspension of 21 g of the intermediate compound (IV) in 100 mL dimethylformamide is added dropwise. The mixture is stirred for another 15 minutes, then cooled to 0° C. A mixture of 29.9 mL (0.37 mol) ethyl formate (Va) and 60 mL benzene is added dropwise and the reaction mixture is diluted with another 100 mL benzene. Gradually a precipitate is formed and stirring is continued at 0° C. for 3.5 hours. The suspension is hydrolysed with 370 mL 1 molar hydrochloric acid, the solid precipitated is suction filtered. The two phases of the mother liquor are separated, the aqueous phase is extracted with dichloromethane. The resulting organic phase is dried and evaporated to dryness. The solid and the residue from the extraction are recrystallised from acetonitrile. Yield: 20 g of the intermediate compound (VI.1)
    Synthesis of Intermediate Compound (VIII.1)
    Figure US20070238746A1-20071011-C00070
  • 4.00 g (16.79 mmol) of intermediate compound (VI.1) are placed in 10 ml of pyridine, 3.95 g (20 mmol) 2-bromo-benzamidine are added. The reaction mixture is stirred for 4 hours at 160° C. After cooling the mixture is precipitated with ethanol and water. The precipitate formed is suction filtered and dried.
  • Yield: 3.50 g (52% of theoretical) of intermediate compound (VIII.1)
  • The intermediates (VIII.2) to (VIII.6) may also be obtained analogously by reacting the intermediate (VI.1) with the appropriate amidines (VII.2-VII.6).
    Figure US20070238746A1-20071011-C00071
    Synthesis of Intermediate Compound (IX.1)
    Figure US20070238746A1-20071011-C00072
  • 3.50 g (9 mmol) of the intermediate compound (VIII.1) are refluxed in 10 ml conc. hydrochloric acid and 10 ml of water for 2 hours with stirring. Then the precipitate formed is suction filtered and dried.
  • Yield: 2.40 g (77% of theoretical) of the intermediate compound (IX.1)
  • The intermediates (IX.2) to (IX.6) may also be prepared analogously by saponification of the intermediates (VIII.2) to (VIII.6).
    Figure US20070238746A1-20071011-C00073
    Synthesis of Intermediate Compound (XI.1)
    Figure US20070238746A1-20071011-C00074
  • 2.40 g (7 mmol) of the intermediate compound (IX.1) and 0.73 ml (6.72 mmol) ethylchlorothiolformate are stirred in 2 ml of pyridine for 4 hours at 60° C. Then the reaction mixture is extracted with water and dichloromethane, the organic phase is treated with activated charcoal, dried and evaporated to dryness. The residue is purified by chromatography.
  • Yield: 1.50 g (50% of theoretical) of the intermediate compound (XI.1)
  • The intermediates (XI.2) to (XI.6) may also be prepared analogously by reacting the intermediates (IX.2) to (IX.6) with ethylchlorothiolformate (X.1).
    Figure US20070238746A1-20071011-C00075
    Synthesis of Intermediate Compound (XVII.1)
    Figure US20070238746A1-20071011-C00076
  • 2.42 g (6 mmol of intermediate compound (XI.2), 1.12 g (6 mmol) (3S)-(+)-3-(tert.butoxycarbonylamino)pyrrolidine, 2.05 ml (12 mmol) diisopropylethylamine and 10 μl triethylamine are stirred in 30 ml of ethanol for 3 hours at 80° C. Then the mixture is stirred with dichloromethane, water and sodium carbonate, the organic phase is separated off using a phase separation cartridge and evaporated to dryness. The residue is stirred with diethyl ether and suction filtered.
  • Yield: 2.54 g (80% of theoretical) of the intermediate compound (XVII.1)
  • The intermediate compound (XVII.2) may also be obtained analogously.
    Figure US20070238746A1-20071011-C00077
    Synthesis of Intermediate Compound (XVIII.1)
    Figure US20070238746A1-20071011-C00078
  • 2.60 g (4.92 mmol) of the intermediate compound (XVII.1) are stirred in 30 ml 2 molar ethereal hydrochloric acid for 3 hours at ambient temperature. The reaction mixture is evaporated to dryness.
  • Yield: 2.60 g (100% of theoretical) of the intermediate compound (XVIII.1)
  • The intermediate compound may also be obtained analogously (XVIII.2).
    Figure US20070238746A1-20071011-C00079
    Synthesis of Intermediate Compound (XXVII.1)
    Figure US20070238746A1-20071011-C00080
  • 3.00 g (7.45 mmol) of intermediate compound (XI.2), 1.41 g (7.50 mmol) 3-aminomethyl-benzoic acid hydrochloride and 5.13 ml (30 mmol) triethylamine are stirred in 25 ml of tetrahydrofuran for 7 hours at 80° C. The resulting suspension is mixed with diethyl ether, the precipitate formed is suction filtered. This is stirred with dilute sodium hydrogen carbonate solution and suction filtered.
  • Yield: 3.30 g (90% of theoretical) of the intermediate compound (XXVII.1)
    Synthesis of Intermediate Compound (XXV.1)
    Figure US20070238746A1-20071011-C00081
  • 800 mg (1.73 mmol) of the intermediate compound (XVIII.1) and 195.49 μl (1.80 mmol) ethylchlorothiolformate are stirred in 5 ml of pyridine for 48 hours at 60° C. Then the reaction mixture is evaporated down, the residue is extracted with water and dichloromethane. The organic phase is dried and evaporated to dryness. The product is crystallised with diethyl ether.
  • Yield: 510 mg (57% of theoretical) of the intermediate compound (XXV.1) HPLC-MS: method A, RT=2.82 min, MH+=515/517
    Synthesis of Intermediate Compound (XXIX.1)
    Figure US20070238746A1-20071011-C00082
  • 2.25 g (5.79 mmol) of the intermediate compound (XI.2), 1.50 g (6.75 mmol) tert.butyl (3-aminomethyl-phenyl)-carbamate and 3.74 ml (27 mmol) triethylamine are stirred in 20 ml of ethanol for 16 hours at 80° C. Then the reaction mixture is evaporated down, the residue is extracted with water and dichloromethane. The organic phase is dried and evaporated to dryness. The residue is crystallised from ethanol and diethyl ether.
  • Yield: 2.63 g (81% of theoretical) of the intermediate compound (XXIX.1)
    Synthesis of Intermediate Compound (XXX.1)=Example 5
    Figure US20070238746A1-20071011-C00083
  • 2.63 g (4.67 mmol) of the intermediate compound (XXIX.1) are suspended in 20 ml ethereal hydrochloric acid, then stirred for 16 hours at ambient temperature. Then the precipitate is suction filtered and dried.
  • Yield: 2.50 g (100% of theoretical) of the intermediate compound (XXX.1)
    Synthesis of Intermediate Compound (XXXIII.1)
    Figure US20070238746A1-20071011-C00084
  • 2.00 g (5.14 mmol) of the intermediate compound (XI.2), 600 mg (6.74 mmol) β-alanine and 0.80 ml (5.77 mmol) triethylamine are stirred in 10 ml of ethanol for 16 hours at 80° C. The precipitate formed is suction filtered, the mother liquor evaporated down. The residue is crystallised with dimethylformamide, water and trifluoroacetic acid.
  • Yield: 1.00 g (45% of theoretical) of the intermediate compound (XXXIII.1)
    Synthesis of Intermediate Compound (XXXI.1)
    Figure US20070238746A1-20071011-C00085
  • 600 mg (1.20 mmol) of the intermediate compound (XXX.1) and 135.76 μl (1.25 mmol) ethylchlorothiolformate are stirred in 12 ml of pyridine for 16 hours at ambient temperature. As the reaction is still incomplete, a further 0.2 eq ethylchlorothiolformate are added, and the mixture is stirred for 3 hours at 60° C. Then the reaction mixture is extracted with water and dichloromethane. The organic phase is dried and evaporated to dryness. The residue is crystallised with diethyl ether.
  • Yield: 540 mg (82% of theoretical) of the intermediate compound (XXXI.1)
  • Synthesis of the Compounds of Formula (I)
  • Methods A and B:
  • Waters ZMD, Alliance 2690/2695 HPLC, Waters 2700 Autosampler, Waters 996/2996 Diode array detector (wavelength range 210-400 nm).
  • Stationary phase (column temperature: constant at 25° C.):
  • Method A: column XTerra®, MS C18 2.5 μm, 4.6 mm×30 mm.
  • method B: column Merck Chromolith™ SpeedROD RP-18e, 4.6 mm×50 mm.
  • Mobile phase: L1: water with 0.10% TFA; L2: acetonitrile with 0.10% TFA flow rates:
  • Method A: 1.00 mLl/min
  • Method B: 2.00 mL/min
    time (min) % L1 % L2
    0.0 95 5
    0.1 95 5
    3.1 2 98
    4.5 2 98
    5.0 95 5

    Methods C and D:
    Waters ZMD, Alliance 2790/2795 HPLC, Waters 2700 Autosampler, Waters 996/2996 Diode array detector (wavelength range 210-500 nm).
    Stationary phase (column temperature: constant at 40° C.):
    column X-Terra MS C18 4.6×50 mm, 3.5 μm.
  • Mobile phase: L1: water with 0.10% TFA; L2: acetonitrile with 0.10% TFA flow rates: 1.00 mL/min
    time (min) % L1 % L2
    0.0 95 5
    0.1 95 5
    5.1 2 98
    6.5 2 98
    7.0 95 5
  • The symbol X used in Table A in the structural formula of the substituent is to be understood as being the linkage point to the remainder of the molecule. The substituent replaces the groups Ra and Rb according to the arrangement of the columns.
    • EXAMPLES Synthesis of Example 17
  • 70 mg (0.156 mmol) of intermediate compound (XI.1), 40.82 mg (0.172 mmol) 2-(4-ethyl-thiazol-2-yl)-ethylamine-hydrobromide and 0.10 ml (0.721 mmol) triethylamine are stirred in 1 ml of ethanol for 16 hours at 80° C. The reaction mixture is evaporated down, the residue is purified by chromatography. Corresponding fractions are lyophilised.
  • Yield: 73.7 mg (87% of theoretical)
  • Examples 1, 6-16, 18-153 and 264 may also be obtained analogously by reacting the appropriate intermediate products (XI.1)-(XI.6) in each case with the appropriate amines (either known from the literature or described under “Synthesis of the reagents”).
    • Synthesis of Example 154
  • 20.15 mg (0.050 mmol) of the intermediate compound (XI.2) and 22.77 mg (0.225 mmol) triethylamine are placed in 1 ml of ethanol, 9.62 mg (0.075 mmol) (1-methyl-piperidin-4-yl)-methylamine in 1 ml of ethanol are added. The reaction mixture is stirred for 16 hours at 70° C. Then it is evaporated down, the residue is purified by chromatography (LCMS). Corresponding fractions are lyophilised. Yield: 24.80 mg (85% of theoretical)
  • Examples 155-223 may also be obtained analogously by reacting the appropriate intermediate products (XI.1)-(XI.6) with the appropriate amines (either known from the literature or described under “Synthesis of the reagents”).
    • Synthesis of Example 225
  • 60 mg (0.129 mmol) of the intermediate compound (XVIII.1) and 100 μl (0.573 mmol) diisopropylethylamine are placed in 1 ml dimethylformamide, 22.96 μl (0.200 mmol) 4-morpholino-carbonyl chloride are added. The mixture is stirred for 16 hours at ambient temperature, then purified by chromatography (HPLC). Corresponding fractions are lyophilised.
  • Yield: 47 mg (67% of theoretical)
  • Examples 224 and 226-237 may also be obtained analogously by reacting the intermediate products (XVIII.1) with the respective appropriate carboxylic acid chlorides, sulphonic acid chlorides, carbamoyl chlorides, sulphamoyl chlorides or chloroformates. Moreover Examples 279 and 280 may be prepared analogously starting from intermediate compound (XXX.1).
    • Synthesis of Example 238
  • 19.62 μl (0.180 mmol) isovaleric acid are placed in 5 ml dichloromethane, 100 μl (0.585 mmol) diisopropylethylamine and 64.87 mg (0.200 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) are added. The mixture is stirred for 0.5 hours at ambient temperature, then 80 mg (0.173 mmol) of the intermediate compound (XVIII.1) are added. The reaction mixture is stirred for 16 hours at ambient temperature, then stirred with dichloromethane, water and potassium carbonate. The organic phase is separated off using a phase separation cartridge and evaporated to dryness. The residue is crystallised with diethyl ether.
  • Yield: 51 mg (58% of theoretical)
  • Example 239 may also be prepared analogously by reacting the intermediate products (XVIII.1) with the appropriate carboxylic acid.
    • Synthesis of Example 241
  • 80 mg (0.173 mmol) of the intermediate compound (XVIII.2) and 150 μl (0.860 mmol) diisopropylethylamine are placed in 1.50 ml dimethylformamide, 26.19 μl (0.200 mmol) isobutyryl chloride are added while cooling. The mixture is stirred for 16 hours at ambient temperature, then purified by chromatography (HPLC). Corresponding fractions are lyophilised.
  • Yield: 58 mg (68% of theoretical)
  • Examples 240 and 242-249 may also be obtained analogously by reacting the intermediate compound (XVIII.2) with the respective appropriate carboxylic acid chlorides, sulphonic acid chlorides, carbamoyl chlorides, sulphamoyl chlorides or chloroformates.
    • Synthesis of Example 250
  • 19.62 μl (0.180 mmol) isovaleric acid are placed in 5 ml dichloromethane, 100 μl (0.585 mmol) diisopropylethylamine and 64.87 mg (0.200 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) are added. The mixture is stirred for 0.5 hours at ambient temperature, then 80 mg (0.173 mmol) of the intermediate compound (XVIII.2) are added. The reaction mixture is stirred for 16 hours at ambient temperature, then stirred with dichloromethane, water and potassium carbonate. The organic phase is separated off using a phase separation cartridge and evaporated to dryness. The residue is crystallised with diethyl ether.
  • Yield: 62 mg (70% of theoretical)
  • mp: 203°-204° C.
  • Example 251 may also be prepared analogously by reacting the intermediate compound (XVIII.2) with the appropriate carboxylic acid.
    • Synthesis of Example 252
  • 100 mg (0.203 mmol) of the intermediate compound (XXVII.1) are placed in 4 ml dichloromethane, 100 μl (0.585 mmol) diisopropylethylamine and 75 mg (0.231 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) are added. The mixture is stirred for 0.5 hours at ambient temperature, then 24.84 μl (0.250 mmol) isobutylamine are added. The reaction mixture is stirred for 16 hours at ambient temperature, then stirred with dichloromethane, water and potassium carbonate. The organic phase is separated off using a phase separation cartridge and evaporated to dryness. The residue is purified by chromatography (HPLC), corresponding fractions are lyophilised.
  • Yield: 53 mg (48% of theoretical)
  • Examples 253-259 may also be obtained analogously by reacting the intermediate compound (XXVII.1) with the appropriate amines.
    • Synthesis of Example 260
  • 75 mg (0.146 mmol) of the intermediate compound (XXV.1), 30 ml (0.350 mmol) isopropylamine, 51.29 μl (0.300 mmol) diisopropylethylamine and 10 μl triethylamine are stirred in 1 ml of ethanol for 3 hours at 80° C. Then the reaction mixture is stirred with dichloromethane and water, the organic phase is separated off using a phase separation cartridge and evaporated down. The residue is crystallised with diethyl ether.
  • Yield: 53 mg (71% of theoretical)
  • mp: 198-199° C.
  • HPLC-MS: method A, RT=2.54 min, MH+=512
  • Examples 261-263 and 265 may also be obtained analogously by reacting the intermediate compound (XXV.1) with the appropriate amines.
    • Synthesis of Example 266
  • 10 mg (0.100 mmol) cyclopropylacetic acid are placed in 1 ml dimethylformamide, 37 mg (0.113 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 90 ml (0.516 mmol) diisopropylethylamine are added. The mixture is stirred for 0.5 hours at ambient temperature, then combined with 60 mg (0.141 mmol) of the intermediate compound (XVIII.1). The reaction mixture is stirred for 24 hours at ambient temperature, then extracted with potassium carbonate solution and dichloromethane. The organic phase is dried and evaporated to dryness. The residue is purified by chromatography (HPLC). Corresponding fractions are lyophilised.
  • Yield: 35.5 mg (70% of theoretical)
  • HPLC-MS: method A, RT=2.65 min, MH+=509
  • Examples 267-273 may also be obtained analogously by reacting the intermediate products of the intermediate compound (XVIII.1) with the respective appropriate carboxylic acids.
    • Synthesis of Example 274
  • 14.43 mg (0.240 mmol) acetic acid, 92.59 mg (0.288 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 213.90 μl (1.25 mmol) diisopropylethylamine are placed in 2 ml dimethylformamide, and the mixture is stirred for 0.5 hours at ambient temperature. 120 mg (0.240 mmol) of the intermediate compound (XXX.1) are added and the mixture is stirred for 16 hours at ambient temperature. Then the reaction mixture is purified by chromatography (HPLC). Corresponding fractions are lyophilised.
  • Yield: 77 mg (63% of theoretical)
  • Examples 275-278 may also be obtained analogously by reacting the intermediate compound (XXX.1) with the respective appropriate carboxylic acids.
    • Synthesis of Example 281
  • 70 mg (0.163 mmol) of the intermediate compound (XXXIII.1), 62.74 mg (0.195 mmol) O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 144.96 μl diisopropylethylamine are suspended in 2 ml dimethylformamide and the mixture is stirred for 0.5 hours at ambient temperature. 10.59 mg (0.179 mmol) isopropylamine are added and the mixture is stirred for 16 hours at ambient temperature. Then the reaction mixture is purified by chromatography (HPLC). Corresponding fractions are lyophilised.
  • Yield: 22 mg (29% of theoretical)
  • Examples 282-293 may also be obtained analogously by reacting the intermediate compound (XXXIII.1) with the appropriate amines.
    • Synthesis of Example 294
  • 80 mg (0.145 mmol) of the intermediate compound (XXXI.1) and 200 μl (0.400 mmol) 2 molar dimethylamine solution in tetrahydrofuran are stirred in 1 ml of ethanol for 3 hours at 80° C. Then the mixture is evaporated down, the residue is extracted with water and dichloromethane. The organic phase is dried and evaporated to dryness. The product is crystallised with diethyl ether.
  • Yield: 50 mg (64% of theoretical)
  • Examples 295-299 may also be obtained analogously by reacting the intermediate compound (XXXI.1) with the appropriate amines.
    • Synthesis of Example 3
  • 20 mg (0.032 mmol) of the Example compound 133 are stirred in 20 ml ethereal hydrochloric acid for 16 hours at ambient temperature. Then the precipitate is suction filtered and dried.
  • Yield: 10 mg (56% of theoretical)
  • MP: 240° C.
  • Analogously, Examples 2 and 4 may be obtained from the Example compounds 132 and 135, respectively.
  • The following compounds are prepared analogously:
    TABLE A
    (IA)
    Figure US20070238746A1-20071011-C00086
    Ex. No.
    Figure US20070238746A1-20071011-C00087
         		Ra mp [° C.] HPLC method RT [min]
    1
    Figure US20070238746A1-20071011-C00088
    Figure US20070238746A1-20071011-C00089
         		B 1.83
    2
    Figure US20070238746A1-20071011-C00090
    Figure US20070238746A1-20071011-C00091
         		149
    3
    Figure US20070238746A1-20071011-C00092
    Figure US20070238746A1-20071011-C00093
    4
    Figure US20070238746A1-20071011-C00094
    Figure US20070238746A1-20071011-C00095
         		240
    5
    Figure US20070238746A1-20071011-C00096
    Figure US20070238746A1-20071011-C00097
         		210-250
    6
    Figure US20070238746A1-20071011-C00098
    Figure US20070238746A1-20071011-C00099
         		B 2.26
    7
    Figure US20070238746A1-20071011-C00100
    Figure US20070238746A1-20071011-C00101
         		A 2.81
    8
    Figure US20070238746A1-20071011-C00102
    Figure US20070238746A1-20071011-C00103
         		240-241
    9
    Figure US20070238746A1-20071011-C00104
    Figure US20070238746A1-20071011-C00105
    10
    Figure US20070238746A1-20071011-C00106
    Figure US20070238746A1-20071011-C00107
         		A 2.77
    11
    Figure US20070238746A1-20071011-C00108
    Figure US20070238746A1-20071011-C00109
    12
    Figure US20070238746A1-20071011-C00110
    Figure US20070238746A1-20071011-C00111
    13
    Figure US20070238746A1-20071011-C00112
    Figure US20070238746A1-20071011-C00113
    14
    Figure US20070238746A1-20071011-C00114
    Figure US20070238746A1-20071011-C00115
         		230
    15
    Figure US20070238746A1-20071011-C00116
    Figure US20070238746A1-20071011-C00117
    16
    Figure US20070238746A1-20071011-C00118
    Figure US20070238746A1-20071011-C00119
    17
    Figure US20070238746A1-20071011-C00120
    Figure US20070238746A1-20071011-C00121
    18
    Figure US20070238746A1-20071011-C00122
    Figure US20070238746A1-20071011-C00123
    19
    Figure US20070238746A1-20071011-C00124
    Figure US20070238746A1-20071011-C00125
    20
    Figure US20070238746A1-20071011-C00126
    Figure US20070238746A1-20071011-C00127
    21
    Figure US20070238746A1-20071011-C00128
    Figure US20070238746A1-20071011-C00129
    22
    Figure US20070238746A1-20071011-C00130
    Figure US20070238746A1-20071011-C00131
    23
    Figure US20070238746A1-20071011-C00132
    Figure US20070238746A1-20071011-C00133
    24
    Figure US20070238746A1-20071011-C00134
    Figure US20070238746A1-20071011-C00135
         		A 2.68
    25
    Figure US20070238746A1-20071011-C00136
    Figure US20070238746A1-20071011-C00137
    26
    Figure US20070238746A1-20071011-C00138
    Figure US20070238746A1-20071011-C00139
    27
    Figure US20070238746A1-20071011-C00140
    Figure US20070238746A1-20071011-C00141
    28
    Figure US20070238746A1-20071011-C00142
    Figure US20070238746A1-20071011-C00143
    29
    Figure US20070238746A1-20071011-C00144
    Figure US20070238746A1-20071011-C00145
    30
    Figure US20070238746A1-20071011-C00146
    Figure US20070238746A1-20071011-C00147
    31
    Figure US20070238746A1-20071011-C00148
    Figure US20070238746A1-20071011-C00149
    32
    Figure US20070238746A1-20071011-C00150
    Figure US20070238746A1-20071011-C00151
         		A 2.90
    33
    Figure US20070238746A1-20071011-C00152
    Figure US20070238746A1-20071011-C00153
    34
    Figure US20070238746A1-20071011-C00154
    Figure US20070238746A1-20071011-C00155
    35
    Figure US20070238746A1-20071011-C00156
    Figure US20070238746A1-20071011-C00157
    36
    Figure US20070238746A1-20071011-C00158
    Figure US20070238746A1-20071011-C00159
    37
    Figure US20070238746A1-20071011-C00160
    Figure US20070238746A1-20071011-C00161
    38
    Figure US20070238746A1-20071011-C00162
    Figure US20070238746A1-20071011-C00163
    39
    Figure US20070238746A1-20071011-C00164
    Figure US20070238746A1-20071011-C00165
    40
    Figure US20070238746A1-20071011-C00166
    Figure US20070238746A1-20071011-C00167
    41
    Figure US20070238746A1-20071011-C00168
    Figure US20070238746A1-20071011-C00169
    42
    Figure US20070238746A1-20071011-C00170
    Figure US20070238746A1-20071011-C00171
    43
    Figure US20070238746A1-20071011-C00172
    Figure US20070238746A1-20071011-C00173
         		331-333
    44
    Figure US20070238746A1-20071011-C00174
    Figure US20070238746A1-20071011-C00175
    45
    Figure US20070238746A1-20071011-C00176
    Figure US20070238746A1-20071011-C00177
         		A 2.73
    46
    Figure US20070238746A1-20071011-C00178
    Figure US20070238746A1-20071011-C00179
         		135 A 3.04
    47
    Figure US20070238746A1-20071011-C00180
    Figure US20070238746A1-20071011-C00181
         		218 A 2.90
    48
    Figure US20070238746A1-20071011-C00182
    Figure US20070238746A1-20071011-C00183
         		139 A 3.19
    49
    Figure US20070238746A1-20071011-C00184
    Figure US20070238746A1-20071011-C00185
         		138
    50
    Figure US20070238746A1-20071011-C00186
    Figure US20070238746A1-20071011-C00187
         		153-155 A 2.64
    51
    Figure US20070238746A1-20071011-C00188
    Figure US20070238746A1-20071011-C00189
         		A 2.72
    52
    Figure US20070238746A1-20071011-C00190
    Figure US20070238746A1-20071011-C00191
         		A 2.84
    53
    Figure US20070238746A1-20071011-C00192
    Figure US20070238746A1-20071011-C00193
         		B 1.83
    54
    Figure US20070238746A1-20071011-C00194
    Figure US20070238746A1-20071011-C00195
    55
    Figure US20070238746A1-20071011-C00196
    Figure US20070238746A1-20071011-C00197
         		A 2.51
    56
    Figure US20070238746A1-20071011-C00198
    Figure US20070238746A1-20071011-C00199
         		>300  
    57
    Figure US20070238746A1-20071011-C00200
    Figure US20070238746A1-20071011-C00201
         		>300  
    58
    Figure US20070238746A1-20071011-C00202
    Figure US20070238746A1-20071011-C00203
         		>300   A 2.59
    59
    Figure US20070238746A1-20071011-C00204
    Figure US20070238746A1-20071011-C00205
         		251
    60
    Figure US20070238746A1-20071011-C00206
    Figure US20070238746A1-20071011-C00207
         		A 2.71
    61
    Figure US20070238746A1-20071011-C00208
    Figure US20070238746A1-20071011-C00209
         		B 2.02
    62
    Figure US20070238746A1-20071011-C00210
    Figure US20070238746A1-20071011-C00211
         		A 2.72
    63
    Figure US20070238746A1-20071011-C00212
    Figure US20070238746A1-20071011-C00213
    64
    Figure US20070238746A1-20071011-C00214
    Figure US20070238746A1-20071011-C00215
    65
    Figure US20070238746A1-20071011-C00216
    Figure US20070238746A1-20071011-C00217
    66
    Figure US20070238746A1-20071011-C00218
    Figure US20070238746A1-20071011-C00219
         		B 1.81
    67
    Figure US20070238746A1-20071011-C00220
    Figure US20070238746A1-20071011-C00221
    68
    Figure US20070238746A1-20071011-C00222
    Figure US20070238746A1-20071011-C00223
    69
    Figure US20070238746A1-20071011-C00224
    Figure US20070238746A1-20071011-C00225
    70
    Figure US20070238746A1-20071011-C00226
    Figure US20070238746A1-20071011-C00227
    71
    Figure US20070238746A1-20071011-C00228
    Figure US20070238746A1-20071011-C00229
    72
    Figure US20070238746A1-20071011-C00230
    Figure US20070238746A1-20071011-C00231
    73
    Figure US20070238746A1-20071011-C00232
    Figure US20070238746A1-20071011-C00233
         		194-196
    74
    Figure US20070238746A1-20071011-C00234
    Figure US20070238746A1-20071011-C00235
         		203-205 A 2.98
    75
    Figure US20070238746A1-20071011-C00236
    Figure US20070238746A1-20071011-C00237
         		125-127
    76
    Figure US20070238746A1-20071011-C00238
    Figure US20070238746A1-20071011-C00239
         		129-131
    77
    Figure US20070238746A1-20071011-C00240
    Figure US20070238746A1-20071011-C00241
         		206-207
    78
    Figure US20070238746A1-20071011-C00242
    Figure US20070238746A1-20071011-C00243
         		126-129
    79
    Figure US20070238746A1-20071011-C00244
    Figure US20070238746A1-20071011-C00245
         		A 2.76
    80
    Figure US20070238746A1-20071011-C00246
    Figure US20070238746A1-20071011-C00247
         		B 2.00
    81
    Figure US20070238746A1-20071011-C00248
    Figure US20070238746A1-20071011-C00249
         		271-273 B 1.73
    82
    Figure US20070238746A1-20071011-C00250
    Figure US20070238746A1-20071011-C00251
         		A 2.81
    83
    Figure US20070238746A1-20071011-C00252
    Figure US20070238746A1-20071011-C00253
         		A 2.54
    84
    Figure US20070238746A1-20071011-C00254
    Figure US20070238746A1-20071011-C00255
         		A 2.91
    85
    Figure US20070238746A1-20071011-C00256
    Figure US20070238746A1-20071011-C00257
         		A 3.01
    86
    Figure US20070238746A1-20071011-C00258
    Figure US20070238746A1-20071011-C00259
         		A 1.97
    87
    Figure US20070238746A1-20071011-C00260
    Figure US20070238746A1-20071011-C00261
         		A 2.37
    88
    Figure US20070238746A1-20071011-C00262
    Figure US20070238746A1-20071011-C00263
    89
    Figure US20070238746A1-20071011-C00264
    Figure US20070238746A1-20071011-C00265
    90
    Figure US20070238746A1-20071011-C00266
    Figure US20070238746A1-20071011-C00267
    91
    Figure US20070238746A1-20071011-C00268
    Figure US20070238746A1-20071011-C00269
         		, >300    
    92
    Figure US20070238746A1-20071011-C00270
    Figure US20070238746A1-20071011-C00271
         		95-96
    93
    Figure US20070238746A1-20071011-C00272
    Figure US20070238746A1-20071011-C00273
         		A 2.69
    94
    Figure US20070238746A1-20071011-C00274
    Figure US20070238746A1-20071011-C00275
    95
    Figure US20070238746A1-20071011-C00276
    Figure US20070238746A1-20071011-C00277
         		230
    96
    Figure US20070238746A1-20071011-C00278
    Figure US20070238746A1-20071011-C00279
         		 99
    97
    Figure US20070238746A1-20071011-C00280
    Figure US20070238746A1-20071011-C00281
         		185
    98
    Figure US20070238746A1-20071011-C00282
    Figure US20070238746A1-20071011-C00283
         		184
    99
    Figure US20070238746A1-20071011-C00284
    Figure US20070238746A1-20071011-C00285
         		135
    100
    Figure US20070238746A1-20071011-C00286
    Figure US20070238746A1-20071011-C00287
         		>300  
    101
    Figure US20070238746A1-20071011-C00288
    Figure US20070238746A1-20071011-C00289
    102
    Figure US20070238746A1-20071011-C00290
    Figure US20070238746A1-20071011-C00291
         		232
    103
    Figure US20070238746A1-20071011-C00292
    Figure US20070238746A1-20071011-C00293
         		102
    104
    Figure US20070238746A1-20071011-C00294
    Figure US20070238746A1-20071011-C00295
         		142
    105
    Figure US20070238746A1-20071011-C00296
    Figure US20070238746A1-20071011-C00297
    106
    Figure US20070238746A1-20071011-C00298
    Figure US20070238746A1-20071011-C00299
    107
    Figure US20070238746A1-20071011-C00300
    Figure US20070238746A1-20071011-C00301
         		108
    108
    Figure US20070238746A1-20071011-C00302
    Figure US20070238746A1-20071011-C00303
    109
    Figure US20070238746A1-20071011-C00304
    Figure US20070238746A1-20071011-C00305
    110
    Figure US20070238746A1-20071011-C00306
    Figure US20070238746A1-20071011-C00307
    111
    Figure US20070238746A1-20071011-C00308
    Figure US20070238746A1-20071011-C00309
    112
    Figure US20070238746A1-20071011-C00310
    Figure US20070238746A1-20071011-C00311
         		269
    113
    Figure US20070238746A1-20071011-C00312
    Figure US20070238746A1-20071011-C00313
         		285
    114
    Figure US20070238746A1-20071011-C00314
    Figure US20070238746A1-20071011-C00315
         		186
    115
    Figure US20070238746A1-20071011-C00316
    Figure US20070238746A1-20071011-C00317
    116
    Figure US20070238746A1-20071011-C00318
    Figure US20070238746A1-20071011-C00319
         		A 2.36
    117
    Figure US20070238746A1-20071011-C00320
    Figure US20070238746A1-20071011-C00321
         		A 3.16
    118
    Figure US20070238746A1-20071011-C00322
    Figure US20070238746A1-20071011-C00323
         		A 3.12
    119
    Figure US20070238746A1-20071011-C00324
    Figure US20070238746A1-20071011-C00325
         		A 3.14
    120
    Figure US20070238746A1-20071011-C00326
    Figure US20070238746A1-20071011-C00327
         		A 2.99
    121
    Figure US20070238746A1-20071011-C00328
    Figure US20070238746A1-20071011-C00329
         		A 3.09
    122
    Figure US20070238746A1-20071011-C00330
    Figure US20070238746A1-20071011-C00331
         		A 3.11
    123
    Figure US20070238746A1-20071011-C00332
    Figure US20070238746A1-20071011-C00333
    124
    Figure US20070238746A1-20071011-C00334
    Figure US20070238746A1-20071011-C00335
    125
    Figure US20070238746A1-20071011-C00336
    Figure US20070238746A1-20071011-C00337
         		Decom posn at 230
    126
    Figure US20070238746A1-20071011-C00338
    Figure US20070238746A1-20071011-C00339
         		Decom posn at 195
    127
    Figure US20070238746A1-20071011-C00340
    Figure US20070238746A1-20071011-C00341
         		Decom posn at 182
    128
    Figure US20070238746A1-20071011-C00342
    Figure US20070238746A1-20071011-C00343
         		210
    129
    Figure US20070238746A1-20071011-C00344
    Figure US20070238746A1-20071011-C00345
    130
    Figure US20070238746A1-20071011-C00346
    Figure US20070238746A1-20071011-C00347
    131
    Figure US20070238746A1-20071011-C00348
    Figure US20070238746A1-20071011-C00349
    132
    Figure US20070238746A1-20071011-C00350
    Figure US20070238746A1-20071011-C00351
    133
    Figure US20070238746A1-20071011-C00352
    Figure US20070238746A1-20071011-C00353
    134
    Figure US20070238746A1-20071011-C00354
    Figure US20070238746A1-20071011-C00355
    135
    Figure US20070238746A1-20071011-C00356
    Figure US20070238746A1-20071011-C00357
    136
    Figure US20070238746A1-20071011-C00358
    Figure US20070238746A1-20071011-C00359
    137
    Figure US20070238746A1-20071011-C00360
    Figure US20070238746A1-20071011-C00361
    138
    Figure US20070238746A1-20071011-C00362
    Figure US20070238746A1-20071011-C00363
    139
    Figure US20070238746A1-20071011-C00364
    Figure US20070238746A1-20071011-C00365
    140
    Figure US20070238746A1-20071011-C00366
    Figure US20070238746A1-20071011-C00367
    141
    Figure US20070238746A1-20071011-C00368
    Figure US20070238746A1-20071011-C00369
         		A 2.68
    142
    Figure US20070238746A1-20071011-C00370
    Figure US20070238746A1-20071011-C00371
         		A 2.67
    143
    Figure US20070238746A1-20071011-C00372
    Figure US20070238746A1-20071011-C00373
         		B 1.61
    144
    Figure US20070238746A1-20071011-C00374
    Figure US20070238746A1-20071011-C00375
         		A 2.82
    145
    Figure US20070238746A1-20071011-C00376
    Figure US20070238746A1-20071011-C00377
         		B 1.82
    146
    Figure US20070238746A1-20071011-C00378
    Figure US20070238746A1-20071011-C00379
         		B 1.65
    147
    Figure US20070238746A1-20071011-C00380
    Figure US20070238746A1-20071011-C00381
         		B 1.74
    148
    Figure US20070238746A1-20071011-C00382
    Figure US20070238746A1-20071011-C00383
         		A 2.72
    149
    Figure US20070238746A1-20071011-C00384
    Figure US20070238746A1-20071011-C00385
         		347-349
    150
    Figure US20070238746A1-20071011-C00386
    Figure US20070238746A1-20071011-C00387
         		340-343
    151
    Figure US20070238746A1-20071011-C00388
    Figure US20070238746A1-20071011-C00389
    152
    Figure US20070238746A1-20071011-C00390
    Figure US20070238746A1-20071011-C00391
         		A 1.66
    153
    Figure US20070238746A1-20071011-C00392
    Figure US20070238746A1-20071011-C00393
         		351-353
    154
    Figure US20070238746A1-20071011-C00394
    Figure US20070238746A1-20071011-C00395
         		C 3.23
    155
    Figure US20070238746A1-20071011-C00396
    Figure US20070238746A1-20071011-C00397
         		C 3.29
    156
    Figure US20070238746A1-20071011-C00398
    Figure US20070238746A1-20071011-C00399
         		C 3.28
    157
    Figure US20070238746A1-20071011-C00400
    Figure US20070238746A1-20071011-C00401
         		C 3.73
    158
    Figure US20070238746A1-20071011-C00402
    Figure US20070238746A1-20071011-C00403
         		C 3.38
    159
    Figure US20070238746A1-20071011-C00404
    Figure US20070238746A1-20071011-C00405
         		C 3.73
    160
    Figure US20070238746A1-20071011-C00406
    Figure US20070238746A1-20071011-C00407
         		C 4.31
    161
    Figure US20070238746A1-20071011-C00408
    Figure US20070238746A1-20071011-C00409
         		C 3.95
    162
    Figure US20070238746A1-20071011-C00410
    Figure US20070238746A1-20071011-C00411
         		C 3.88
    163
    Figure US20070238746A1-20071011-C00412
    Figure US20070238746A1-20071011-C00413
         		C 4.41
    164
    Figure US20070238746A1-20071011-C00414
    Figure US20070238746A1-20071011-C00415
         		C 3.62
    165
    Figure US20070238746A1-20071011-C00416
    Figure US20070238746A1-20071011-C00417
         		C 4.54
    166
    Figure US20070238746A1-20071011-C00418
    Figure US20070238746A1-20071011-C00419
         		C 4.58
    167
    Figure US20070238746A1-20071011-C00420
    Figure US20070238746A1-20071011-C00421
         		C 4.59
    168
    Figure US20070238746A1-20071011-C00422
    Figure US20070238746A1-20071011-C00423
         		C 4.61
    169
    Figure US20070238746A1-20071011-C00424
    Figure US20070238746A1-20071011-C00425
         		C 4.63
    170
    Figure US20070238746A1-20071011-C00426
    Figure US20070238746A1-20071011-C00427
         		C 4.28
    171
    Figure US20070238746A1-20071011-C00428
    Figure US20070238746A1-20071011-C00429
         		C 4.34
    172
    Figure US20070238746A1-20071011-C00430
    Figure US20070238746A1-20071011-C00431
         		C 4.58
    173
    Figure US20070238746A1-20071011-C00432
    Figure US20070238746A1-20071011-C00433
         		C 3.38
    174
    Figure US20070238746A1-20071011-C00434
    Figure US20070238746A1-20071011-C00435
         		C 4.84
    175
    Figure US20070238746A1-20071011-C00436
    Figure US20070238746A1-20071011-C00437
         		C 4.3
    176
    Figure US20070238746A1-20071011-C00438
    Figure US20070238746A1-20071011-C00439
         		C 4.28
    177
    Figure US20070238746A1-20071011-C00440
    Figure US20070238746A1-20071011-C00441
         		C 4.31
    178
    Figure US20070238746A1-20071011-C00442
    Figure US20070238746A1-20071011-C00443
         		C 4.66
    179
    Figure US20070238746A1-20071011-C00444
    Figure US20070238746A1-20071011-C00445
         		C 4.58
    180
    Figure US20070238746A1-20071011-C00446
    Figure US20070238746A1-20071011-C00447
         		C 4.69
    181
    Figure US20070238746A1-20071011-C00448
    Figure US20070238746A1-20071011-C00449
         		C 4.7
    182
    Figure US20070238746A1-20071011-C00450
    Figure US20070238746A1-20071011-C00451
         		C 3.64
    183
    Figure US20070238746A1-20071011-C00452
    Figure US20070238746A1-20071011-C00453
         		C 5.14
    184
    Figure US20070238746A1-20071011-C00454
    Figure US20070238746A1-20071011-C00455
         		C 4.23
    185
    Figure US20070238746A1-20071011-C00456
    Figure US20070238746A1-20071011-C00457
         		C 3.95
    186
    Figure US20070238746A1-20071011-C00458
    Figure US20070238746A1-20071011-C00459
         		C 4.74
    187
    Figure US20070238746A1-20071011-C00460
    Figure US20070238746A1-20071011-C00461
         		C 3.5
    188
    Figure US20070238746A1-20071011-C00462
    Figure US20070238746A1-20071011-C00463
         		C 5.02
    189
    Figure US20070238746A1-20071011-C00464
    Figure US20070238746A1-20071011-C00465
         		C 4.16
    190
    Figure US20070238746A1-20071011-C00466
    Figure US20070238746A1-20071011-C00467
         		D 4.07
    191
    Figure US20070238746A1-20071011-C00468
    Figure US20070238746A1-20071011-C00469
         		C 4.41
    192
    Figure US20070238746A1-20071011-C00470
    Figure US20070238746A1-20071011-C00471
         		D 3.79
    193
    Figure US20070238746A1-20071011-C00472
    Figure US20070238746A1-20071011-C00473
         		C 3.71
    194
    Figure US20070238746A1-20071011-C00474
    Figure US20070238746A1-20071011-C00475
         		C 3.72
    195
    Figure US20070238746A1-20071011-C00476
    Figure US20070238746A1-20071011-C00477
         		C 3.81
    196
    Figure US20070238746A1-20071011-C00478
    Figure US20070238746A1-20071011-C00479
         		C 4.05
    197
    Figure US20070238746A1-20071011-C00480
    Figure US20070238746A1-20071011-C00481
         		C 3.68
    198
    Figure US20070238746A1-20071011-C00482
    Figure US20070238746A1-20071011-C00483
         		C 3.24
    199
    Figure US20070238746A1-20071011-C00484
    Figure US20070238746A1-20071011-C00485
         		C 4.04
    200
    Figure US20070238746A1-20071011-C00486
    Figure US20070238746A1-20071011-C00487
         		C 3.72
    201
    Figure US20070238746A1-20071011-C00488
    Figure US20070238746A1-20071011-C00489
         		C 4.54
    202
    Figure US20070238746A1-20071011-C00490
    Figure US20070238746A1-20071011-C00491
         		D 2.99
    203
    Figure US20070238746A1-20071011-C00492
    Figure US20070238746A1-20071011-C00493
         		C 4.38
    204
    Figure US20070238746A1-20071011-C00494
    Figure US20070238746A1-20071011-C00495
         		C 4.82
    205
    Figure US20070238746A1-20071011-C00496
    Figure US20070238746A1-20071011-C00497
         		C 4.33
    206
    Figure US20070238746A1-20071011-C00498
    Figure US20070238746A1-20071011-C00499
         		D 3.24
    207
    Figure US20070238746A1-20071011-C00500
    Figure US20070238746A1-20071011-C00501
         		C 4.83
    208
    Figure US20070238746A1-20071011-C00502
    Figure US20070238746A1-20071011-C00503
         		C 3.92
    209
    Figure US20070238746A1-20071011-C00504
    Figure US20070238746A1-20071011-C00505
         		C 4.63
    210
    Figure US20070238746A1-20071011-C00506
    Figure US20070238746A1-20071011-C00507
         		C 3.45
    211
    Figure US20070238746A1-20071011-C00508
    Figure US20070238746A1-20071011-C00509
         		C 4.76
    212
    Figure US20070238746A1-20071011-C00510
    Figure US20070238746A1-20071011-C00511
         		C 4.55
    213
    Figure US20070238746A1-20071011-C00512
    Figure US20070238746A1-20071011-C00513
         		C 3.64
    214
    Figure US20070238746A1-20071011-C00514
    Figure US20070238746A1-20071011-C00515
         		C 3.58
    215
    Figure US20070238746A1-20071011-C00516
    Figure US20070238746A1-20071011-C00517
         		C 3.56
    216
    Figure US20070238746A1-20071011-C00518
    Figure US20070238746A1-20071011-C00519
         		C 3.23
    217
    Figure US20070238746A1-20071011-C00520
    Figure US20070238746A1-20071011-C00521
         		C 3.23
    218
    Figure US20070238746A1-20071011-C00522
    Figure US20070238746A1-20071011-C00523
         		C 3.24
    219
    Figure US20070238746A1-20071011-C00524
    Figure US20070238746A1-20071011-C00525
         		C 4.43
    220
    Figure US20070238746A1-20071011-C00526
    Figure US20070238746A1-20071011-C00527
         		C 4.63
    221
    Figure US20070238746A1-20071011-C00528
    Figure US20070238746A1-20071011-C00529
         		C 3.62
    222
    Figure US20070238746A1-20071011-C00530
    Figure US20070238746A1-20071011-C00531
         		C 3.46
    223
    Figure US20070238746A1-20071011-C00532
    Figure US20070238746A1-20071011-C00533
         		C 4.44
    224
    Figure US20070238746A1-20071011-C00534
    Figure US20070238746A1-20071011-C00535
         		A 2.76
    225
    Figure US20070238746A1-20071011-C00536
    Figure US20070238746A1-20071011-C00537
    226
    Figure US20070238746A1-20071011-C00538
    Figure US20070238746A1-20071011-C00539
    227
    Figure US20070238746A1-20071011-C00540
    Figure US20070238746A1-20071011-C00541
         		A 2.84
    228
    Figure US20070238746A1-20071011-C00542
    Figure US20070238746A1-20071011-C00543
         		A 2.67
    229
    Figure US20070238746A1-20071011-C00544
    Figure US20070238746A1-20071011-C00545
    230
    Figure US20070238746A1-20071011-C00546
    Figure US20070238746A1-20071011-C00547
    231
    Figure US20070238746A1-20071011-C00548
    Figure US20070238746A1-20071011-C00549
    232
    Figure US20070238746A1-20071011-C00550
    Figure US20070238746A1-20071011-C00551
    233
    Figure US20070238746A1-20071011-C00552
    Figure US20070238746A1-20071011-C00553
    234
    Figure US20070238746A1-20071011-C00554
    Figure US20070238746A1-20071011-C00555
    235
    Figure US20070238746A1-20071011-C00556
    Figure US20070238746A1-20071011-C00557
    236
    Figure US20070238746A1-20071011-C00558
    Figure US20070238746A1-20071011-C00559
    237
    Figure US20070238746A1-20071011-C00560
    Figure US20070238746A1-20071011-C00561
    238
    Figure US20070238746A1-20071011-C00562
    Figure US20070238746A1-20071011-C00563
         		207-209
    239
    Figure US20070238746A1-20071011-C00564
    Figure US20070238746A1-20071011-C00565
    240
    Figure US20070238746A1-20071011-C00566
    Figure US20070238746A1-20071011-C00567
    241
    Figure US20070238746A1-20071011-C00568
    Figure US20070238746A1-20071011-C00569
    242
    Figure US20070238746A1-20071011-C00570
    Figure US20070238746A1-20071011-C00571
    243
    Figure US20070238746A1-20071011-C00572
    Figure US20070238746A1-20071011-C00573
    244
    Figure US20070238746A1-20071011-C00574
    Figure US20070238746A1-20071011-C00575
    245
    Figure US20070238746A1-20071011-C00576
    Figure US20070238746A1-20071011-C00577
    246
    Figure US20070238746A1-20071011-C00578
    Figure US20070238746A1-20071011-C00579
    247
    Figure US20070238746A1-20071011-C00580
    Figure US20070238746A1-20071011-C00581
    248
    Figure US20070238746A1-20071011-C00582
    Figure US20070238746A1-20071011-C00583
    249
    Figure US20070238746A1-20071011-C00584
    Figure US20070238746A1-20071011-C00585
    250
    Figure US20070238746A1-20071011-C00586
    Figure US20070238746A1-20071011-C00587
         		203-204
    251
    Figure US20070238746A1-20071011-C00588
    Figure US20070238746A1-20071011-C00589
         		204-205
    252
    Figure US20070238746A1-20071011-C00590
    Figure US20070238746A1-20071011-C00591
    253
    Figure US20070238746A1-20071011-C00592
    Figure US20070238746A1-20071011-C00593
         		217-218
    254
    Figure US20070238746A1-20071011-C00594
    Figure US20070238746A1-20071011-C00595
         		178-182
    255
    Figure US20070238746A1-20071011-C00596
    Figure US20070238746A1-20071011-C00597
    256
    Figure US20070238746A1-20071011-C00598
    Figure US20070238746A1-20071011-C00599
    257
    Figure US20070238746A1-20071011-C00600
    Figure US20070238746A1-20071011-C00601
         		225-226
    258
    Figure US20070238746A1-20071011-C00602
    Figure US20070238746A1-20071011-C00603
         		140-148
    259
    Figure US20070238746A1-20071011-C00604
    Figure US20070238746A1-20071011-C00605
         		204-206
    260
    Figure US20070238746A1-20071011-C00606
    Figure US20070238746A1-20071011-C00607
         		198-199 A 2.54
    261
    Figure US20070238746A1-20071011-C00608
    Figure US20070238746A1-20071011-C00609
         		189-190 A 2.63
    262
    Figure US20070238746A1-20071011-C00610
    Figure US20070238746A1-20071011-C00611
         		168-169 A 2.65
    263
    Figure US20070238746A1-20071011-C00612
    Figure US20070238746A1-20071011-C00613
         		171-172 A 2.78
    264
    Figure US20070238746A1-20071011-C00614
    Figure US20070238746A1-20071011-C00615
         		B 1.56
    265
    Figure US20070238746A1-20071011-C00616
    Figure US20070238746A1-20071011-C00617
         		B 1.73
    266
    Figure US20070238746A1-20071011-C00618
    Figure US20070238746A1-20071011-C00619
         		A 2.65
    267
    Figure US20070238746A1-20071011-C00620
    Figure US20070238746A1-20071011-C00621
         		A 2.46
    268
    Figure US20070238746A1-20071011-C00622
    Figure US20070238746A1-20071011-C00623
         		A 2.58
    269
    Figure US20070238746A1-20071011-C00624
    Figure US20070238746A1-20071011-C00625
         		A 2.48
    270
    Figure US20070238746A1-20071011-C00626
    Figure US20070238746A1-20071011-C00627
         		B 1.67
    271
    Figure US20070238746A1-20071011-C00628
    Figure US20070238746A1-20071011-C00629
         		B 1.54
    272
    Figure US20070238746A1-20071011-C00630
    Figure US20070238746A1-20071011-C00631
         		B 1.74
    273
    Figure US20070238746A1-20071011-C00632
    Figure US20070238746A1-20071011-C00633
         		B 1.86
    274
    Figure US20070238746A1-20071011-C00634
    Figure US20070238746A1-20071011-C00635
    275
    Figure US20070238746A1-20071011-C00636
    Figure US20070238746A1-20071011-C00637
    276
    Figure US20070238746A1-20071011-C00638
    Figure US20070238746A1-20071011-C00639
         		A 2.96
    277
    Figure US20070238746A1-20071011-C00640
    Figure US20070238746A1-20071011-C00641
         		A 3.03
    278
    Figure US20070238746A1-20071011-C00642
    Figure US20070238746A1-20071011-C00643
         		A 2.82
    279
    Figure US20070238746A1-20071011-C00644
    Figure US20070238746A1-20071011-C00645
    280
    Figure US20070238746A1-20071011-C00646
    Figure US20070238746A1-20071011-C00647
    281
    Figure US20070238746A1-20071011-C00648
    Figure US20070238746A1-20071011-C00649
    282
    Figure US20070238746A1-20071011-C00650
    Figure US20070238746A1-20071011-C00651
    283
    Figure US20070238746A1-20071011-C00652
    Figure US20070238746A1-20071011-C00653
    284
    Figure US20070238746A1-20071011-C00654
    Figure US20070238746A1-20071011-C00655
    285
    Figure US20070238746A1-20071011-C00656
    Figure US20070238746A1-20071011-C00657
    286
    Figure US20070238746A1-20071011-C00658
    Figure US20070238746A1-20071011-C00659
         		A 2.90
    287
    Figure US20070238746A1-20071011-C00660
    Figure US20070238746A1-20071011-C00661
    288
    Figure US20070238746A1-20071011-C00662
    Figure US20070238746A1-20071011-C00663
         		A 2.58
    289
    Figure US20070238746A1-20071011-C00664
    Figure US20070238746A1-20071011-C00665
         		A 2.80
    290
    Figure US20070238746A1-20071011-C00666
    Figure US20070238746A1-20071011-C00667
         		A 2.57
    291
    Figure US20070238746A1-20071011-C00668
    Figure US20070238746A1-20071011-C00669
         		A 2.42
    292
    Figure US20070238746A1-20071011-C00670
    Figure US20070238746A1-20071011-C00671
    293
    Figure US20070238746A1-20071011-C00672
    Figure US20070238746A1-20071011-C00673
         		A 2.77
    294
    Figure US20070238746A1-20071011-C00674
    Figure US20070238746A1-20071011-C00675
    295
    Figure US20070238746A1-20071011-C00676
    Figure US20070238746A1-20071011-C00677
    296
    Figure US20070238746A1-20071011-C00678
    Figure US20070238746A1-20071011-C00679
    297
    Figure US20070238746A1-20071011-C00680
    Figure US20070238746A1-20071011-C00681
    298
    Figure US20070238746A1-20071011-C00682
    Figure US20070238746A1-20071011-C00683
    299
    Figure US20070238746A1-20071011-C00684
    Figure US20070238746A1-20071011-C00685

    Biological Test
  • The compounds of formula (I) mentioned by way of example are characterised by an affinity for PI3-kinase, i.e. in the test by an IC50 value of below 800 nmol/litre.
  • In order to determine the inhibitory activity of the compounds on PI3Kγ, an in-vitro kinase assay was used. The expression and purification of Gβ1γ2-His and p101-GST/p110γ from Sf9-cells (Spodoptera frugiperda 9) has already been described (Maier et al., J. Biol. Chem. 1999 (274) 29311-29317). Alternatively, the following method was used to determine the activity:
  • 10 μl of the compound to be tested were placed on 96 well PVDF filter plates (0.45 μM) and incubated for 20 min with 30 μl lipid vesicles (PIP2 (0.7 μg/well), phosphatidylethanolamine (7.5 μg/well), phosphatidylserine (7.5 μg/well), sphingomyelin (0.7 μg/well) and phosphatidylcholine (3.2 μg/well)) which contained 1-3 ng PI3K□ and 20-60 ng G□1□2-His. The reaction was started by the addition of 10 μl reaction buffer (40 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM EGTA, 1 mM □-glycerophosphate, 1 mM DTT, 7 mM MgCl2 and 0.1% BSA; 1 μM ATP and 0.2 μCi [□-33P]-ATP) and incubated for 120 min at ambient temperature. The reaction solution was sucked through the filters by the application of a vacuum and washed with 200 μl PBS. After the plates had been dried at 50° C. the radioactivity remaining in the plates was determined after the addition of 50 μl scintillation liquid using a Top-Count measuring device.
  • Ranges of Indications
  • It has been found that the compounds of formula (I) are characterised by a variety of possible applications in the therapeutic field. Particular mention should be made of those applications for which the compounds of formula (I) according to the invention are preferably used by virtue of their pharmaceutical activity as PI3-kinase modulators.
  • Generally speaking, these are diseases in whose pathology PI3-kinases are implicated, particularly inflammatory and allergic diseases. Particular mention should be made of inflammatory and allergic respiratory complaints, inflammatory diseases of the gastrointestinal tract, inflammatory diseases of the motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic ailments which involve autoimmune reactions or inflammation of the kidneys. The treatment may be symptomatic, adaptive, curative or preventative.
  • Respiratory complaints deserving special mention would be chronic and/or obstructive respiratory complaints. The compounds of formula I according to the invention may, by virtue of their pharmacological properties, bring about a reduction in
      • Tissue damage
      • Inflammation of the airways
      • bronchial hyperreactivity
      • the process of reconstruction of the lung as a result of inflammation
      • worsening of the disease (progression).
  • The compounds according to the invention are particularly preferred for preparing a medicament for the treatment of chronic bronchitis, acute bronchitis, bronchitis caused by bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive pulmonary disease (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases such as e.g. pulmonary fibrosis, asbestosis and silicosis and alveolitis; hyperreactive airways, nasal polyps, pulmonary oedema such as e.g. toxic pulmonary oedema and ARDS/IRDS, pneumonitis of different origins, e.g. radiation-induced or caused by aspiration or infectious pneumonitis, collagenoses such as lupus erythematodes, systemic sclerodermy, sarcoidosis or Boeck's disease.
  • The compounds of formula (I) are also suitable for the treatment of diseases of the skin, such as e.g. psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyodermy, endogenous and exogenous acne, acne rosacea and other inflammatory or allergic or proliferative skin diseases.
  • Moreover, the compounds of formula (I) are suitable for therapeutic use in cases of inflammatory or allergic complaints which involve autoimmune reactions, such as e.g. inflammatory bowel diseases, e.g. Crohn's disease or ulcerative colitis; diseases of the arthritis type, such as e.g. rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis.
  • The following general inflammatory or allergic diseases may also be mentioned, which can be treated with medicaments containing compounds of formula (I):
      • inflammation of the eye, such as e.g. conjunctivitis of various kinds, e.g. caused by infections with fungi or bacteria, allergic conjunctivitis, irritable conjunctivitis, drug-induced conjunctivitis, keratitis, uveitis
      • diseases of the nasal mucosa, such as e.g. allergic rhinitis/sinusitis or nasal polyps
      • inflammatory or allergic conditions, such as e.g. systemic lupus erythematodes, chronic hepatitis, kidney inflammations such as glomerulonephritis, interstitial nephritis or idiopathic nephrotic syndrome.
  • Other diseases which may be treated with a drug containing compounds of formula (I) on the basis of their pharmacological activity include toxic or septic shock syndrome, atherosclerosis, middle ear infections (otitis media), hypertrophy of the heart, cardiac insufficiency, stroke, ischaemic reperfusion injury or neurodegenerative diseases such as Parkinson's disease or Alzheimer's.
  • Combinations
  • The compounds of formula (I) may be used on their own or in combination with other active substances of formula (I). If desired the compounds of formula (I) may also be used in combination with W, where W denotes a pharmacologically active substance and (for example) is selected from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors, preferably PI3-{tilde over (□)}Kinase inhibitors. Moreover, double or triple combinations of W may be combined with the compounds of formula (I). Combinations of W might be, for example:
      • W denotes a betamimetic, combined with an active substance selected from among the anticholinergics, corticosteroids, PDE4-inhibitors, EGFR-inhibitors and LTD4-antagonists,
      • W denotes an anticholinergic, combined with an active substance selected from among the betamimetics, corticosteroids, PDE4-inhibitors EGFR-inhibitors and LTD4-antagonists,
      • W denotes a corticosteroid, combined with an active substance selected from among the PDE4-inhibitors, EGFR-inhibitors and LTD4-antagonists
      • W denotes a PDE4-inhibitor, combined with an active substance selected from among the EGFR-inhibitors and LTD4-antagonists
      • W denotes an EGFR-inhibitor, combined with an LTD4-antagonist.
  • The compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
    • 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzyl-sulphonamide
      • 5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinoline-2-one
    • 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulphonyl}ethyl]-amino}ethyl]2(3H)-benzothiazolone
    • 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
    • 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
    • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol
    • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol
    • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol
    • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazole-3-yl]-2-methyl-2-butylamino}ethanol
    • 5-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-on
    • 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol
    • 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
    • 6-hydroxy-8-{1-hydroxy-2-[2-(ethyl 4-phenoxy-acetate)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
    • 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
    • 8-{2-[1,1-dimethyl-2-(2.4.6-trimethylphenyl)-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
    • 6-hydroxy-8-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
    • 6-hydroxy-8-{1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
    • 8-{2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
    • 8-{2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
    • 4-(4-{2-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-ethylamino]-2-methyl-propyl}-phenoxy)-butyric acid
    • 8-{2-[2-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
    • 1-(4-ethoxy-carbonylamino-3-cyano-5-fluorophenyl)-2-(tert-butylamino)ethanol
      optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine. In the above-mentioned salts the cations are the pharmacologically active constituents. As anions the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions. Of all the salts the chlorides, bromides, iodides and methanesulphonates are particularly preferred.
  • Other specified compounds are:
      • tropenol 2,2-diphenylpropionate methobromide
      • scopine 2,2-diphenylpropionate methobromide
      • scopine 2-fluoro-2,2-diphenylacetate methobromide
      • tropenol 2-fluoro-2,2-diphenylacetate methobromide
      • tropenol 3,3′,4,4′-tetrafluorobenzilate methobromide
      • scopine 3,3′,4,4′-tetrafluorobenzilate methobromide
      • tropenol 4,4′-difluorobenzilate methobromide
      • scopine 4,4′-difluorobenzilate methobromide
      • tropenol 3,3′-difluorobenzilate methobromide
      • scopine 3,3′-difluorobenzilate methobromide
      • tropenol 9-hydroxy-fluorene-9-carboxylate methobromide
      • tropenol 9-fluoro-fluorene-9-carboxylate methobromide
      • scopine 9-hydroxy-fluorene-9-carboxylate methobromide
      • scopine 9-fluoro-fluorene-9-carboxylate methobromide
      • tropenol 9-methyl-fluorene-9-carboxylate methobromide
      • scopine 9-methyl-fluorene-9-carboxylate methobromide
      • cyclopropyltropine benzilate methobromide
      • cyclopropyltropine 2,2-diphenylpropionate methobromide
      • cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide
      • cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide
      • cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide
      • cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide
      • cyclopropyltropine methyl 4,4′-difluorobenzilate methobromide
      • tropenol 9-hydroxy-xanthene-9-carboxylate methobromide
      • scopine 9-hydroxy-xanthene-9-carboxylate methobromide
      • tropenol 9-methyl-xanthene-9-carboxylate-methobromide
      • scopine 9-methyl-xanthene-9-carboxylate-methobromide
      • tropenol 9-ethyl-xanthene-9-carboxylate methobromide
      • tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide
      • scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide
  • As corticosteroids it is preferable to use compounds selected from among prednisolone, prednisone, butixocort propionate, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, betamethasone, deflazacort, RPR-106541, NS-126, ST-26 and
    • (S)-fluoromethyl 6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate
    • (S)-(2-oxo-tetrahydro-furan-3S-yl)6,9-difluoro-1′-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothionate,
    • etiprednol-dichloroacetate
      optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof. Any reference to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof which may exist. Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325.366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, CI-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
    • N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide
    • (−)p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide
    • (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone
    • 3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N′-[N-2-cyano-5-methyl-isothioureido]benzyl)-2-pyrrolidone
    • cis[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid]
    • 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)cyclohexan-1-one
    • cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol]
    • (R)-(+)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate
    • (S)-(−)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate
    • 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine
    • 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine
      optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof. According to the invention the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
    • 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid,
    • 1-(((1(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
    • [2-[[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid
      optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof. According to the invention the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate. By salts or derivatives which the LTD4-antagonists may optionally be capable of forming are meant, for example: alkali metal salts, such as for example sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinyl-carbonyl)amino]-quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine
    • 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline
    • 4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline
    • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(methoxymethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-hydroxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-aminocarbonylmethyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(tetrahydropyran-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)sulphonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-ethoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-acetylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(piperidin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(4-methyl-piperazin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-isopropyloxycarbonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[N-(2-methoxy-acetyl)-N-methyl-amino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
    • 4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(cis-2,6-dimethyl-morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methyl-morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(S,S)-(2-oxa-5-aza-bicyclo[2,2,1]hept-5-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(3-methoxypropyl-amino)-carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
    • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline
      optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The PAF-antagonists used are preferably compounds selected from among
    • 4-(2-chlorophenyl)-9-methyl-2-[3(4-morpholinyl)-3-propanon-1-yl]-6H-thieno-[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepine
    • 6-(2-chlorophenyl)-8,9-dihydro-1-methyl-8-[(4-morpholinyl)carbonyl]-4H,7H-cyclo-penta-[4,5]thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine,
      optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the preferred acid addition salts of the betamimetics are selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The PI3-kinase-δ-inhibitors used are preferably compounds selected from among: IC87114, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one; 2-(6-aminopurin-o-ylmethyl)-6-bromo-3-(2-chlorophenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-o-ylmethyl)-3-(2-chlorophenyl)-7-fluoro-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-6-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one; 2-(6-aminopurin-o-ylmethyl)-5-chloro-3-(2-chloro-phenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-methyl-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-chloro-3H-quinazolin-4-one; 5-chloro-2-(9H-purin-6-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H -quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluorophenyl)-3H-quinazolin-4-one; 3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H -quinazolin-4-one; 3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-yl-sulphanylmethyl)-3H -quinazolin-4-one; 3-(2-chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 6-bromo-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-8-trifluoromethyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulphanylmethyl)-3H-benzo[g]quinazolin-4-one; 6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-7-nitro-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulphanylmethyl)-3H -quinazolin-4-one; 3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-yl-sulphanylmethyl)-3H -quinazolin-4-one; 3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-6-fluoro-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-methyl-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-yl-sulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H -quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-phenyl)-3H -quinazolin-4-one; 2-(2-amino-9H-purin-6-ylsulphanylmethyl)-3-cyclopropyl-5-methyl-3H-quinazolin-4-one; 3-cyclopropylmethyl-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one; 2-(2-amino-9H-purin-6-ylsulphanylmethyl)-3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3-phenethyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(2-amino-9H -purin-6-ylsulphanylmethyl)-5-methyl-3-phenethyl-3H-quinazolin-4-one; 3-cyclopentyl-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-cyclopentyl-5-methyl-3H-quinazolin-4-one; 3-(2-chloropyridin-3-yl)-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-chloropyridin-3-yl)-5-methyl-3H-quinazolin-4-one; 3-methyl-4-[5-methyl-4-oxo-2-(9H-purin-6-ylsulphanylmethyl)-4H-quinazolin-3-yl]-benzoic acid; 3-cyclopropyl-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-cyclopropyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3-(4-nitrobenzyl)-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-cyclohexyl-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-cyclohexyl-5-methyl-3H-quinazolin-4-one; 2-(2-amino-9H-purin-6-ylsulphanylmethyl)-3-cyclohexyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3-(E-2-phenylcyclopropyl)-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-5-fluoro-2-[(9H-purin-6-ylamino)methyl]-3H-quinazolin-4-one; 2-[(2-amino-9H-purin-6-ylamino)methyl]-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one; 5-methyl-2-[(9H-purin-6-ylamino)methyl]-3-o-tolyl-3H-quinazolin-4-one; 2-[(2-amino-9H-purin-6-ylamino)methyl]-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-[(2-fluoro-9H-purin-6-ylamino)methyl]-5-methyl-3-o-tolyl-3H-quinazolin-4-one; (2-chlorophenyl)-dimethylamino-(9H -purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 5-(2-benzyloxyethoxy)-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethyl 6-aminopurine-9-carboxylate; N-[3-(2-chlorophenyl)-5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethyl]-2-(9H-purin-6-ylsulphanyl)-acetamide; 2-[1-(2-fluoro-9H-purin-6-ylamino)ethyl]-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-[1-(9H-purin-6-ylamino)ethyl]-3-o-tolyl-3H-quinazolin-4-one; 2-(6-dimethylaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-7-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-9-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 2-(amino-dimethylaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(2-amino-9H-purin-6-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(4-amino-1,3,5-triazin-2-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(7-methyl-7H-purin-6-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(2-oxo-1,2-dihydro-pyrimidin-4-ylsulphanyl methyl)-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-purin-7-ylmethyl-3-o-tolyl-3H -quinazolin-4-one; 5-methyl-2-purin-9-ylmethyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(9-methyl-9H-purin-6-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 2-(2,6-diamino-pyrimidin-4-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(5-methyl-[1,2,4]triazolo[1.5-a]pyrimidin-7-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(2-methylsulphanyl-9H -purin-6-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 2-(2-hydroxy-9H-purin-6-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(1-methyl-1H-imidazol-2-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-3-O-tolyl-2-(H-[1,2,4]triazol-3-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(2-amino-6-chloro-purin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(6-aminopurin-7-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(7-amino-1,2,3-triazolo[4,5-d]pyrimidin-3-yl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(7-amino-1,2,3-triazolo[4,5-d]pyrimidin-1-yl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(6-amino-9H-purin-2-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(2-amino-6-ethylamino-pyrimidin-4-ylsulphanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(3-amino-5-methylsulphanyl-1,2,4-triazol-1-yl-methyl)-5-methyl-3-o-tolyl-3Hquinazolin-4-one; 2-(5-amino-3-methylsulphanyl-1,2,4-triazol-1-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(6-methylaminopurin-9-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 2-(6-benzylaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(2,6-diaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 3-isobutyl-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; N-{2-[5-methyl-4-oxo-2-(9H-purin-6-ylsulphanylmethyl)-4H-quinazolin-3-yl]-phenyl}-acetamide; 5-methyl-3-(E-2-methyl-cyclohexyl)-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-[5-methyl-4-oxo-2-(9H-purin-6-ylsulphanylmethyl)-4H-quinazolin-3-yl]-benzoic acid; 3-{2-[(2-dimethylaminoethyl)methylamino]phenyl}-5-methyl-2-(9H-purin-6-ylsulphanylmethyl)-3H-quin-azolin-4-one; 3-(2-chlorophenyl)-5-methoxy-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-5-(2-morpholin-4-yl-ethylamino)-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 3-benzyl-5-methoxy-2-(9H-purin-6-ylsulphanylmethyl)-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-benzyloxyphenyl)-5-methyl-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-hydroxyphenyl)-5-methyl-3H-quinazolin-4-one; 2-(1-(2-amino-9H-purin-6-ylamino)ethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-[1-(9H-purin-6-ylamino)propyl]-3-o-tolyl-3H-quinazolin-4-one; 2-(1-(2-fluoro-9H-purin-6-ylamino)propyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(1-(2-amino-9H-purin-6-ylamino)propyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(2-benzyloxy-1-(9H-purin-6-ylamino)ethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-{2-(2-(1-methylpyrrolidin-2-yl)-ethoxy)-phenyl}-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-3-(2-(3-dimethylamino-propoxy)-phenyl)-5-methyl-3H-quinazolin-4-one; 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-(2-prop-2-ynyloxyphenyl)-3H-quinazolin-4-one; 2-(2-(1-(6-aminopurin-9-ylmethyl)-5-methyl-4-oxo-4H-quinazolin-3-yl]-phenoxy}-acetamide; 5-chloro-3-(3,5-difluoro-phenyl)-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 3-(2,6-difluoro-phenyl)-5-methyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 3-(3,5-difluoro-phenyl)-5-methyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 3-(2,3-difluoro-phenyl)-5-methyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 5-methyl-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 3-(3-chloro-phenyl)-5-methyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 5-methyl-3-phenyl-2-[(9H-purin-6-ylamino)-methyl]-3H-quinazolin-4-one; 2-[(2-amino-9H-purin-6-ylamino)-methyl]-3-(3,5-difluoro-phenyl)-5-methyl-3H-quinazolin-4-one; 3-{2-[1,2]-diethylamino-ethyl)-methyl-amino]-phenyl)-5-methyl-2-[(9H-purin-6-ylamino)-methyl]-3H-quinazolin-4-one; 5-chloro-3-(2-fluoro-phenyl)-2-[(9H-purin-6-ylamino)-methyl]-3H-quinazolin-4-one; 5-chloro-2-[(9H-purin-6-ylamino)-methyl]-3-o-tolyl-3H-quinazolin-4-one; 5-chloro-3-(2-chloro-phenyl)-2-[(9H-purin-6-ylamino)-methyl]-3H-quinazolin-4-one; 6-fluoro-3-(3-fluoro-phenyl)-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one; 2-[1-(2-amino-9H-purin-6-ylamino)-ethyl]-5-chloro-3-(3-fluoro-phenyl)-3H-quinazolin-4-one; and the pharmaceutically acceptable salts and solvates thereof.
  • Formulations
  • The compounds according to the invention may be administered by oral, transdermal, inhalative, parenteral or sublingual route. The compounds according to the invention are present as active ingredients in conventional preparations, for example in compositions consisting essentially of an inert pharmaceutical carrier and an effective dose of the active substance, such as for example tablets, coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc. An effective dose of the compounds according to the invention is between 0.1 and 5000, preferably between 1 and 500, more preferably between 5-300 mg/dose for oral administration, and between 0.001 and 50, preferably between 0.1 and 10 mg/dose for intravenous. subcutaneous or intramuscular administration. Examples of inhalable formulations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions. Within the scope of the present invention the term propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions. For use by inhalation it is preferable to use powders, ethanolic or aqueous solutions. For inhalation, according to the invention, solutions containing 0.01 to 1.0, preferably 0.1 to 0.5% active substance are suitable. It is also possible to use the compounds according to the invention as a solution for infusion, preferably in a physiological saline or nutrient saline solution.
  • The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. Suitable formulations include, for example, tablets, capsules, suppositories, solutions, syrups, emulsions or dispersible powders. Corresponding tablets may be obtained for example by mixing the active substance(s) with known excipients, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • Solutions for injection are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
  • Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • The inhalable powders which may be used according to the invention may contain the active substance according to the invention either on its own or in admixture with suitable physiologically acceptable excipients.
  • If the active substances according to the invention are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
  • Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250 μm, preferably between 10 and 150 μm, most preferably between 15 and 80 μm. In some cases it may seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 μm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substances according to the invention, preferably with an average particle size of 0.5 to 10 μm, more preferably from 1 to 5 μm, are added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and finally mixing the ingredients together are known from the prior art.
  • The inhalable powders according to the invention may be administered using inhalers known from the prior art.
  • Inhalation aerosols containing propellant gas according to the invention may contain active substances according to the invention dissolved in the propellant gas or in dispersed form. The propellant gases which may be used to prepare the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases may be used on their own or in admixture. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
  • The propellant-driven inhalation aerosols may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
  • The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs=metered dose inhalers).
  • Moreover, the active substances according to the invention may be administered in the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and ethanol. The relative proportion of ethanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of water. The solutions or suspensions containing the active substance according to the invention are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
  • The addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent may optionally be omitted in these formulations. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100 ml, preferably less than 50 mg/100 ml, more preferably less than 20 mg/100 ml. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10 mg/100 ml are preferred.
  • Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols—particularly isopropyl alcohol, glycols—particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
  • The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
  • Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably present in concentrations of up to 50 mg/100 ml, more preferably between 5 and 20 mg/100 ml.
  • Preferred formulations contain, in addition to the solvent water and the active substance according to the invention, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is present.
  • A therapeutically effective daily dose is between 1 and 2000 mg, preferably 10-500 mg per adult.
  • The Examples which follow illustrate the present invention without restricting its scope:
    • Examples of Pharmaceutical Formulations
  • A) Tablets per tablet
    active substance 100 mg
    lactose 140 mg
    maize starch 240 mg
    polyvinylpyrrolidone 15 mg
    magnesium stearate 5 mg
    500 mg
  • The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, granulated while wet and dried. The granulate, the rest of the corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to form tablets of a suitable shape and size.
    B) Tablets per tablet
    active substance 80 mg
    corn starch 190 mg
    lactose 55 mg
    microcrystalline cellulose 35 mg
    polyvinylpyrrolidone 15 mg
    sodium-carboxymethyl starch 23 mg
    magnesium stearate 2 mg
    400 mg
  • The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
    C) Coated tablets per coated tablet
    Active substance 5 mg
    Corn starch 41.5 mg
    Lactose 30 mg
    Polyvinylpyrrolidone 3 mg
    Magnesium stearate 0.5 mg
    80 mg
  • The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in a known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax
    D) Capsules per capsule
    Active substance 50 mg
    Corn starch 268.5 mg
    Magnesium stearate 1.5 mg
    320 mg
  • The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.
    E) Ampoule solution
    active substance 50 mg
    sodium chloride 50 mg
    water for inj. 5 ml
  • The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
    F) Suppositories
    Active substance 50 mg
    Solid fat 1650 mg
    1700 mg
  • The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.
    G) Oral suspension
    active substance 50 mg
    hydroxyethylcellulose 50 mg
    sorbic acid 5 mg
    sorbitol (70%) 600 mg
    glycerol 200 mg
    flavouring 15 mg
    water ad 5 ml
  • Distilled water is heated to 70° C. Hydroxyethyl-cellulose is dissolved therein with stirring. After the addition of sorbitol solution and glycerol the mixture is cooled to ambient temperature. At ambient temperature, sorbic acid, flavouring and substance are added. To eliminate air from the suspension it is evacuated with stirring.
  • and 50 mg of active substance.
    H) Metered-dose aerosol (suspension)
    active substance 0.3 wt. %
    sorbitolan trioleate 0.6 wt. %
    HFA134A:HFA227 2:1 99.1 wt. %
  • The suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 μl of suspension are delivered per spray. The active substance may also be metered in higher doses if desired.
    I) Metered-dose aerosol (solution)
    active substance 0.3 wt. %. %
    abs. ethanol 20 wt. %
    aqueous HCl 0.01 mol/l 2.0 wt. %
    HFA134A 77.7 wt. %
  • The solution is produced in the usual way by mixing the individual ingredients together.
    J) Inhalable powder
    active substance 80 μg
    lactose monohydrate ad 10 mg
  • The powder for inhalation is produced in the usual way by mixing the individual ingredients together.

Claims (16)

1. A compound of the formula (I),
Figure US20070238746A1-20071011-C00686
wherein
A denotes N or CH;
Ra denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl and C3-C8-heterocycloalkyl-C1-C4-alkyl,
Rb denotes hydrogen, OH or NH2
or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl, CONH2, C6-C14-aryl-NH, C3-C8-heterocycloalkyl-NH— and O—C1-C3-alkyl,
R1 denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl and C6-C14-aryl-C1-C5-alkyl-;
or
R2 denotes hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C6-alkyl, C9-C13-spiro, C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C6-C14-aryl-C1-C6-alkyl-;
or
R1 and R2 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen.
or
R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
or
R2 denotes a group selected from among general formulae (A1) to (A18)
Figure US20070238746A1-20071011-C00687
Figure US20070238746A1-20071011-C00688
wherein
X and Y may be linked to the same or different atoms of G, and
X denotes a bond or an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene,
or
X together with R1, R3 or R4 may form a C1-C7-alkylene bridge;
Y denotes a bond or optionally substituted C1-C4-alkylene;
Q denotes an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene, or
Q together with R1, R3 or R4 may form a C1-C7-alkylene bridge;
R3, R4, R5 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, NR7R8, NR7R8—C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, C6-C14-aryl and C5-C10-heteroaryl;
or in each case two of the substituents
R3, R4, R5 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;
R6 which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C1-C8-alkyl, C2-C6-alkenyl C3-C8-cycloalkyl, C2-C6-haloalkyl, C6-C14-aryl, C5-C10-heteroaryl and C3-C8-heterocycloalkyl,
or
a group selected from among NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8—O—C1-C3-alkyl-NR7R8, CONR7R8, NR7COR8, —CO—C1-C3-alkyl-NR7(CO)OR8, —O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, —O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl and halogen;
n denotes 1, 2 or 3
R7, R8, R9 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, C6-C14-aryl, C1-C4-alkyl-C6-C14-aryl, C6-C14-aryl-C1-C4-alkyl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C4-alkyl, C1-C4-alkyl (CO)— and C1-C4-alkyl-O(CO)—;
or in each case two of the substituents
R7, R8, R9 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, as well as optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof,
with the proviso that the following compounds are excluded:
a) 8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
b) 1-methyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
c) 1,1-dimethyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
d) 1-(2-dimethylamino-ethyl)-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
e) 4-methyl-piperazine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
f) piperidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
g) pyrrolidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
h) 1-methyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
i) (8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea
j) 1,1-dimethyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea and
k) [8-(2-methoxy-phenyl)-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl]-urea and
l) morpholine-4-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide
2. The compound according to claim 1,
wherein
X, Y, Q and G may have the meaning specified and
A denotes N,
Ra denotes hydrogen or a group selected from among C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl and C3-C8-heterocycloalkyl-C1-C4-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among
C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C2-C6-alkynyl-NR5R6, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, C1-C4-alkoxy, CN, NO2, NR10R11, OR10, COR10, COOR10, CONR10R11, NR10COR11, NR10(CO)NR11R12, O(CO)NR10R11, NR10(CO)OR11, SO2R10, SOR10, SO2NR10R11, NR10SO2NR11R12 and NR10SO2R11;
or Ra is optionally substituted by a group of general formula (B)
Figure US20070238746A1-20071011-C00689
wherein,
R13 to R16 which may be identical or different, represent hydrogen or C1-C6-alkyl,
or two of the substituents
R13 to R16 together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
R10, R11, R12 which may be identical or different, denote hydrogen or a group selected from among
C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl and C1-C6 haloalkyl;
or
in each case two of the groups
R10, R11, R12 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;
Rb denotes hydrogen, OH or NH2
or an optionally substituted group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C4-alkyl, spiro, C3-C8-heterocycloalkyl, CONH2, C6-C14-aryl-NH, C3-C8-heterocycloalkyl-NH— and O—C1-C3-alkyl,
which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among
C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, OMe, CN, NH2, NHMe and NMe2;
R1 denotes hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C2-C8-alkynyl and C6-C14-aryl-C1-C5-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, COOH, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)-alkyl and —(CO)O-alkyl,
R2 denotes hydrogen or a group selected from among C1-C8 alkyl, C3-C8-cycloalkyl, C2-C8-alkenyl, C3-C8-cycloalkenyl, C1-C6-haloalkyl, C6-C14-aryl, C6-C14-aryl-C1-C5-alkyl, C5-C10-heteroaryl, C3-C8-cycloalkyl-C1-C4-alkyl, C3-C8-cycloalkenyl-C1-C4-alkyl, C5-C10-heteroaryl-C1-C6-alkyl, C9-C13-spiro, C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C6-alkyl- and C6-C14-aryl-C1-C6-alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)-alkyl, ═O, COOH and —(CO)O-alkyl.
or
R1 and R2 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, C1-C6-alkyl, OMe, —NH(CO)—C1-C4-alkyl, and —(CO)O—C1-C4-alkyl.
or
R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
or
R2 denotes a group selected from among general formulae (A1) to (A18)
Figure US20070238746A1-20071011-C00690
Figure US20070238746A1-20071011-C00691
wherein
R3, R4, R5 which may be identical or different, denote hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, NR7R8, NR7R8—C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, C6-C14-aryl and C5-C10-heteroaryl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, NR9R10, —NH(CO)—C1-C4-alkyl and MeO,
or in each case two of the substituents
R3, R4, R5 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, NR9R10, —NH(CO)—C1-C4-alkyl and MeO,
R6 which may be identical or different, denote hydrogen or a group, selected from among C1-C8-alkyl, C2-C6-alkenyl C3-C8-cycloalkyl, C2-C6-haloalkyl, C6-C14-aryl, C5-C10-heteroaryl and C3-C8-heterocycloalkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among NH2, NHMe, NMe2, OH, OMe, CN, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl, C1-C6-alkyl and —(CO)O—C1-C6-alkyl
or
a group selected from among ═O, NR7R8, OR7, —CO—C1-C3-alkyl-NR7R8—R—C1-C3-alkyl-NR7R8, CONR7R8, NR7COR8, —CO—C1-C3-alkyl-NR7(CO)OR8, —O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, —O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN and halogen;
n denotes 1, 2 or 3
R7, R8, R9 which may be identical or different, denote hydrogen or a group selected from among C1-C8-alkyl, C3-C8-cycloalkyl, C2-C6-haloalkyl, C1-C4-alkyl-C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C3-alkyl, C6-C14-aryl, C1-C4-alkyl-C6-C14-aryl, C6-C14-aryl-C1-C4-alkyl, C3-C8-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl, C3-C8-heterocycloalkyl-C1-C4-alkyl, C1-C4-alkyl (CO)— and C1-C4-alkyl-O(CO), which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, OMe, NHMe, NMe2, C1-C6-alkyl and (CO)O C1-C6-alkyl,
or in each case two of the substituents
R7, R8, R9 together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH2, OH, CN, OMe, NH Me, NMe2, C1-C6-alkyl and (CO)OC1-C6-alkyl.
3. The compound according to claim 2,
wherein
A, Ra and R1 to R16 may have the meaning specified and
Rb denotes hydrogen.
4. The compound according to claim 2,
wherein
A, R1 to R16 may have the meaning specified,
Ra denotes C6-C14-aryl or C1-C6-alkyl
wherein Ra may optionally be substituted by one or more of the groups, which may be identical or different, selected from among C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C1-C6-haloalkyl, halogen, OH, C1-C4-alkoxy, CN, NO2, NR10R11, OR10, COR10, COOR10, CONR10R11, NR10COR11, NR10(CO)NR11R12, O(CO)NR10R11, NR10(CO)OR11, SO2R10, SOR10, SO2NR10R11, NR10SO2NR11R12 and NR10SO2R11; and
Rb denotes hydrogen.
5. The compound according to claim 4,
wherein
A, Ra and Rb may have the meaning specified and
R1 denotes hydrogen, C1-C5-alkyl or C3-C8-cycloalkyl,
R2 denotes hydrogen, C1-C5-alkyl or C3-C8-cycloalkyl, phenyl
or
R1 and R2 together form an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1 to 2 nitrogen atoms,
or
R1 and R2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring,
or
R1, R2 which may be identical or different, denote a group selected from among general formulae (A1)-A(17),
wherein
X denotes a bond or an optionally substituted C1-C3-alkylene,
or
X together with R1, R3 or R4 may form a 5- or 6-membered heterocyclic group;
Q denotes an optionally substituted C1-C3-alkylene,
Q together with R1, R3 or R4 may form a C1-C7-alkylene bridge;
R3, R4, R5 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C4-alkyl, C1-C4-alkoxy, C3-C6-cycloalkyl, C3-C8-heterocycloalkyl, —C1-C3-alkyl-C3-C6-cycloalkyl, phenyl and C5-C10-heteroaryl
or in each case two of the substituents
R3, R4, R5 together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.
6. The compound according to claim 4,
wherein
A, Ra and Rb may have the meaning specified and
R1 denotes H, Me
R2 denotes hydrogen or a group of general formulae (A18),
wherein
X denotes a bond or an optionally substituted group selected from among C1-C7-alkylene, C3-C7-alkenylene and C3-C7-alkynylene,
or
X together with R1 may form a C1-7 alkylene bridge
Y denotes a bond or methylene, ethylene;
X and Y may be linked to the same or different atoms of G, and
G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;
R6 which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C1-C4-alkyl, C2-C6-alkenyl, C3-C6-cycloalkyl, C6-C14-aryl, C5-C6-heterocycloalkyl, and C5-C6-heteroaryl
or
a group selected from among NR7R8, OR7, —O—C1-C3-alkyl-NR7R8, CONR7R8, CO—C1-C3-alkyl-NR7R8, NR7COR8, NR7(CO)OR8, —CO—C1-C3-alkyl-NR7(CO)OR8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, COR7, (SO2)R7, —C1-C3-alkyl-C6-C14-aryl, —NH—CO—NH—C1-C3-alkyl and CN
n denotes 1 or 2
R7, R8, R9 which may be identical or different, denote hydrogen or an optionally substituted group selected from among C1-C5-alkyl, C1-C4-alkyl-C6-C14-aryl, C3-C6-heterocycloalkyl, C1-C5-alkyl-C3-C8-heterocycloalkyl- and C3-C6-cycloalkyl,
or in each case two of the substituents
R7, R8, R9 together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.
7. A method of treating a disease or condition chosen from chronic bronchitis, acute bronchitis, bronchitis caused by bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary oedema, pneumonitis of different origins, e.g. radiation-induced or caused by aspiration, or infectious pneumonitis, collagenoses such as lupus erythematodes, systemic sclerodermy, sarcoidosis and Boeck's disease comprising administering a therapeutically effective amount of a compound according to claim 1.
8. A method of treating a disease or condition chosen from psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyodermy, endogenous and exogenous acne, acne rosacea and other inflammatory and allergic or proliferative skin diseases comprising administering a therapeutically effective amount of a compound according to claim 1.
9. A method of treating a disease or condition chosen from inflammation of the conjunctiva (conjunctivitis) of various kinds, such as e.g. caused by infection with fungi or bacteria, allergic conjunctivitis, irritable conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis comprising administering a therapeutically effective amount of a compound according to claim 1.
10. A method of treating a disease or condition chosen from allergic rhinitis, allergic sinusitis and nasal polyps comprising administering a therapeutically effective amount of a compound according to claim 1.
11. A method of treating a disease or condition chosen from Crohn's disease, ulcerative colitis, systemic lupus erythematodes, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, rheumatoid spondylitis comprising administering a therapeutically effective amount of a compound according to claim 1.
12. A method of treating a disease or condition chosen from glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome comprising administering a therapeutically effective amount of a compound according to claim 1.
13. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1.
14. The pharmaceutical composition according to claim 13 for inhalative administration.
15. The pharmaceutical composition according to claim 13 for oral administration.
16. The pharmaceutical composition according to claim 13, comprising as a further active substance, one or more compounds which are selected from the categories of the betamimetics, anticholinergics, corticosteroids, other PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors or double or triple combinations thereof.
US11/690,355 2006-04-06 2007-03-23 Thiazolyl-dihydro-chinazoline Abandoned US20070238746A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/351,017 US8354418B2 (en) 2006-04-06 2009-01-09 Thiazolyl-dihydro-quinazolines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112296 2006-04-06
EP06112296 2006-04-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/351,017 Continuation US8354418B2 (en) 2006-04-06 2009-01-09 Thiazolyl-dihydro-quinazolines

Publications (1)

Publication Number Publication Date
US20070238746A1 true US20070238746A1 (en) 2007-10-11

Family

ID=36928335

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/690,355 Abandoned US20070238746A1 (en) 2006-04-06 2007-03-23 Thiazolyl-dihydro-chinazoline
US12/351,017 Active 2028-09-11 US8354418B2 (en) 2006-04-06 2009-01-09 Thiazolyl-dihydro-quinazolines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/351,017 Active 2028-09-11 US8354418B2 (en) 2006-04-06 2009-01-09 Thiazolyl-dihydro-quinazolines

Country Status (15)

Country Link
US (2) US20070238746A1 (en)
EP (1) EP2007772A1 (en)
JP (1) JP5237262B2 (en)
KR (1) KR20090023560A (en)
CN (1) CN101460508A (en)
AR (1) AR060265A1 (en)
AU (1) AU2007236046A1 (en)
BR (1) BRPI0710583A2 (en)
CA (1) CA2646571A1 (en)
IL (1) IL194495A0 (en)
MX (1) MX2008012645A (en)
RU (1) RU2430923C2 (en)
TW (1) TW200804403A (en)
WO (1) WO2007115932A1 (en)
ZA (1) ZA200807791B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244104A1 (en) * 2006-04-06 2007-10-18 Trixi Brandl Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
WO2010023307A1 (en) * 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
US20110003786A1 (en) * 2009-07-02 2011-01-06 Novartis Ag 2-Carboxamide Cycloamino Ureas
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
DE102011083283A1 (en) 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazoles, their cosmetic or dermatological use and cosmetic or dermatological preparations containing such Heteroalkylamidothiazolen
WO2015054148A1 (en) * 2013-10-07 2015-04-16 The Board Of Trustees Of The University Of Illinois Amphotericin b derivatives with improved therapeutic index
EP3023097A1 (en) 2008-10-01 2016-05-25 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597833A (en) * 2009-09-28 2014-01-31 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
CA3022896A1 (en) * 2016-05-04 2017-11-09 B.C.I. Pharma Adenine derivatives as protein kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
US20060100254A1 (en) * 2004-10-07 2006-05-11 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380640A (en) 1980-01-21 1983-04-19 Ciba-Geigy Corporation Novel benzthiazolylurea derivatives, compositions containing them and their use as herbicides
NZ331053A (en) 1998-07-21 2002-12-20 Osmose New Zealand Process for electrochemical generation of higher oxidate state values from lower oxidation state values above zero of transition metal(s) [eg;
CA2339806A1 (en) 1998-08-06 2000-02-17 Simon Alexander Jackson Control means for air emitting apparatus
AU2001236698A1 (en) * 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
AR038703A1 (en) * 2002-02-28 2005-01-26 Novartis Ag DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3
FR2841138B1 (en) 2002-06-25 2005-02-25 Cll Pharma SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS
US7401363B2 (en) 2002-08-19 2008-07-22 Point Blank Body Armor, Inc. Adjustable concealed body armor
WO2005006820A1 (en) 2003-06-13 2005-01-20 Ictel, Llc Electronic ballast
KR20060070486A (en) 2003-06-13 2006-06-23 젠타리스 게엠베하 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
UY29149A1 (en) 2004-10-07 2006-05-31 Boehringer Ingelheim Int TIAZOLIL-DIHIDRO-INDAZOLES
DE602006020447D1 (en) 2005-06-28 2011-04-14 Merck Sharp & Dohme NIACIN RECEPTOR AGONISTS, COMPOSITIONS WITH DE
US20070259855A1 (en) 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
RU2008143555A (en) 2006-04-06 2010-06-27 Бёрингер Ингельхайм Интернациональ Гмбх (De) Thiazolyl dihydroindazoles
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
KR20090029182A (en) 2006-04-06 2009-03-20 베링거 인겔하임 인터내셔날 게엠베하 Thiazolyldihydroindazole derivatives as protein kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
US20060100254A1 (en) * 2004-10-07 2006-05-11 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
US20060106013A1 (en) * 2004-10-07 2006-05-18 Boehringer Ingelheim International Gmbh PI3-kinases

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334378B2 (en) 2006-04-06 2012-12-18 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline compounds and processes for preparing same
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20070244104A1 (en) * 2006-04-06 2007-10-18 Trixi Brandl Thiazolyl-dihydro-quinazoline
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20100145041A1 (en) * 2006-04-06 2010-06-10 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline compounds and processes for preparing same
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
WO2010023307A1 (en) * 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
CN102186822A (en) * 2008-08-29 2011-09-14 顶标公司 Novel urea and thiourea derivatives
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
AU2009286604B2 (en) * 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
US8871747B2 (en) 2008-08-29 2014-10-28 Topotarget A/S Urea and thiourea derivatives
EP3023097A1 (en) 2008-10-01 2016-05-25 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
US20110003786A1 (en) * 2009-07-02 2011-01-06 Novartis Ag 2-Carboxamide Cycloamino Ureas
US8357707B2 (en) 2009-07-02 2013-01-22 Novartis Ag 2-carboxamide cycloamino ureas
WO2013041537A1 (en) 2011-09-23 2013-03-28 Beiersdorf Ag Heterocyclocarbonylaminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonylaminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
DE102011083283A1 (en) 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazoles, their cosmetic or dermatological use and cosmetic or dermatological preparations containing such Heteroalkylamidothiazolen
WO2015054148A1 (en) * 2013-10-07 2015-04-16 The Board Of Trustees Of The University Of Illinois Amphotericin b derivatives with improved therapeutic index
KR20160068861A (en) * 2013-10-07 2016-06-15 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Amphotericin b derivatives with improved therapeutic index
US10323057B2 (en) 2013-10-07 2019-06-18 The Board Of Trustees Of The University Of Illinois Amphotericin B derivatives with improved therapeutic index
US11028114B2 (en) 2013-10-07 2021-06-08 The Board Of Trustees Of The University Of Illinois Amphotericin B derivatives with improved therapeutic index
US11117920B2 (en) 2013-10-07 2021-09-14 The Board Of Trustees Of The University Of Illinois Amphotericin B derivatives with improved therapeutic index
KR102321482B1 (en) 2013-10-07 2021-11-02 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Amphotericin b derivatives with improved therapeutic index
KR20210132248A (en) * 2013-10-07 2021-11-03 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Amphotericin b derivatives with improved therapeutic index
KR102548341B1 (en) 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Amphotericin b derivatives with improved therapeutic index
US11970512B2 (en) 2013-10-07 2024-04-30 The Board Of Trustees Of The University Of Illinois Amphotericin B derivatives with improved therapeutic index
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Also Published As

Publication number Publication date
IL194495A0 (en) 2009-08-03
RU2008143548A (en) 2010-05-20
CA2646571A1 (en) 2007-10-18
EP2007772A1 (en) 2008-12-31
BRPI0710583A2 (en) 2012-06-19
RU2430923C2 (en) 2011-10-10
JP5237262B2 (en) 2013-07-17
JP2009532416A (en) 2009-09-10
AR060265A1 (en) 2008-06-04
US20090131424A1 (en) 2009-05-21
US8354418B2 (en) 2013-01-15
ZA200807791B (en) 2009-08-26
TW200804403A (en) 2008-01-16
AU2007236046A1 (en) 2007-10-18
MX2008012645A (en) 2008-10-13
WO2007115932A1 (en) 2007-10-18
KR20090023560A (en) 2009-03-05
CN101460508A (en) 2009-06-17

Similar Documents

Publication Publication Date Title
US8354418B2 (en) Thiazolyl-dihydro-quinazolines
US7517995B2 (en) Thiazolyl-dihydro-cyclopentapyrazole
US20090093474A1 (en) Thiazolyl-dihydro-indazole
US20070259855A1 (en) Thiazolyl-dihydro-indazole
US8232286B2 (en) Inhibitors of PI3-kinases
US8334378B2 (en) Thiazolyl-dihydro-quinazoline compounds and processes for preparing same

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRANDL, TRIXI;MAIER, UDO;HOENKE, CHRISTOPH;AND OTHERS;REEL/FRAME:022082/0270;SIGNING DATES FROM 20070330 TO 20070514

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRANDL, TRIXI;MAIER, UDO;HOENKE, CHRISTOPH;AND OTHERS;SIGNING DATES FROM 20070330 TO 20070514;REEL/FRAME:022082/0270

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION